

Processing text_000N_42208.tx.1: Prognostic Factors

Phrase: Prognostic Factors
>>>> Phrase
prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]
<<<< Mappings
Processing text_000N_7494.tx.1: Certain clinical and laboratory features exhibited at diagnosis as well as rate of early response to induction therapy have prognostic value.

Phrase: Certain clinical
>>>> Phrase
certain clinical
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Certain (Certain (qualifier value)
{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 861 Clinical {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: laboratory features
>>>> Phrase
laboratory features
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
 694 LABORATORY (Laboratory
{CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_FDA,SNOMEDCT_US}
) [hcro,mnob]
 827 Feature (Characteristics {MTH,NCI,NCI_NICHED}) [qlco]
<<<< Mappings

Phrase: exhibited at diagnosis
>>>> Phrase
exhibited at diagnosis
<<<< Phrase
>>>> Mappings
Meta Mapping (730):
 756 Exhibit (Exhibits as Topic {CHV,MSH,MTH,NCI,NCI_FDA}) [inpr]
 790 DIAGNOSIS (Diagnosis
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_

NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: as well as
>>>> Phrase
<<<< Phrase

Phrase: rate of early response
>>>> Phrase
rate of early response
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
 819 rate response (Frequency of Responses {CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [tmco]
 604 Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase: to induction therapy
>>>> Phrase
induction therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Induction Therapy (Neoadjuvant Therapy {CHV,MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn,PDQ}) [topp]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: prognostic value.
>>>> Phrase
prognostic value
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
 861 Value (Numerical value {MTH,NCI,NLMSubSyn}) [qncos]
<<<< Mappings
Processing text_000N_7494.tx.2: The identification of such factors has become essential in the design and analysis of modern therapeutic trials.

Phrase: The identification of such factors
>>>> Phrase
the identification of such factors
<<<< Phrase
>>>> Mappings

Meta Mapping (669):
760 Identification (Identification (Psychology)
{AOD,CSP,LCH,LCH_NW,MSH,MTH,SNOMEDCT_US}) [menp]
560 Factor {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: become
>>>> Phrase
become
<<<< Phrase

Phrase: essential in the design
>>>> Phrase
essential in the design
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
770 Essential {CHV,NCI,SNMI,SNOMEDCT_US} [qlco]
604 Design {MTH,NCI} [acty]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: analysis of modern therapeutic trials.
>>>> Phrase
analysis of modern therapeutic trials
<<<< Phrase
>>>> Mappings
Meta Mapping (745):

760 analysis (analysis aspect {MSH,MTH}) [ftcn]
640 Therapeutic Trials (Therapeutic Clinical Trial
{NCI,NLMSubSyn}) [resa]
<<<< Mappings

Processing text_000N_7494.tx.3: It is common practice to assign patients on the basis of prognostic factors into different risk groups and to tailor treatment accordingly.

Phrase: It
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: common practice to
>>>> Phrase
common practice to
<<<< Phrase
>>>> Mappings
Meta Mapping (771):
 623 Common (shared attribute {MTH,NCI}) [ftcn]
 790 practice (Practice Experience {CHV,MTH}) [menp]
<<<< Mappings

Phrase: assign
>>>> Phrase
assign
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Assign (Assignment – action {MTH,NCI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: patients on the basis of prognostic factors
>>>> Phrase
patients on the basis of prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (692):
 748 Patients
 {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
 A,SNOMEDCT_US} [podg]
 581 BASIS (Basis {MTH,NDFRT,RXNORM,VANDF}) [phsu]
 612 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]
<<<< Mappings

Phrase: into different risk groups
>>>> Phrase
different risk groups
<<<< Phrase
>>>> Mappings
Meta Mapping (884):
 660 Different {MTH,NCI} [qlco]
 867 risk Group (Population at Risk {CHV,MSH,MTH,NCI,NLMSubSyn})
 [popg]
<<<< Mappings

Phrase: and to tailor treatment accordingly.
>>>> Phrase
and to tailor treatment accordingly
<<<< Phrase
>>>> Mappings
Meta Mapping (695):

760 Tailor (tailor {CHV,SNOMEDCT_US}) [prog]
760 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings
Processing text_000N_7494.tx.4: Important prognostic characteristics
of childhood ALL include the initial leukocyte count, age at
diagnosis, sex, race and ethnicity, genetic alterations,
immunophenotype, extramedullary disease, response to treatment, and
nutritional status (Table 19.6).

Phrase: Important prognostic characteristics of childhood ALL

>>>> Phrase

important prognostic characteristics of childhood all

<<<< Phrase

>>>> Mappings

Meta Mapping (697):

586 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
586 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
753 Characteristics {MTH,NCI,NCI_NICHHD} [qlco]
586 Childhood
{AOD,CHV,LNC,MTH,NCI,NCI_NICHHD,SNM,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase: include

>>>> Phrase

include

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Include (Include (action) {MTH,NCI}) [acty]

<<<< Mappings

Phrase: the initial leukocyte count,

>>>> Phrase

initial leukocyte count

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

660 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
901 Leukocyte Count (White Blood Cell Count procedure
{AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
[lbpr]
<<<< Mappings

Phrase: age at diagnosis,

>>>> Phrase

age at diagnosis

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Age at diagnosis {LNC,MTH,SNOMEDCT_US} [clna]
<<<< Mappings

Phrase: sex,
>>>> Phrase
sex
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  sex (Gender
{AOD,CHV,CSP,LNC,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNOMEDCT_US}) [orga]
<<<< Mappings

Phrase: race
>>>> Phrase
race
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  RACE (Racial group
{AOD,CHV,CSP,HL7V2.5,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDISC,
NCI_FDA,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: ethnicity,
>>>> Phrase
ethnicity
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Ethnicity (Ethnic group
{AOD,CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NICHD,NL
MSubSyn,SNMI,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: genetic alterations,
>>>> Phrase
genetic alterations
<<<< Phrase
>>>> Mappings
Meta Mapping (983):
  983  Genetic Alteration (Molecular Genetic Abnormality
{LNC,MTH,NCI,NLMSubSyn}) [fndg]
```

<<<< Mappings

Phrase: immunophenotype,

>>>> Phrase

immunophenotype

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Immunophenotype (Immunophenotyping

{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Phrase: extramedullary disease,

>>>> Phrase

extramedullary disease

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

861 Extramedullary {NCI} [spco]

861 Disease {CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NDFRT,SNMI,SNOMEDCT_US} [dsyn]

<<<< Mappings

Phrase: response to treatment,

>>>> Phrase

response to treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Response to treatment {CHV,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}

[clna]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: nutritional status

>>>> Phrase

nutritional status

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Nutritional Status (Nutritional status

{AOD,CHV,CSP,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US})

[fndg]

<<<< Mappings

Phrase: (Table 19.6

>>>> Phrase

table 19 6

<<<< Phrase

>>>> Mappings

Meta Mapping (827):

 827 Table (Table – furniture {CHV,MTH,SNMI,SNOMEDCT_US}) [mnob]

<<<< Mappings

Phrase:).

>>>> Phrase

<<<< Phrase

Processing text_000N_7494.tx.5: Numerous other prognostic factors have been utilized in the past, for example, organomegaly and lymphadenopathy, presence of a mediastinal mass, initial hemoglobin and platelet count, FAB morphologic classification, co-expression of myeloid antigens, serum immunoglobulin level, and HLA type.

Phrase: Numerous

>>>> Phrase

numerous

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Numerous {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: other prognostic factors

>>>> Phrase

prognostic factors

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]

<<<< Mappings

Phrase: have

>>>> Phrase

<<<< Phrase

Phrase: been

>>>> Phrase

<<<< Phrase

Phrase: utilized in the past,

>>>> Phrase

utilized in the past

<<<< Phrase

>>>> Mappings

Meta Mapping (770):

 770 Past (In the past {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: for example,

>>>> Phrase

example

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Example {NCI} [cnce]

<<<< Mappings

Phrase: organomegaly

>>>> Phrase

organomegaly

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Organomegaly {NCI} [fndg]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: lymphadenopathy,

>>>> Phrase

lymphadenopathy

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 LYMPHADENOPATHY (Lymphadenopathy
 {AIR,AOD,CHV,COSTAR,CSP,CST,HPO,ICD10CM,LNC,MSH,MTH,MTHICD9,NCI,NCI_FD
 A,NCI_NCI-
 GLOSS,NCI_NICH,NDFT,NLMSubSyn,OMIM,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET
 }) [dsyn]

<<<< Mappings

Phrase: presence of a mediastinal mass,

>>>> Phrase

presence of a mediastinal mass

<<<< Phrase

>>>> Mappings

Meta Mapping (789):

 760 Presence (Providing presence (regime/therapy)
 {CHV,MTH,SNOMEDCT_US}) [topp]

 645 Mass of mediastinum (Mediastinal mass
 {CHV,DXP,NCI,NCI_NICH,SNMI,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: initial hemoglobin

>>>> Phrase

```
initial hemoglobin
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
  861  Hemoglobin
{AOD,CHV,CSP,FMA,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA} [aapp,bacs]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: platelet count,
>>>> Phrase
platelet count
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Platelet Count (Platelet Count measurement
{AOD,CHV,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: FAB morphologic classification,
>>>> Phrase
fab morphologic classification
<<<< Phrase
>>>> Mappings
Meta Mapping (754):
  589  Morphology {CHV,CSP,LCH,LNC,MTH,SNOMEDCT_US} [qlco]
  827  classification (Taxonomic {MSH,MTH}) [ftcn]
<<<< Mappings

Phrase: co-expression of myeloid antigens,
>>>> Phrase
co expression of myeloid antigens
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  760  Expression (Expression procedure
{CHV,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}) [topp]
  593  Myeloid {CHV,LNC,NCI,NCI_NCI-GLOSS,SNOMEDCT_US} [qlco]
  593  Antigens {AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,SNM,SNMI,SNOMEDCT_US} [imft]
<<<< Mappings

Phrase: serum immunoglobulin level,
>>>> Phrase
```

serum immunoglobulin level

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

 734 serum immunoglobulin (serum immunoglobulin a {CHV,NLMSubSyn})
[lbpr]

 827 Level (Levels (qualifier value)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

Meta Mapping (734):

 734 serum immunoglobulin (serum immunoglobulin a {CHV,NLMSubSyn})
[lbpr]

Meta Mapping (901):

 660 SERUM (Serum
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsu]

 901 Immunoglobulin level (Immunoglobulin level - finding
{CHV,NLMSubSyn,SNOMEDCT_US}) [lbtr]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: HLA type.

>>>> Phrase

hla type

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 hla type (HLA Typing
{CHV,CSP,MSH,MTH,NCI,SNM,SNMI,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Processing text_000N_7494.tx.6: These factors will not be discussed further since they either do not retain independent prognostic significance in multivariate analyses that include the factors listed in Table 19.6, or prognostic significance has disappeared on contemporary intensive treatment regimens.

Phrase: These factors

>>>> Phrase

factors

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

 966 Factor {LNC,MTH,NCI} [ftcn]

<<<< Mappings

Phrase: will

>>>> Phrase

<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: discussed
>>>> Phrase
discussed
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Discuss (Discussion (communication) {ICF,ICF-CY,MTH,NCI})
 [socb]
<<<< Mappings

Phrase: further
>>>> Phrase
further
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Further {NCI} [spco]
<<<< Mappings

Phrase: since
>>>> Phrase
<<<< Phrase

Phrase: they
>>>> Phrase
<<<< Phrase

Phrase: either
>>>> Phrase
either
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Either {LNC} [fndg]
<<<< Mappings

Phrase: do
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: retain
>>>> Phrase
retain
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Retain (Retained {CHV,NCI,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: independent prognostic significance in multivariate analyses
>>>> Phrase
independent prognostic significance in multivariate analyses
<<<< Phrase
>>>> Mappings
Meta Mapping (741):
 586 Independent (Independence {CHV,LNC,MTH,NCI}) [idcn]
 586 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
 753 Significance (Significant {CHV,MTH,NCI,SNOMEDCT_US}) [idcn]
 623 Multivariate Analyses (Multivariate Analysis
 {AOD,CHV,LCH_NW,MSH}) [qnco]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: include
>>>> Phrase
include
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Include (Include (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: the factors
>>>> Phrase

```
factors
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
    966    Factor {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: listed in Table 19.6,
>>>> Phrase
listed in table 19 6
<<<< Phrase
>>>> Mappings
Meta Mapping (669):
    726    List {LNC,MTH,NCI} [inpr]
    760    Table (Table – furniture {CHV,MTH,SNMI,SNOMEDCT_US}) [mnob]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: prognostic significance
>>>> Phrase
prognostic significance
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
    694    Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
    861    Significance (Significant {CHV,MTH,NCI,SNOMEDCT_US}) [idcn]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: disappeared on contemporary intensive treatment regimens.
>>>> Phrase
disappeared on contemporary intensive treatment regimens
<<<< Phrase
>>>> Mappings
Meta Mapping (701):
    733    Treatment intent {CHV,HL7V3.0,MTH,NLMSubSyn,SNOMEDCT_US}
    [ftcn]
    753    regimens (Regimen – CHV concept {CHV,MTH}) [inpr]
<<<< Mappings
Processing text_000N_7494.tx.7: To a certain extent, intensity of
therapy has become an important prognostic factor.

Phrase: To a certain extent,
>>>> Phrase
```

certain extent
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Certain (Certain (qualifier value)
{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 861 Extent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [spco]
<<<< Mappings

Phrase: intensity of therapy
>>>> Phrase
intensity of therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 Intensity (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
 [qlco]
 623 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: become
>>>> Phrase
become
<<<< Phrase

Phrase: an important prognostic factor.
>>>> Phrase
important prognostic factor
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 660 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
 901 Prognostic Factor (Prognostic Factors {MSH,NCI,NCI_NCI-
GLOSS,NLMSubSyn}) [clna]
<<<< Mappings
Processing text_000N_7494.tx.8: As modern therapy for ALL has become
more intensive, many clinical and laboratory features that were once
important prognostic features have lost significance.

Phrase: As modern therapy for ALL
>>>> Phrase
as modern therapy for all
<<<< Phrase

```
>>>> Mappings
Meta Mapping (760):
  760 Therapy (Therapeutic procedure
  {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
  CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
  [topp]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: become
>>>> Phrase
become
<<<< Phrase

Phrase: more intensive,
>>>> Phrase
more intensive
<<<< Phrase
>>>> Mappings
Meta Mapping (838):
  694 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
  761 Intense (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
  [qlco]
<<<< Mappings

Phrase: many clinical
>>>> Phrase
clinical
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Clinical {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: laboratory
>>>> Phrase
laboratory
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 LABORATORY (Laboratory
  {CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_FDA,SNOMEDCT_US}
  ) [hcro,mnob]
```

<<<< Mappings

Phrase: features

>>>> Phrase

features

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Feature (Characteristics {MTH,NCI,NCI_NICHD}) [qlco]

<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: were

>>>> Phrase

<<<< Phrase

Phrase: once

>>>> Phrase

<<<< Phrase

Phrase: important prognostic features

>>>> Phrase

important prognostic features

<<<< Phrase

>>>> Mappings

Meta Mapping (840):

660 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]

660 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]

793 Feature (Characteristics {MTH,NCI,NCI_NICHD}) [qlco]

<<<< Mappings

Phrase: have

>>>> Phrase

<<<< Phrase

Phrase: lost significance.

>>>> Phrase

lost significance

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Lost {CHV,LNC,MTH,NCI} [ftcn]

861 Significance (Significant {CHV,MTH,NCI,SNOMEDCT_US}) [idcn]

<<<< Mappings

Processing text_000N_7494.tx.9: It is also important to recognize that cooperative groups report somewhat different prognostic factors on contemporary treatment regimens, since the specifics of each treatment

regimen affects outcomes.

Phrase: It

>>>> Phrase

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: also important

>>>> Phrase

also important

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 TO (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: recognize

>>>> Phrase

recognize

<<<< Phrase

Phrase: that cooperative groups

>>>> Phrase

cooperative groups

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Cooperative Groups (Clinical Trials Cooperative Group

{NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]

<<<< Mappings

Phrase: report

>>>> Phrase

report

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Report (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: somewhat different prognostic factors on contemporary treatment regimens,

>>>> Phrase

somewhat different prognostic factors on contemporary treatment regimens

<<<< Phrase

>>>> Mappings

Meta Mapping (714):

578 Somewhat {LNC,NCI} [fndg]

578 Different {MTH,NCI} [qlco]

770 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]

587 Treatment Regimen (Treatment Protocols

{CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [topp]

<<<< Mappings

Phrase: since

>>>> Phrase

<<<< Phrase

Phrase: the specifics of each treatment regimen

>>>> Phrase

the specifics of each treatment regimen

<<<< Phrase

>>>> Mappings

Meta Mapping (711):

719 Specific (Specific qualifier value
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

623 Treatment Regimen (Treatment Protocols

{CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [topp]

<<<< Mappings

Phrase: affects

>>>> Phrase

affects

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Affects (Affect (mental function)
{CSP,MSH,MTH,SNM,SNMI,SNOMEDCT_US}) [menp]

<<<< Mappings

Phrase: outcomes.

>>>> Phrase

outcomes

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

966 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings
Processing text_000N_7494.tx.10: Leukocyte Count and Age

Phrase: Leukocyte Count
>>>> Phrase
leukocyte count
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Leukocyte Count (White Blood Cell Count procedure
{AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
 [lbpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Age
>>>> Phrase
age
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNM,SNOMEDCT_US}) [orga]
<<<< Mappings
Processing text_000N_42328.tx.1: Because they are readily available and relatively independent predictors of prognosis, the parameters of initial leukocyte count and age at diagnosis have traditionally provided the most reliable basis for initial patient stratification, and remarkably these factors have retained significance after adjustment for other criteria even with improved cure rates in specific subgroups and the general increase in treatment intensity over the past several decades.¹⁶⁴ To facilitate comparisons of results between cooperative groups, an NCI workshop developed a set of consensus prognostic factors for age and WBC count outlined in Table 19.7 and is known as the NCI Rome criteria.

Phrase: Because
>>>> Phrase
<<<< Phrase

Phrase: they
>>>> Phrase
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: readily available
>>>> Phrase
readily available
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
861 Available (Availability of {AOD,CHV,NCI,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: relatively independent predictors of prognosis,
>>>> Phrase
relatively independent predictors of prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (779):
631 Independent of {CHV,MTH,SNMI,SNOMEDCT_US} [ftcn]
726 Predictor {NCI} [idcn]
593 Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: the parameters of initial leukocyte count
>>>> Phrase
the parameters of initial leukocyte count
<<<< Phrase
>>>> Mappings
Meta Mapping (725):
753 Parameters (Observation parameter {CHV,MTH,SNOMEDCT_US})
[fndg]
586 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
623 Leukocyte Count (White Blood Cell Count procedure
{AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
[lbpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: age at diagnosis
>>>> Phrase
age at diagnosis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Age at diagnosis {LNC,MTH,SNOMEDCT_US} [clna]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: traditionally
>>>> Phrase
traditionally
<<<< Phrase

Phrase: provided
>>>> Phrase
provided
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Provided (Providing (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: the most reliable basis for initial patient stratification,
>>>> Phrase
the most reliable basis for initial patient stratification
<<<< Phrase
>>>> Mappings
Meta Mapping (693):
 578 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
 578 reliable {HL7V3.0} [inpr]
 744 BASIS (Basis {MTH,NDFRT,RXNORM,VANDF}) [phsu]
 578 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
 [idcn]
 578 *^patient (Patients
 {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_DICOM,NCI_FD
 A,SNOMEDCT_US}) [podg]
 578 Stratification {HL7V3.0,NCI} [resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: remarkably
>>>> Phrase

remarkably
<<<< Phrase

Phrase: these factors
>>>> Phrase
factors
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Factor {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: retained significance after adjustment
>>>> Phrase
retained significance after adjustment
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 604 Retained {CHV,NCI,SNMI,SNOMEDCT_US} [ftcn]
 770 Significance (Significant {CHV,MTH,NCI,SNOMEDCT_US}) [idcn]
 604 Adjustment (Individual Adjustment
 {CHV,MSH,MTH,NLMSubSyn,SNOMEDCT_US}) [inbe]
<<<< Mappings

Phrase: for other criteria even with improved cure rates
>>>> Phrase
for other criteria even with improved cure rates
<<<< Phrase
>>>> Mappings
Meta Mapping (647):
 744 Criteria (criteria {HL7V3.0,MSH,NCI}) [idcn]
 578 Improved {CHV,LNC,MTH,SNOMEDCT_US} [fndg]
 578 Cure (Cure (remedy) {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [cnce]
 544 Rate {LNC,MTH,NCI} [qnco]
<<<< Mappings

Phrase: in specific subgroups
>>>> Phrase
specific subgroups
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Specific (Specific qualifier value
 {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 861 subgroups (Subgroup A Nepoviruses {CHV,MTH}) [virs]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: the general increase in treatment intensity over the past several decades.164

>>>> Phrase
the general increase in treatment intensity over the past several decades 164

<<<< Phrase

>>>> Mappings

Meta Mapping (634):

584 General treatment {CHV,NLMSubSyn,SNMI,SNOMEDCT_US} [hlca]
570 Increase {CHV,MTH,NCI,SNOMEDCT_US} [ftcn]
736 Intensity (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
[qlco]
570 Past (In the past {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
536 Decade {NCI} [qnco]

Meta Mapping (634):

570 General (Generalized
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
570 Increase {CHV,MTH,NCI,SNOMEDCT_US} [ftcn]
753 treatment intensity (care by level of intensity {AOD}) [qlco]
570 Past (In the past {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
536 Decade {NCI} [qnco]

Meta Mapping (634):

570 General (Generalized
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
570 Increase {CHV,MTH,NCI,SNOMEDCT_US} [ftcn]
736 Intensity (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
[qlco]
584 past treatment {CHV,NLMSubSyn} [fndg]
536 Decade {NCI} [qnco]

<<<< Mappings

Phrase: To

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: facilitate

>>>> Phrase

facilitate

<<<< Phrase

Phrase: comparisons of results

>>>> Phrase

comparisons of results

<<<< Phrase

>>>> Mappings

Meta Mapping (713):

756 Comparison {LNC,NCI} [acty]

590 Result (Experimental Result {MTH,NCI,NLMSubSyn}) [fndg]

<<<< Mappings

Phrase: between cooperative groups,

>>>> Phrase

cooperative groups

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Cooperative Groups (Clinical Trials Cooperative Group {NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]

<<<< Mappings

Phrase: an NCI workshop

>>>> Phrase

nci workshop

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 NCI (National Cancer Institute {LNC,MSH,MTH,NCI,NCI_NCI-GLOSS}) [hcro]

861 Workshop (Educational workshop {CHV,CSP,MSH,MTH}) [edac]

<<<< Mappings

Phrase: developed

>>>> Phrase

developed

<<<< Phrase

Phrase: a set of consensus prognostic factors

>>>> Phrase

a set of consensus prognostic factors

<<<< Phrase

>>>> Mappings

Meta Mapping (734):

753 Set (Set scale {LNC,MTH}) [ftcn]

586 Consensus {CHV,MSH,NCI} [socb]

586 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]

600 factor A {CHV,MSH} [orch]

<<<< Mappings

Phrase: for age

>>>> Phrase

age
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SNOMEDCT_US}) [orga]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: WBC count
>>>> Phrase
wbc count
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 WBC count (White Blood Cell Count procedure
{AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
[lbpr]
<<<< Mappings

Phrase: outlined in Table 19.7
>>>> Phrase
outlined in table 19 7
<<<< Phrase
>>>> Mappings
Meta Mapping (760):
 760 Table (Table - furniture {CHV,MTH,SNMI,SNOMEDCT_US}) [mnob]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: known as the NCI Rome criteria.
>>>> Phrase
known as the nci rome criteria
<<<< Phrase
>>>> Mappings
Meta Mapping (704):
 753 Known {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
 767 NCI Criterion {NCI} [sosy]
<<<< Mappings

Processing text_000N_42328.tx.2: Although each cooperative group remains free to stratify patients into different risk-group-directed therapy, there is also a strong commitment to record and report outcomes according to these uniformly defined criteria, so that the results can be more easily compared across studies.

Phrase: Although

>>>> Phrase

<<<< Phrase

Phrase: each cooperative group

>>>> Phrase

cooperative group

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Cooperative Group (Clinical Trials Cooperative Group {NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]

<<<< Mappings

Phrase: remains

>>>> Phrase

remains

<<<< Phrase

Phrase: free

>>>> Phrase

free

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Free (Free (available (qualifier)) {LNC,MTH}) [qlco]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: stratify

>>>> Phrase

stratify

<<<< Phrase

Phrase: patients into different risk-group-directed therapy,

>>>> Phrase

patients into different risk group directed therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (743):

 748 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

 581 Different {MTH,NCI} [qlco]

 612 risk Group (Population at Risk {CHV,MSH,MTH,NCI,NLMSubSyn})

[popg]

 562 directive therapy {AOD} [topp]

<<<< Mappings

Phrase: there

>>>> Phrase

there

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: also

>>>> Phrase

also

<<<< Phrase

Phrase: a strong commitment

>>>> Phrase

strong commitment

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 Strong {CHV,LNC,NCI,SNOMEDCT_US} [qlco]

 861 commitment {CHV} [menp]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 To {MTH,NCI} [qlco]

<<<< Mappings

Phrase: record

>>>> Phrase

record

<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  Record (Records {CHV,HL7V3.0,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA})
[inpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: report outcomes according to these uniformly defined criteria,
>>>> Phrase
report outcomes according to these uniformly defined criteria
<<<< Phrase
>>>> Mappings
Meta Mapping (664):
  578  Report (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
  711  Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]
    578  according (Agreement {AOD,CHV,MTH,NCI}) [socb]
    578  Defined (Definition {HL7V3.0,MTH,NCI,NCI_CareLex}) [inpr]
    578  Criteria (criteria {HL7V3.0,MSH,NCI}) [idcn]
<<<< Mappings

Phrase: so
>>>> Phrase
so
<<<< Phrase

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: the results
>>>> Phrase
results
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Result (Experimental Result {MTH,NCI,NLMSubSyn}) [fndg]
<<<< Mappings

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase
```

Phrase: more
>>>> Phrase
more
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: easily
>>>> Phrase
easily
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Easily (Easy {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: compared across studies.

>>>> Phrase
compared across studies
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 Compared (Comparison {LNC,NCI}) [acty]
 790 studies (Scientific Study {CHV,MTH}) [lbpr]
<<<< Mappings

Processing text_000N_45297.tx.1: There is a linear relation between the initial leukocyte count and outcome in B-ALL, with higher leukocyte counts associated with a poorer prognosis, although this difference is not observed in T-ALL.¹⁷⁰ The NCI Rome criteria identify patients with an initial leukocyte count greater than or equal to 50,000 cells per mm³ (approximately 20% of children with ALL) as high risk and those less than 50,000 as standard risk.

Phrase: There
>>>> Phrase
there
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: a linear relation between the initial leukocyte count
>>>> Phrase
a linear relation between the initial leukocyte count
<<<< Phrase
>>>> Mappings
Meta Mapping (688):

```
578 Linear {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [spco]
744 Relation (Relative (related person)
{AOD,CHV,MSH,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [famg]
578 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
604 Leukocyte Count (White Blood Cell Count procedure
{AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
[lbpr]
<<<< Mappings
```

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: outcome in B-ALL,

```
>>>> Phrase
outcome in b all
<<<< Phrase
```

>>>> Mappings
Meta Mapping (770):

```
770 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings
```

Phrase: with higher leukocyte counts

```
>>>> Phrase
higher leukocyte counts
<<<< Phrase
>>>> Mappings  
Meta Mapping (983):
```

```
983 high Leukocyte Counts (White blood cell count increased (lab
result)
{CHV,COSTAR,CST,DXP,ICD10CM,ICD9CM,MTH,NCI,NCI_CTCAE,NCI_NICHD,NLMSubS
yn,OMIM,SNOMEDCT_US}) [fndg]
<<<< Mappings
```

Phrase: associated with a poorer prognosis,

```
>>>> Phrase
associated with a poorer prognosis
<<<< Phrase
>>>> Mappings  
Meta Mapping (771):
```

```
806 Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
790 Poor prognosis (Prognosis bad
{CHV,NLMSubSyn,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings
```

Phrase: although
>>>> Phrase
<<<< Phrase

Phrase: this difference
>>>> Phrase
difference
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: observed in T-ALL.170
>>>> Phrase
observed in t all 170
<<<< Phrase
>>>> Mappings
Meta Mapping (760):
 760 Observed {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: The NCI Rome criteria
>>>> Phrase
nci rome criteria
<<<< Phrase
>>>> Mappings
Meta Mapping (896):
 896 N NCI Criterion {NCI} [sosy]
<<<< Mappings

Phrase: identify
>>>> Phrase
identify
<<<< Phrase

Phrase: patients with an initial leukocyte count
>>>> Phrase
patients with an initial leukocyte count
<<<< Phrase

```
>>>> Mappings
Meta Mapping (725):
    753 Patients
    {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
     A,SNOMEDCT_US} [podg]
        586 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
        [idcn]
            623 Leukocyte Count (White Blood Cell Count procedure
            {AOD,CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
            [lbpr]
<<<< Mappings
```

Phrase: greater than

```
>>>> Phrase
greater than
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Greater Than {MTH,NCI,SNOMEDCT_US} [qnco]
<<<< Mappings
```

Phrase: or

```
>>>> Phrase
<<<< Phrase
```

Phrase: equal to 50,000 cells

```
>>>> Phrase
equal to 50 000 cells
<<<< Phrase
>>>> Mappings
Meta Mapping (761):
    806 Equal To (Equal {CHV,HL7V3.0,MTH,NCI,SNMI,SNOMEDCT_US})
    [qlco]
        593 <50 {LNC} [fndg]
        593 CELLS (Cell Count
        {CHV,CSP,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNOMEDCT_US}) [lbpr]
<<<< Mappings
```

Phrase: per mm3

```
>>>> Phrase
mm3
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 mm3 (Cubic Millimeter {CHV,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_NCI-
     GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]
<<<< Mappings
```

Phrase: (approximately 20% of children

```
>>>> Phrase
```

approximately 20 of children

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

 770 Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
[qlco]

 770 20% {LNC} [qnco]

 770 Children (Offspring
{AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]

<<<< Mappings

Phrase: with ALL

>>>> Phrase

all

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 ALL (All

 {CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: as high risk

>>>> Phrase

high risk

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 HIGH RISK (High risk of

 {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: those less than 50,000

>>>> Phrase

those less than 50 000

<<<< Phrase

>>>> Mappings

Meta Mapping (926):

 926 Less than \$50,000 {LNC} [fndg]

<<<< Mappings

Phrase: as standard risk.

>>>> Phrase

standard risk
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Standard Risk (Standard Risk Acute Leukemia {NCI}) [hlca]
<<<< Mappings
Processing text_000N_45297.tx.2: The biologic basis for higher initial leukocyte counts is unclear, although there are definite associations between certain biologic features and this pattern of presentation.

Phrase: The biologic basis for higher initial leukocyte counts
>>>> Phrase
the biologic basis for higher initial leukocyte counts
<<<< Phrase
>>>> Mappings
Meta Mapping (727):
 578 Biologic (biological {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US}) [qlco]
 744 BASIS (Basis {MTH,NDFRT,RXNORM,VANDF}) [phsu]
 610 high Leukocyte Counts (White blood cell count increased (lab result)
 {CHV,COSTAR,CST,DXP,ICD10CM,ICD9CM,MTH,NCI,NCI_CTCAE,NCI_NICHLD,NLMSubS
 yn,OMIM,SNOMEDCT_US}) [fndg]
 578 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
 [idcn]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: unclear,
>>>> Phrase
unclear
<<<< Phrase

Phrase: although
>>>> Phrase
<<<< Phrase

Phrase: there
>>>> Phrase
there
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: definite associations between certain biologic features

```
>>>> Phrase
definite associations between certain biologic features
<<<< Phrase
>>>> Mappings
Meta Mapping (702):
  586  Definite {CHV,LNC,MTH,SNOMEDCT_US} [qlco]
  753  Associations (Mental association
{CHV,CSP,MSH,MTH,SNM,SNOMEDCT_US}) [menp]
  514  Certainty (Certain (qualifier value)
{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
  586  Biologic (biological {CHV,MTH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [qlco]
  553  Feature (Characteristics {MTH,NCI,NCI_NICHED}) [qlco]
<<<< Mappings
```

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: this pattern of presentation.

```
>>>> Phrase
this pattern of presentation
<<<< Phrase
>>>> Mappings
Meta Mapping (819):
  819  Pattern presentation {SNOMEDCT_US} [spco]
<<<< Mappings
Processing text_000N_45297.tx.3: Patients with T-ALL and infants with
t(4;11) often have a high initial leukocyte count.
```

Phrase: Patients with T-ALL
>>>> Phrase
patients with t all
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
 770 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: infants with t(4
>>>> Phrase
infants with t 4
<<<< Phrase
>>>> Mappings

Meta Mapping (770):
770 Infants (Infant
{AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,
SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: ;11
>>>> Phrase
11
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: often
>>>> Phrase
often
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Often (Frequently {CHV,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US})
[tmco]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: a high initial leukocyte count.
>>>> Phrase
high initial leukocyte count
<<<< Phrase
>>>> Mappings
Meta Mapping (916):

923 high Leukocyte count (White blood cell count increased (lab
result)
{CHV,COSTAR,CST,DXP,ICD10CM,ICD9CM,MTH,NCI,NCI_CTCAE,NCI_NICHHD,NLMSubS
yn,OMIM,SNOMEDCT_US}) [fndg]
645 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
<<<< Mappings
Processing text_000N_45297.tx.4: For age, NCI Rome criteria define
absolute cut-offs of <1 year of age and 10 years of age as bearing an
inferior prognosis compared with children in the intermediate age
group (1 to 10 years).

Phrase: For age,
>>>> Phrase
age

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SN
OMEDCT_US}) [orga]
<<<< Mappings

Phrase: NCI Rome criteria
>>>> Phrase
nci rome criteria
<<<< Phrase
>>>> Mappings
Meta Mapping (896):
  896  NCI Criterion {NCI} [sosy]
<<<< Mappings

Phrase: define
>>>> Phrase
define
<<<< Phrase

Phrase: absolute cut-offs of
>>>> Phrase
absolute cut offs of
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
  604  ABSOLUTE (Absolute {CHV,NCI,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
  770  Cut (Incised wound
{CHV,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [inpo]
<<<< Mappings

Phrase: <1 year of age
>>>> Phrase
1 year of age
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
  604  1+ (1+ Score, WHO {MTH,NCI}) [clas]
  770  /Year (per year {CHV,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [tmco]
  604  AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SN
OMEDCT_US}) [orga]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase
```

Phrase: 10 years of age

>>>> Phrase

10 years of age

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

833 < 10 years (Life Expectancy Less than Ten Years {NCI}) [inpr]

604 AGE (Age

{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SNOMEDCT_US}) [orga]

Meta Mapping (783):

604 10% {LNC} [qnco]

819 Age-Years {NCI,NCI_NCPDP} [tmco]

<<<< Mappings

Phrase: as bearing

>>>> Phrase

bearing

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Bearing (Bearing Device Component {MTH,NCI,NCI_FDA}) [medd]

<<<< Mappings

Phrase: an inferior prognosis

>>>> Phrase

inferior prognosis

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 inferior (inferiority {AOD,CHV,MTH}) [socb]

861 Prognosis (Forecast of outcome

{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]

<<<< Mappings

Phrase: compared with children

>>>> Phrase

compared with children

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 Compared (Comparison {LNC,NCI}) [acty]

790 Children (Offspring

{AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]

<<<< Mappings

Phrase: in the intermediate age group

>>>> Phrase

intermediate age group

```
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
  660  Intermediate (Observation Interpretation - intermediate
{HL7V3.0,MTH}) [lbtr]
  901  Age Group (Human Age Group
{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn}) [aggp]
<<<< Mappings

Phrase: (1 to 10 years
>>>> Phrase
1 to 10 years
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
  819  1-10 {LNC} [fndg]
  770  YEARS (year
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
Meta Mapping (783):
  770  1+ (1+ Score, WHO {MTH,NCI}) [clas]
  833  < 10 years (Life Expectancy Less than Ten Years {NCI}) [inpr]
<<<< Mappings

Phrase: .
>>>> Phrase
<<<< Phrase
Processing text_000N_45297.tx.5: For patients above age 10, there is a
continuous relationship between increasing age at diagnosis and
outcome.1 In infant ALL (below 1 year of age), prognosis is poorest
for infants below 3 months of age (with EFS that remains <30%),
intermediate in the 3-to-6-month age group, and best in those 6 to 12
months of age.171 Infants have an increased incidence of other poor
prognostic features, including high initial leukocyte count, CNS
involvement, MLL rearrangement, and slow response to treatment.

Phrase: For patients above age 10,
>>>> Phrase
for patients above age 10
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  760  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
  593  AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SN
OMEDCT_US}) [orga]
  593  10% {LNC} [qnc]
<<<< Mappings
```

Phrase: there
>>>> Phrase
there
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: a continuous relationship between increasing age
>>>> Phrase
a continuous relationship between increasing age
<<<< Phrase
>>>> Mappings
Meta Mapping (691):
 586 CONTINUOUS (Continuous
 {CHV,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,SNMI,SNOMEDCT_US}) [idcn]
 753 Relationship (Relationships
 {CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
 586 Increasing {CHV,SNOMEDCT_US} [ftcn]
 586 AGE (Age
 {AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SNOMEDCT_US}) [orga]
<<<< Mappings

Phrase: at diagnosis
>>>> Phrase
diagnosis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 DIAGNOSIS (Diagnosis
 {AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: outcome.1 In infant ALL
>>>> Phrase
outcome 1 in infant all
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
 760 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US}) [ftcn]
 760 INFANT (Infant
 {AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,NDFRT,NLMSubSyn,

```
SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: below 1 year of age
>>>> Phrase
below 1 year of age
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  593  1+ (1+ Score, WHO {MTH,NCI}) [clas]
  760  /Year (per year {CHV,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [tmco]
  593  AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SN
OMEDCT_US}) [orga]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: prognosis
>>>> Phrase
prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: poorest for infants
>>>> Phrase
poorest for infants
<<<< Phrase
>>>> Mappings
Meta Mapping (730):
  756  Poor (Poor - qualifier {LNC,MTH,NCI,NCI_FDA}) [qlco]
```

623 Infants (Infant
{AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,NDFRT,NLMSubSyn,
SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: below 3 months of age

>>>> Phrase

below 3 months of age

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

806 3 Months {HL7V2.5,LNC,MTH} [tmco]

593 AGE (Age

{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SNMI,SN
OMEDCT_US}) [orga]

Meta Mapping (745):

593 <3 (<3 (qualifier value) {MTH,SNOMEDCT_US}) [qnco]

797 Age-Months {NCI,NCI_NCPDP} [orga]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: with EFS

>>>> Phrase

efs

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 EFS (Disease-Free Survival {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]

<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: remains

>>>> Phrase

remains

<<<< Phrase

Phrase: <30%

>>>> Phrase

30

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 30% {LNC} [qnco]

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: intermediate in the 3-to-6-month age group,
>>>> Phrase

intermediate in the 3 to 6 month age group

<<<< Phrase

>>>> Mappings

Meta Mapping (671):

742 Intermediate (Observation Interpretation – intermediate {HL7V3.0,MTH}) [lbtr]
575 Month (month {CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
598 Age Group (Human Age Group {CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn}) [aggp]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: best in those 6

>>>> Phrase

best in those 6

<<<< Phrase

>>>> Mappings

Meta Mapping (770):

770 Best (best (quality) {MTH,NCI}) [qlco]

<<<< Mappings

Phrase: to 12 months of age.171 Infants

>>>> Phrase

to 12 months of age 171 infants

<<<< Phrase

>>>> Mappings

Meta Mapping (701):

774 Age-Months {NCI,NCI_NCPDP} [orga]
581 Infants (Infant {AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,SNOMEDCT_US}) [aggp]

<<<< Mappings

Phrase: have

```
>>>> Phrase
<<<< Phrase

Phrase: an increased incidence of other poor prognostic features,
>>>> Phrase
an increased incidence of other poor prognostic features
<<<< Phrase
>>>> Mappings
Meta Mapping (664):
    578 Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
    744 Incidence {AOD,CHV,MSH,MTH,NCI,NCI_NCI-GLOSS} [qnc]
    578 Poor (Poor - qualifier {LNC,MTH,NCI,NCI_FDA}) [qlco]
    578 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
    544 Feature (Characteristics {MTH,NCI,NCI_NICH}) [qlco]
<<<< Mappings

Phrase: including
>>>> Phrase
including
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Including (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})
    [ftcn]
<<<< Mappings

Phrase: high initial leukocyte count,
>>>> Phrase
high initial leukocyte count
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
    923 high Leukocyte count (White blood cell count increased (lab
    result)
    {CHV,COSTAR,CST,DXP,ICD10CM,ICD9CM,MTH,NCI,NCI_CTCAE,NCI_NICH,NLMSubS
    yn,OMIM,SNOMEDCT_US}) [fndg]
    645 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
    [idcn]
<<<< Mappings

Phrase: CNS involvement,
>>>> Phrase
cns involvement
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 cns involvement (Central nervous system (CNS) metastases
    (tumor staging) {CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [clas]
<<<< Mappings
```

Phrase: MLL rearrangement,
>>>> Phrase
mll rearrangement
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 Rearrangement (DNA Sequence Rearrangement
 {LNC,NCI,NLMSubSyn}) [genf]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: slow response to treatment.
>>>> Phrase
slow response to treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
 604 Slow {AOD,CHV,LNC,NCI,SNOMEDCT_US} [qlco]
 909 Response to treatment {CHV,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}
 [crna]
<<<< Mappings
Processing text_000N_45297.tx.6: Infants below 3 months of age with
MLL rearrangement have the poorest prognosis.

Phrase: Infants below 3 months of age
>>>> Phrase
infants below 3 months of age
<<<< Phrase
>>>> Mappings
Meta Mapping (716):
 753 Infants (Infant
 {AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,
 SNOMEDCT_US}) [aggp]
 617 Age-Months {NCI,NCI_NCPDP} [orga]
<<<< Mappings

Phrase: with MLL rearrangement
>>>> Phrase
mll rearrangement
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 Rearrangement (DNA Sequence Rearrangement
 {LNC,NCI,NLMSubSyn}) [genf]
<<<< Mappings

Phrase: have

```
>>>> Phrase
<<<< Phrase

Phrase: the poorest prognosis.
>>>> Phrase
poorest prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (983):
    983 Poor prognosis (Prognosis bad
{CHV,NLMSubSyn,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings
Processing text_000N_45297.tx.7: Because of their poor prognosis,
infants are stratified separately from other early B-ALL patients for
treatment (see further details in Treatment section).

Phrase: Because of their poor prognosis,
>>>> Phrase
poor prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Poor prognosis (Prognosis bad
{CHV,NLMSubSyn,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: infants
>>>> Phrase
infants
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Infants (Infant
{AOD,CHV,DXP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NICHD,NDFRT,NLMSubSyn,
SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: stratified
>>>> Phrase
stratified
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Stratified {CHV,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings
```

Phrase: separately from other early B-ALL patients

>>>> Phrase
separately from other early b all patients

<<<< Phrase

>>>> Mappings

Meta Mapping (663):

748 Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US} [tmco]
748 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: for treatment

>>>> Phrase
treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: see

>>>> Phrase
see

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 see (Vision {AOD,CHV,CSP,G0,ICF,ICF-
CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [orgf]

<<<< Mappings

Phrase: further details in Treatment section

>>>> Phrase
further details in treatment section

<<<< Phrase

>>>> Mappings

Meta Mapping (757):

637 Further {NCI} [spco]
637 Details {LNC,MTH,NCI} [qlco]
637 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

804 Section (section sample {MTH,NCI,NLMSubSyn}) [sbst]
Meta Mapping (574):
637 Further {NCI} [spco]
637 Details {LNC,MTH,NCI} [qlco]
637 Treatment (Therapeutic procedure)
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase:).
>>>> Phrase
<<<< Phrase
Processing text_000N_45297.tx.8: Genetic Alterations

Phrase: Genetic Alterations

>>>> Phrase
genetic alterations

<<<< Phrase
>>>> Mappings

Meta Mapping (983):

983 Genetic Alteration (Molecular Genetic Abnormality
{LNC,MTH,NCI,NLMSubSyn}) [fndg]

<<<< Mappings

Processing text_000N_9253.tx.1: As discussed in the Molecular Genetics
section, ALL is characterized by recurrent genetic lesions, a number
of which have significant prognostic impact.

Phrase: As
>>>> Phrase
<<<< Phrase

Phrase: discussed in the Molecular Genetics

>>>> Phrase
discussed in the molecular genetics

<<<< Phrase
>>>> Mappings

Meta Mapping (729):

726 Discuss (Discussion (communication) {ICF,ICF-CY,MTH,NCI})
[socb]

806 Molecular Genetics (Molecular Genetics (discipline)
{AOD,CHV,CSP,MSH,MTH,NCI,NLMSubSyn}) [bmod]

<<<< Mappings

Phrase: section
>>>> Phrase
section
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

```
1000  Section (section sample {MTH,NCI,NLMSubSyn}) [sbst]
<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: ALL
>>>> Phrase
all
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  ALL (All
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: characterized by recurrent genetic lesions,
>>>> Phrase
characterized by recurrent genetic lesions
<<<< Phrase
>>>> Mappings
Meta Mapping (740):
 760  Characterized (Characterization {NCI}) [acty]
 760  Recurrent (Episodic {HPO,MTH,OMIM,SNMI,SNOMEDCT_US}) [qlco]
 765  genital lesions (Lesion of genitalia
{CHV,HL7V2.5,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: a number of which
>>>> Phrase
a number of which
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
 770  *Number (Numbers
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_UCUM,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: significant prognostic impact.
>>>> Phrase
significant prognostic impact
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
  660  Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
  660  Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
  827  IMPACT (IMPACT gene {HGNC,MTH,OMIM}) [gngm]
<<<< Mappings
Processing text_000N_9253.tx.2: Favorable and unfavorable genetic
features are discussed in detail in that section, and summarized in
Table 19.1.

Phrase: Favorable
>>>> Phrase
favorable
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Favorable {NCI} [qlco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: unfavorable genetic features
>>>> Phrase
unfavorable genetic features
<<<< Phrase
>>>> Mappings
Meta Mapping (866):
  660  Unfavorable {NCI} [qlco]
  848  Gene Feature {MTH,NCI,NLMSubSyn} [gngm]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: discussed in detail
>>>> Phrase
discussed in detail
<<<< Phrase
>>>> Mappings
Meta Mapping (730):
  756  Discuss (Discussion (communication) {ICF,ICF-CY,MTH,NCI})
[socb]
  790  Detail (Details {LNC,MTH,NCI}) [qlco]
<<<< Mappings

Phrase: in
```

```
>>>> Phrase
<<<< Phrase

Phrase: that section,
>>>> Phrase
section
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Section (section sample {MTH,NCI,NLMSubSyn}) [sbst]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: summarized in Table 19.1.
>>>> Phrase
summarized in table 19 1
<<<< Phrase
>>>> Mappings
Meta Mapping (760):
  760  Table (Table - furniture {CHV,MTH,SNMI,SNOMEDCT_US}) [mnob]
<<<< Mappings
Processing text_000N_13066.tx.1: Gender

Phrase: Gender
>>>> Phrase
gender
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Gender (sex
{CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_NICHHD,SNMI,SNOME
DCT_US}) [orga]
<<<< Mappings
Processing text_000N_9781.tx.1: The prognostic importance of gender
has been well documented (see also Epidemiology section), with girls
having a better prognosis than boys.

Phrase: The prognostic importance of gender
>>>> Phrase
the prognostic importance of gender
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
  593  Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
  688  Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
  593  Gender (sex
{CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_NICHHD,SNMI,SNOME
```

DCT_US}) [orga]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: well documented

>>>> Phrase
well documented

<<<< Phrase
>>>> Mappings

Meta Mapping (888):

861 Well (Good {CHV,LNC,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
861 Documented (Document completion status – Documented
{HL7V2.5,HL7V3.0,MTH}) [inpr]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: see

>>>> Phrase

see

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 see (Vision {AOD,CHV,CSP,G0,ICF,ICF-CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [orgf]

<<<< Mappings

Phrase: also Epidemiology section

>>>> Phrase

also epidemiology section

<<<< Phrase

>>>> Mappings

Meta Mapping (790):

660 epidemiology (epidemiologic {MSH,MTH}) [ftcn]
827 Section (section sample {MTH,NCI,NLMSubSyn}) [sbst]

Meta Mapping (660):

660 epidemiology (epidemiologic {MSH,MTH}) [ftcn]

<<<< Mappings

Phrase:)

>>>> Phrase

```
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: with girls
>>>> Phrase
girls
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  girls (Female child {CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: having
>>>> Phrase
<<<< Phrase

Phrase: a better prognosis than boys.
>>>> Phrase
a better prognosis than boys
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  593  Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US} [qlco]
  760  Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
  593  Boys {CHV,MSH,NLMSubSyn,SNOMEDCT_US} [aggp]
<<<< Mappings
Processing text_000N_9781.tx.2: This difference has persisted but
narrowed significantly on modern chemotherapy protocols, with a
survival advantage for girls of only 1.1% on the most recently
completed COG ALL trials.1 Potential explanations include the risk of
testicular relapse, the higher incidence of T-ALL and lower incidence
of hyperdiploidy in boys versus girls, and possibly other still
undefined biologic, endocrine, and metabolic differences.

Phrase: This difference
>>>> Phrase
difference
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]
<<<< Mappings

Phrase: has
>>>> Phrase
```

<<<< Phrase

Phrase: persisted

>>>> Phrase

persisted

<<<< Phrase

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: narrowed

>>>> Phrase

narrowed

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Narrowed (Narrow

{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: significantly on modern chemotherapy protocols,

>>>> Phrase

significantly on modern chemotherapy protocols

<<<< Phrase

>>>> Mappings

Meta Mapping (806):

806 Chemotherapy Protocols (Antineoplastic Chemotherapy Protocols
{MSH,NLMSubSyn}) [topp]

<<<< Mappings

Phrase: with a survival advantage for girls of only 1.1%

>>>> Phrase

with a survival advantage for girls of only 1 1

<<<< Phrase

>>>> Mappings

Meta Mapping (460):

573 Survival (Continuance of life

{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]

573 girls (Female child {CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [aggp]

573 Only (Singular {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})

[qnco]

<<<< Mappings

Phrase: on the most recently completed COG ALL trials.1 Potential explanations

>>>> Phrase

most recently completed cog all trials 1 potential explanations

<<<< Phrase

>>>> Mappings

Meta Mapping (737):

700 MOST-1 (C8orf17 gene {HGNC,MTH,OMIM}) [gngm]
624 Recently (Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
624 COMPLETED (Complete
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
591 Trial (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NC_I-GLOSS,SNOMEDCT_US}) [resal]
624 Potential (potential {CHV,HL7V3.0,NCI}) [qlco]
791 Explanations (explanation {AOD,CHV,LNC,NCI}) [inpr]

Meta Mapping (737):

624 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
624 Recently (Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
624 COMPLETED (Complete
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
624 Trial 1 {LNC,NLMSubSyn} [fndg]
624 Potential (potential {CHV,HL7V3.0,NCI}) [qlco]
791 Explanations (explanation {AOD,CHV,LNC,NCI}) [inpr]

<<<< Mappings

Phrase: include

>>>> Phrase

include

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 include (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})
[ftcn]

<<<< Mappings

Phrase: the risk of testicular relapse,

>>>> Phrase

the risk of testicular relapse

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

760 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
593 Testicular (Testiculo- {CHV,MTH,SNMI}) [spco]
593 relapse (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: the higher incidence of T-ALL

>>>> Phrase

the higher incidence of t all

<<<< Phrase

>>>> Mappings

Meta Mapping (679):

586 Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
753 incidence (incidence of cases {MSH,MTH}) [ftcn]

<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: lower incidence of hyperdiploidy
>>>> Phrase
lower incidence of hyperdiploidy
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 604 LOWER (Lower – spatial qualifier
 {CHV,LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [spco]
 770 incidence (incidence of cases {MSH,MTH}) [ftcn]
 604 Hyperdiploidy (Hyperploidy {NCI,SNM,SNMI,SNOMEDCT_US}) [comd]
<<<< Mappings

Phrase: in boys
>>>> Phrase
boys
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Boys {CHV,MSH,NLMSubSyn,SNOMEDCT_US} [aggp]
<<<< Mappings

Phrase: versus
>>>> Phrase
<<<< Phrase

Phrase: girls,
>>>> Phrase
girls
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 girls (Female child {CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: possibly
>>>> Phrase
possibly
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Possibly (Possible diagnosis {MTH,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: other still undefined biologic, endocrine,

>>>> Phrase

still undefined biologic endocrine

<<<< Phrase

>>>> Mappings

Meta Mapping (775):

645 undefined {CHV} [idcn]

645 BIOLOGIC (Biological Factors

{CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-GLOSS,NCI_NICHED,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US}) [bacs]

812 Endocrine (Endocrine system

{AOD,CHV,CSP,CST,FMA,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsy]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: metabolic differences.

>>>> Phrase

metabolic differences

<<<< Phrase

>>>> Mappings

Meta Mapping (872):

694 Metabolic (Metabolic Process, Cellular {GO,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [celf]

827 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnc0]

<<<< Mappings

Processing text_000N_9781.tx.3: Immunophenotype

Phrase: Immunophenotype

>>>> Phrase

immunophenotype

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Immunophenotype (Immunophenotyping

{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Processing text_000N_9741.tx.1: Survival has been and remains significantly better in B-ALL compared with T-ALL, although the difference has narrowed considerably; there was a 10% survival difference reported for patients treated on COG trials between 2000 and 2005.1 Other specific immunophenotypic features are no longer commonly used to assess prognosis, as they tend to be associated with genetic alterations, which are more stable prognostic markers.

Phrase: Survival
>>>> Phrase
survival
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Survival (Continuance of life
 {CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: remains
>>>> Phrase
remains
<<<< Phrase

Phrase: significantly better in B-ALL
>>>> Phrase
significantly better in b all
<<<< Phrase
>>>> Mappings
Meta Mapping (760):
 760 Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: compared with T-ALL,
>>>> Phrase
compared with t all
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
 770 Compared (Comparison {LNC,NCI}) [acty]
<<<< Mappings

Phrase: although
>>>> Phrase
<<<< Phrase

Phrase: the difference

```
>>>> Phrase
difference
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: narrowed
>>>> Phrase
narrowed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Narrowed (Narrow
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: considerably
>>>> Phrase
considerably
<<<< Phrase

Phrase: ;
>>>> Phrase
<<<< Phrase

Phrase: there
>>>> Phrase
there
<<<< Phrase

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: a 10% survival difference
>>>> Phrase
a 10% survival difference
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
  694  A-10 (antineoplaston A10
{CHV,DRUGBANK,MSH,MTH,NCI,NCI_DCP,NCI_FDA,PDQ}) [orch,phsu]
  645  Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
```

```
812 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnc]
<<<< Mappings

Phrase: reported for patients
>>>> Phrase
reported for patients
<<<< Phrase
>>>> Mappings
Meta Mapping (858):
  858 Reported patients (Informing patient
{CHV,NLMSubSyn,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: treated on COG trials
>>>> Phrase
treated on cog trials
<<<< Phrase
>>>> Mappings
Meta Mapping (691):
  770 Treated (Treating {CHV,MTH,NCI}) [ftcn]
  737 Trial (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI
I-GLOSS,SNOMEDCT_US}) [resa]
<<<< Mappings

Phrase: between 2000
>>>> Phrase
2000
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 2000 {LNC,MTH,SNOMEDCT_US} [qnc]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: 2005.1
>>>> Phrase
2005 1
<<<< Phrase

Phrase: Other specific immunophenotypic features
>>>> Phrase
specific immunophenotypic features
<<<< Phrase
>>>> Mappings
Meta Mapping (816):
  660 Specific (Specific qualifier value
```

```
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 589  Immunophenotype (Immunophenotyping
{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]
 793  Feature (Array Feature {MTH,NCI,NLMSubSyn}) [cnce]
<<<< Mappings
```

```
Phrase: are
>>>> Phrase
<<<< Phrase
```

```
Phrase: no longer
>>>> Phrase
longer
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966  LONG (Long {CHV,MTH,NCI,NCI_CDISC,OMIM,SNMI,SNOMEDCT_US})
[qlco]
<<<< Mappings
```

```
Phrase: commonly
>>>> Phrase
commonly
<<<< Phrase
```

```
Phrase: used
>>>> Phrase
used
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 N used (Used by {CHV,SNOMEDCT_US}) [fndg]
<<<< Mappings
```

```
Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]
<<<< Mappings
```

```
Phrase: assess
>>>> Phrase
assess
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
```

```
1000 Assess (Assessed {MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: prognosis,
>>>> Phrase
prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: as
>>>> Phrase
<<<< Phrase

Phrase: they
>>>> Phrase
<<<< Phrase

Phrase: tend
>>>> Phrase
tend
<<<< Phrase

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]
<<<< Mappings

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: associated with genetic alterations,
>>>> Phrase
associated with genetic alterations
<<<< Phrase
>>>> Mappings
Meta Mapping (880):
833 Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
816 Genetic Alteration (Mutation
{AOD,CHV,CSP,LNC,MSH,MTH,SNM,SNMI,SNOMEDCT_US}) [genf]
```

<<<< Mappings

Phrase: which

>>>> Phrase

<<<< Phrase

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: more stable prognostic markers.

>>>> Phrase

more stable prognostic markers

<<<< Phrase

>>>> Mappings

Meta Mapping (852):

645 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

645 ~~Stable (Patient Condition Code – Stable {HL7V2.5,MTH}) [inpr]~~

844 Prognostic Marker {NCI,NLMSubSyn} [qlco]

<<<< Mappings

Processing text_000N_9741.tx.2: Specific immunophenotypic markers do continue to retain importance as targets for specific therapeutic agents, for example, the monoclonal antibodies epratuzumab (anti-CD22), alemtuzumab (anti-CD52), moxetumomab (anti-CD22), and rituximab (anti-CD20); the bispecific T-cell engager blinatumomab (with a target binding site for CD19); and chimeric antigen receptor-modified T cells directed against CD19.

Phrase: Specific immunophenotypic markers

>>>> Phrase

specific immunophenotypic markers

<<<< Phrase

>>>> Mappings

Meta Mapping (816):

660 Specific (Specific qualifier value

{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

589 Immunophenotype (Immunophenotyping

{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]

793 Marker (Biological Markers

{AOD,CHV,CSP,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,PDQ}) [clna]

<<<< Mappings

Phrase: do

>>>> Phrase

<<<< Phrase

Phrase: continue

>>>> Phrase

continue

<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  Continue (Continuous
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,SNMI,SNOMEDCT_US}) [idcn]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: retain
>>>> Phrase
retain
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Retain (Retained {CHV,NCI,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: importance as targets
>>>> Phrase
importance as targets
<<<< Phrase
>>>> Mappings
Meta Mapping (694):
  718  Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
  590  Target {MTH,NCI} [ftcn]
<<<< Mappings

Phrase: for specific therapeutic agents,
>>>> Phrase
specific therapeutic agents
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
  660  Specific (Specific qualifier value
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
  901  therapeutic agents (Therapeutic agent
{CHV,HL7V3.0,MTH,NLMSubSyn}) [mnob]
<<<< Mappings

Phrase: for example,
>>>> Phrase
example
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Example {NCI} [cnce]
<<<< Mappings

Phrase: the monoclonal antibodies epratuzumab
>>>> Phrase
monoclonal antibodies epratuzumab
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 734  Antibodies, Monoclonal (Monoclonal Antibodies
{CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,imft]
 827  EPRATUZUMAB (epratuzumab
{DRUGBANK,MSH,MTH,NCI,NCI_FDA,NCI_NCI-GLOSS,PDQ}) [aapp,phsu]
<<<< Mappings

Phrase: (anti-CD22
>>>> Phrase
anti cd22
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861  CD22 (CD22 protein, human {LNC,MSH,MTH,NCI,NCI_NCI-GLOSS})
[aapp,imft]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: alemtuzumab
>>>> Phrase
alemtuzumab
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  ALEMTUZUMAB (alemtuzumab
{ATC,CHV,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: (anti-CD52
>>>> Phrase
```

anti cd52
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: moxetumomab
>>>> Phrase
moxetumomab
<<<< Phrase

Phrase: (anti-CD22
>>>> Phrase
anti cd22
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
861 CD22 (CD22 protein, human {LNC,MSH,MTH,NCI,NCI_NCI-GLOSS})
[aapp,imft]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: rituximab
>>>> Phrase
rituximab
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 RITUXIMAB (rituximab
{ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: (anti-CD20

```
>>>> Phrase
anti cd20
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861  CD20 (CD20 Expressing Cell Measurement {MTH,NCI,NCI_CDISC})
 [lbpr]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ;
>>>> Phrase
<<<< Phrase

Phrase: the bispecific T-cell engager blinatumomab
>>>> Phrase
bispecific t cell engager blinatumomab
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 673  T Cell (T-Lymphocyte
 {AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
 GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
 804  BLINATUMOMAB (blinatumomab
 {ATC,DRUGBANK,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,PDQ,RXNORM,SNOMEDCT_US,
 VANDF}) [aapp,imft,phsu]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: with a target binding site for CD19
>>>> Phrase
with a target binding site for cd19
<<<< Phrase
>>>> Mappings
Meta Mapping (701):
 774  Target site (Destination site {LNC,NLMSubSyn}) [spco]
 748  Binding (Binding (Molecular Function)
 {AOD,CHV,GO,LNC,MTH,NCI}) [moft]
 581  CD19+ (CD19 Positive {NCI}) [lbtr]
Meta Mapping (701):
 581  Target {MTH,NCI} [ftcn]
 778  Binding site (Binding Sites
 {CHV,CSP,MSH,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}) [rcpt]
 581  CD19+ (CD19 Positive {NCI}) [lbtr]
```

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ;
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: chimeric antigen receptor-modified T cells

>>>> Phrase
chimeric antigen receptor modified t cells
<<<< Phrase
>>>> Mappings
Meta Mapping (864):
694 Chimeric Antigen Receptor (Chimeric antigen receptor
{MTH,NCI,SNOMEDCT_US}) [aapp,imft,rcpt]
632 Modified (Changing
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [ftcn]
827 T cells (T-Lymphocyte
{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]
<<<< Mappings

Phrase: directed against CD19.

>>>> Phrase
directed against cd19
<<<< Phrase
>>>> Mappings
Meta Mapping (730):
756 Direct (Direct type of relationship {CHV,MTH,SNOMEDCT_US})
[qlco]
790 CD19+ (CD19 Positive {NCI}) [lbtr]
<<<< Mappings
Processing text_000N_9741.tx.3: Race and Ethnicity

Phrase: Race

>>>> Phrase
race
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 RACE (Racial group
{AOD,CHV,CSP,HL7V2.5,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDISC,
NCI_FDA,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [popg]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: **Ethnicity**

>>>> Phrase

ethnicity

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Ethnicity (Ethnic group
{AOD,CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NICHD,NL
MSubSyn,SNMI,SNOMEDCT_US}) [popg]

<<<< Mappings

Processing text_000N_8144.tx.1: Older studies reported significantly poorer outcomes in African American and Hispanic patients compared with Caucasians and Asians after adjusting for potential confounders including age, gender, treatment era, and socioeconomic status, for example, large CCG and POG studies that provided data on 8,447 and 5,086 patients diagnosed and treated from the early 1980s to mid-1990s.^{14,172} These patterns were confirmed in a study using SEER epidemiologic data on 4,952 ALL patients, which also found that African American, Hispanic, and American Indian/Alaskan Native children have a worse outcome than whites or Asian/Pacific Islanders.¹⁷³ These race-and-ethnicity-based survival differences have persisted but narrowed significantly in more recent years (Fig. 19.3).^{1,174} In a genome-wide association study examining association of SNPs with ALL relapse risk in 2,534 children, Native American ancestry was associated with an increased risk of relapse, although encouragingly, intensification of therapy mitigated the risk (Fig. 19.4).¹⁷⁵ The basis for racial and ethnic differences in ALL outcome is likely multifactorial,²¹ affected by differences in socioeconomic status, access to care, and compliance with therapy³¹; as well as biologic differences in chemosensitivity of leukemic blasts and host pharmacogenetic factors affecting chemotherapy exposure.¹⁷⁵ Response to Treatment and MRD

Phrase: Older studies

>>>> Phrase

older studies

<<<< Phrase

>>>> Mappings

Meta Mapping (872):

661 Old {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]

861 studies (Scientific Study {CHV,MTH}) [lbpr]

<<<< Mappings

Phrase: reported

```
>>>> Phrase
reported
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Reported (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: significantly poorer outcomes in African American
>>>> Phrase
significantly poorer outcomes in african american
<<<< Phrase
>>>> Mappings
Meta Mapping (724):
  756  Poor outcome {NLMSubSyn,OMIM} [fndg]
  623  AFRICAN AMERICAN (African American
{AOD,CHV,CSP,DXP,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,NLMS
ubSyn,SNMI,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: Hispanic patients
>>>> Phrase
hispanic patients
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  HISPANIC (Hispanics
{AOD,CHV,DXP,HL7V3.0,LNC,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [popg]
  861  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US}) [podg]
<<<< Mappings

Phrase: compared with Caucasians
>>>> Phrase
compared with caucasians
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
  790  Compared (Comparison {LNC,NCI}) [acty]
  790  Caucasians (Caucasoid Race
{AOD,CHV,CSP,DXP,HL7V3.0,LCH_NW,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,NCI_FDA,
NLMSubSyn,SNMI,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: and
```

```
>>>> Phrase
<<<< Phrase

Phrase: Asians after adjusting
>>>> Phrase
asians after adjusting
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
    790    Asians
{AOD,CHV,CSP,DXP,HL7V2.5,HL7V3.0,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDISC,NCI
_FDA,SNOMEDCT_US} [popg]
<<<< Mappings

Phrase: for potential confounders
>>>> Phrase
potential confounders
<<<< Phrase
>>>> Mappings
Meta Mapping (694):
    694    Potential (potential {CHV,HL7V3.0,NCI}) [qlco]
<<<< Mappings

Phrase: including
>>>> Phrase
including
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    Including (Including (qualifier) {CHV,MTH,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: age,
>>>> Phrase
age
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000    AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SN
OMEDCT_US}) [orga]
<<<< Mappings

Phrase: gender,
>>>> Phrase
gender
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
```

1000 Gender
{AOD,CHV,CSP,LNC,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNOMEDCT_US} [orga]
<<<< Mappings

Phrase: treatment era,
>>>> Phrase
treatment era
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHID,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
861 ERA (Enthesitis-Related Arthritis {MTH,NCI,NCI_NICHID,NDFRT})
[dsyn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: socioeconomic status,
>>>> Phrase
socioeconomic status
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Socioeconomic Status {AOD,CHV,HL7V3.0,MSH,MTH,NCI,NLMSubSyn}
[qlco]
<<<< Mappings

Phrase: for example,
>>>> Phrase
example
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Example {NCI} [cnce]
<<<< Mappings

Phrase: large CCG
>>>> Phrase
large ccg
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 LARGE (Large {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[qnco]
861 CCG (Children's Cancer Group {LNC,NCI}) [hcro]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: POG

>>>> Phrase

pog

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 POG (Pediatric Oncology Group {LNC,MTH,NCI}) [hcro]

<<<< Mappings

Phrase: studies

>>>> Phrase

studies

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 studies (Scientific Study {CHV,MTH}) [lbpr]

<<<< Mappings

Phrase: that provided data on 8,447

>>>> Phrase

that provided data on 8 447

<<<< Phrase

>>>> Mappings

Meta Mapping (679):

586 Provided (Providing (action) {MTH,NCI}) [acty]

753 Data {MTH,NCI} [idcn]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: 5,086 patients

>>>> Phrase

5 086 patients

<<<< Phrase

>>>> Mappings

Meta Mapping (802):

660 >5 {SNOMEDCT_US} [qnco]

827 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: diagnosed
>>>> Phrase
diagnosed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Diagnosed (Diagnosis
 {AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_<<<< NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: treated from the early 1980s
>>>> Phrase
treated from the early 1980s
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
 760 Treated (Treating {CHV,MTH,NCI}) [ftcn]
 760 Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US} [tmco]
 760 1980s {AOD} [tmco]
<<<< Mappings

Phrase: to mid-1990s.14,172
>>>> Phrase
mid 1990s 14 172
<<<< Phrase
>>>> Mappings
Meta Mapping (750):
 812 Mid (Middle {CHV,FMA,LNC,MTH,NCI,SNMI,SNOMEDCT_US,UWDA})
 [spco]
 812 1990s {AOD} [tmco]
<<<< Mappings

Phrase: These patterns
>>>> Phrase
patterns
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Patterns {AOD,CHV,NCI,SNOMEDCT_US} [spco]
<<<< Mappings

Phrase: were
>>>> Phrase
<<<< Phrase

Phrase: confirmed in a study
>>>> Phrase
confirmed in a study
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 confirmed (Confirmed by {CHV,MTH,SNMI,SNOMEDCT_US}) [qlco]
 770 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: using
>>>> Phrase
using
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Using (Use of {MTH,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: SEER epidemiologic data on 4,952 ALL patients,
>>>> Phrase
seer epidemiologic data on 4 952 all patients
<<<< Phrase
>>>> Mappings
Meta Mapping (675):
 578 SEER (Surveillance, Epidemiology, and End Results (SEER)
 Program {CHV,LNC,MSH,MTH,NCI}) [hcro]
 578 epidemiologic {MSH,MTH} [ftcn]
 750 Patient data {LNC} [inpr]
<<<< Mappings

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: found
>>>> Phrase
found
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Found (Present {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
 [fndg]
<<<< Mappings

Phrase: that African American, Hispanic,
>>>> Phrase
african american hispanic
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 734 AFRICAN AMERICAN (African American
 {AOD,CHV,CSP,DXP,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,NLMS
 ubSyn,SNMI,SNOMEDCT_US}) [popg]
 827 HISPANIC (Hispanics
 {AOD,CHV,DXP,HL7V3.0,LNC,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: American Indian/Alaskan Native children

>>>> Phrase
american indian alaskan native children
<<<< Phrase
>>>> Mappings
Meta Mapping (840):
 708 American native (Native American Healing {CHV,MTH}) [topp]
 637 INDIAN (Asian Indian
 {CHV,DXP,HL7V3.0,LCH,LNC,MTH,NCI,NCI_CDC,SNMI,SNOMEDCT_US}) [popg]
 637 ALASKAN (alaskan {CHV,DXP}) [popg]
 804 Children (Offspring
 {AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDSC,NCI_NCI-GLOSS}) [famg]
 Meta Mapping (840):
 673 AMERICAN INDIAN (American Indians
 {AOD,CHV,CSP,DXP,HL7V3.0,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,SNMI,SNOMED
 CT_US}) [popg]
 637 ALASKAN (alaskan {CHV,DXP}) [popg]
 637 Native (Native (qualifier value) {CHV,MTH,NCI,SNOMEDCT_US})
 [ftcn]
 804 Children (Offspring
 {AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDSC,NCI_NCI-GLOSS}) [famg]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: a worse outcome than whites

>>>> Phrase
a worse outcome than whites
<<<< Phrase
>>>> Mappings
Meta Mapping (696):

593 Worse (Deterioration of status {MTH,SNOMEDCT_US}) [fndg]
760 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US}) [ftcn]
593 Whites (Caucasoid Race
{AOD,CHV,CSP,DXP,HL7V3.0,LCH_NW,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,NCI_FDA,
NLMSubSyn,SNMI,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: Asian/Pacific Islanders.173

>>>> Phrase
asian pacific islanders 173
<<<< Phrase
>>>> Mappings
Meta Mapping (824):
812 ASIAN (Asians
{AOD,CHV,CSP,DXP,HL7V2.5,HL7V3.0,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,NCI_FDA,SNOMEDCT_US}) [popg]
861 Pacific Islanders (Pacific Islander Americans
{AOD,CHV,CSP,LNC,MSH}) [popg]
<<<< Mappings

Phrase: These race-

>>>> Phrase
race
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 RACE (Racial group
{AOD,CHV,CSP,HL7V2.5,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDSC,NCI_FDA,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: and-

>>>> Phrase

<<<< Phrase

Phrase: ethnicity-based survival differences

>>>> Phrase
ethnicity based survival differences
<<<< Phrase
>>>> Mappings
Meta Mapping (843):
867 ethnic differences {AOD,CHV,CSP,NLMSubSyn} [fndg]
645 Based (Basis - conceptual entity {MTH,NCI}) [ftcn]
645 Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]

<<<< Mappings

Phrase: have

>>>> Phrase

<<<< Phrase

Phrase: persisted

>>>> Phrase

persisted

<<<< Phrase

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: narrowed

>>>> Phrase

narrowed

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Narrowed (Narrow

{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: significantly in more recent years

>>>> Phrase

significantly in more recent years

<<<< Phrase

>>>> Mappings

Meta Mapping (695):

 760 Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]

 760 YEARS (year

{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: (Fig. 19.3

>>>> Phrase

fig 19 3

<<<< Phrase

>>>> Mappings

Meta Mapping (827):

 827 FIG (Fig Flavor {MTH,NCI,NCI_FDA}) [food]

<<<< Mappings

Phrase:).1,174 In a genome-wide association study examining
association of SNPs

>>>> Phrase

1 174 **in a genome wide association study examining association of snps**

<<<< Phrase

>>>> Mappings
Meta Mapping (704):
736 1+ (1+ Score {MTH,NCI}) [qnco]
790 Genome-Wide Association Study {MSH,NCI,NCI_NCI-GLOSS} [mbrt]
736 examining (Examined {CHV,MTH,NCI}) [fndg]
736 SNPs (Single Nucleotide Polymorphism
{CHV,CSP,MSH,MTH,NCI,NCI_NCI-GLOSS}) [nusq]
<<<< Mappings

Phrase: with ALL relapse risk in 2,534 children,
>>>> Phrase

with all relapse risk in 2 534 children

<<<< Phrase

>>>> Mappings

Meta Mapping (678):

578 ALL (All
{CHV,HL7V3.0,HP0,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
578 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]
744 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
584 Child 2 {LNC,NLMSubSyn} [famg]

<<<< Mappings

Phrase: Native American ancestry

>>>> Phrase

native american ancestry

<<<< Phrase

>>>> Mappings

Meta Mapping (734):

734 NATIVE AMERICAN (Native Americans
{AOD,CHV,CSP,DXP,HL7V3.0,LNC,MSH,MTH}) [popg]

<<<< Mappings

Phrase: was

>>>> Phrase

<<<< Phrase

Phrase: associated with an increased risk of relapse,

>>>> Phrase

associated with an increased risk of relapse

<<<< Phrase

>>>> Mappings

Meta Mapping (701):

778 Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
748 Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
748 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
748 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]

<<<< Mappings

Phrase: although

>>>> Phrase

<<<< Phrase

Phrase: encouragingly,

>>>> Phrase

encouragingly

<<<< Phrase

Phrase: intensification of therapy

>>>> Phrase

intensification of therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (858):

858 intensification therapy (consolidation therapy {CHV,NCI,NCI_NCI-GLOSS}) [topp]

<<<< Mappings

Phrase: mitigated

>>>> Phrase

mitigated

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

966 Mitigate {HL7V3.0,NCI,NCI_NCI-GLOSS} [phpr]

<<<< Mappings

Phrase: the risk

>>>> Phrase

risk

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]

<<<< Mappings

Phrase: (Fig. 19.4

>>>> Phrase

fig 19 4

<<<< Phrase

>>>> Mappings

Meta Mapping (827):

827 FIG (Fig Flavor {MTH,NCI,NCI_FDA}) [food]

<<<< Mappings

Phrase:).175

>>>> Phrase

175

<<<< Phrase

Phrase: The basis for racial

```
>>>> Phrase
the basis for racial
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
  770 Basis (Basis - conceptual entity {MTH,NCI}) [ftcn]
  532 Races (Racial group
{AOD,CHV,CSP,HL7V2.5,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDC,NCI_CDISC,
NCI_FDA,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: ethnic differences in ALL outcome
>>>> Phrase
ethnic differences in all outcome
<<<< Phrase
>>>> Mappings
Meta Mapping (745):
  806 ethnic differences {AOD,CHV,CSP,NLMSubSyn} [fndg]
  593 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: likely multifactorial,21
>>>> Phrase
likely multifactorial 21
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
  827 Likely (Probably {CHV,LNC,MTH,NCI}) [idcn]
  827 Multifactorial {OMIM} [fndg]
<<<< Mappings

Phrase: affected by differences
>>>> Phrase
affected by differences
<<<< Phrase
>>>> Mappings
Meta Mapping (730):
  790 Affected (Affecting {MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US})
[ftcn]
  756 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnc]
<<<< Mappings
```

Phrase: in socioeconomic status,
>>>> Phrase
socioeconomic status
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Socioeconomic Status {AOD,CHV,HL7V3.0,MSH,MTH,NCI,NLMSubSyn}
 [qlco]
<<<< Mappings

Phrase: access
>>>> Phrase
access
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 access (Role Class – access {HL7V3.0,MTH}) [ftcn]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 T0 (Tryptophanase
 {CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: care
>>>> Phrase
care
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Care (care activity {MTH,NCI}) [acty]
<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: compliance with therapy31
>>>> Phrase
compliance with therapy31

```
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
  790  COMPLIANCE (Compliance behavior
{AOD,AOT,CHV,COSTAR,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNOMEDCT_US}) [inbe]
<<<< Mappings

Phrase: ;
>>>> Phrase
<<<< Phrase

Phrase: as well as
>>>> Phrase
<<<< Phrase

Phrase: biologic differences in chemosensitivity of leukemic blasts
>>>> Phrase
  biologic differences in chemosensitivity of leukemic blasts
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
  581  BIOLOGIC (Biological Factors
{CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-
GLOSS,NCI_NICHD,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US}) [bacs]
  714  *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnc]
  581  Chemosensitivity {NCI,NCI_NCI-GLOSS} [fnfg]
  612  Leukemic Blasts (Leukemic Blast Count
{MTH,NCI,NCI_CDISC,NLMSubSyn}) [lbpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: host
>>>> Phrase
  host
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Host (Host (organism) {CHV,GO,MTH,NCI}) [orgm]
<<<< Mappings

Phrase: pharmacogenetic factors
>>>> Phrase
  pharmacogenetic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
```

694 pharmacogenetic (Pharmacogenetics
{CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [bmod]
827 Factor {LNC,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: affecting
>>>> Phrase
affecting
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Affecting {MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US} [ftcn]
<<<< Mappings

Phrase: chemotherapy exposure.175 Response to Treatment

>>>> Phrase
chemotherapy exposure 175 response to treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (776):
586 Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
586 Exposure (Exposure to
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_DICOM,SNM,SNMI,SNOMEDCT_US}) [qlco]
833 Response to treatment {CHV,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}
[clna]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: MRD
>>>> Phrase
mrd
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDVRT,NLMSubSyn}) [neop]
<<<< Mappings
Processing text_000N_10055.tx.1: Rapidity of response to treatment is
a very important indicator of prognosis.

Phrase: Rapidity of response
>>>> Phrase
rapidity of response
<<<< Phrase
>>>> Mappings

Meta Mapping (711):
718 Rapid {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US} [qlco]
623 Response (Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn})
[fndg]
<<<< Mappings

Phrase: to treatment
>>>> Phrase
treatment
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: a very important indicator of prognosis.
>>>> Phrase
a very important indicator of prognosis
<<<< Phrase
>>>> Mappings

Meta Mapping (725):
623 Very Important {LNC,NCI} [fndg]
753 indicator (Indicators {CHV,MSH,MTH}) [irda]
586 Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]

Meta Mapping (555):
623 Very Important {LNC,NCI} [fndg]
586 Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Processing text_000N_10055.tx.2: Failure to achieve complete remission within the usual 4-to-6-week induction period, known as induction failure, has long been recognized as having a high rate of relapse and shortened survival.

Phrase: Failure
>>>> Phrase
failure
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

```
    1000  failure (Personal failure {AOD,CHV,MTH}) [inbe]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: achieve
>>>> Phrase
achieve
<<<< Phrase

Phrase: complete remission within the usual 4-to-6-week induction
period,
>>>> Phrase
complete remission within the usual 4 to 6 week induction period
<<<< Phrase
>>>> Mappings
Meta Mapping (653):
    756  Complete Remission (In complete remission
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fndg]
    571  Usual {LNC,MTH,NCI} [qlco]
    571  /week (Weekly
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,SNMI,SNOMEDCT_US}) [tmco]
    571  Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
    571  Period (Period (temporal qualifier)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
Meta Mapping (653):
    738  COMPLETE (Complete
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,SNMI,SNOMEDCT_US}) [qlco]
    754  Induction, Remission (Remission Induction
{CHV,MSH,NLMSubSyn}) [topp]
    571  Usual {LNC,MTH,NCI} [qlco]
    571  /week (Weekly
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,SNMI,SNOMEDCT_US}) [tmco]
    571  Period (Period (temporal qualifier)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: known as induction failure,
>>>> Phrase
known as induction failure
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (733):
  770  Known {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
  770  Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
  [ftcn]
  770  failure (Personal failure {AOD,CHV,MTH}) [inbe]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: long
>>>> Phrase
long
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  LONG (Long {CHV,MTH,NCI,NCI_CDISC,OMIM,SNMI,SNOMEDCT_US})
  [qlco]
<<<< Mappings

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: recognized
>>>> Phrase
recognized
<<<< Phrase

Phrase: as
>>>> Phrase
<<<< Phrase

Phrase: having
>>>> Phrase
<<<< Phrase

Phrase: a high rate of relapse
>>>> Phrase
a high rate of relapse
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
  760  High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
  760  Rate {LNC,MTH,NCI} [qnco]
  593  relapse (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
<<<< Mappings
```

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: shortened survival.

>>>> Phrase
shortened survival
<<<< Phrase
>>>> Mappings
Meta Mapping (888):

694 Shortened {CHV,MTH,SNMI,SNOMEDCT_US} [qlco]
861 Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings
Processing text_000N_10055.tx.3: Multiple groups have shown the prognostic importance of the rapidity of clearance of blasts in peripheral blood and bone marrow during induction therapy, measured after 1 or 2 weeks of therapy.^{2,176} In recent years, measurement of MRD using flow cytometry or PCR amplification of antigen receptor genes has supplanted early morphologic assessment of the bone marrow and assumed increasing importance in risk-stratification schemes.¹⁷⁷ Generally, the faster a patient is rendered MRD negative, the better the prognosis.

Phrase: Multiple groups

>>>> Phrase
multiple groups
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 MULTIPLE (Numerous
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
861 Group (Population Group
{CHV,LNC,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: shown
>>>> Phrase
shown
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
966 Show {HL7V2.5,HL7V3.0} [anim]
<<<< Mappings

Phrase: the prognostic importance of the rapidity of clearance of

blasts
>>>> Phrase
the prognostic importance of the rapidity of clearance of blasts

<<<< Phrase

>>>> Mappings

Meta Mapping (606):

573 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
668 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
501 Rapid {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US} [qlco]
573 Clearance (Clearance [PK] {MTH,NDFRT}) [npop]
573 Blasts (Blast Cell {AOD,CHV,FMA,LNC,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [cell]

<<<< Mappings

Phrase: in peripheral blood

>>>> Phrase

peripheral blood

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Peripheral Blood (peripheral blood
{CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: bone marrow during induction therapy,

>>>> Phrase

bone marrow during induction therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (779):

806 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]
640 Induction Therapy (Neoadjuvant Therapy {CHV,MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn,PDQ}) [topp]

<<<< Mappings

Phrase: measured after 1

>>>> Phrase

measured after 1

<<<< Phrase

>>>> Mappings

Meta Mapping (790):

790 Measured {CHV,LNC,MTH,NCI,NCI_FDA,SNOMEDCT_US} [qlco]

<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: 2 weeks of therapy.2,176

>>>> Phrase
2 weeks of therapy 2 176

<<<< Phrase
>>>> Mappings
Meta Mapping (722):

790 2 Weeks {HL7V2.5,MTH} [tmco]
586 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: In recent years,

>>>> Phrase
recent years
<<<< Phrase
>>>> Mappings

Meta Mapping (888):

694 Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
861 YEARS (year
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: measurement of MRD

>>>> Phrase
measurement of mrd
<<<< Phrase
>>>> Mappings

Meta Mapping (746):

790 MEASUREMENT (Measurement
{AOD,CHV,CSP,LCH,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,NLMSubSyn,SNOMEDCT_US}
) [ftcn]
623 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
<<<< Mappings

Phrase: using

>>>> Phrase
using
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Using (Use of {MTH,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: flow cytometry

>>>> Phrase

flow cytometry

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 FLOW CYTOMETRY (Flow Cytometry
{CHV,CSP,LCH,LCH_NW,LNC,MSH,NCI,NCI_CDSC,NCI_NCI-GLOSS,PDQ,SNMI,SNOMEDCT_US}) [lbpr]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: PCR amplification of antigen receptor genes

>>>> Phrase

pcr amplification of antigen receptor genes

<<<< Phrase

>>>> Mappings

Meta Mapping (752):

586 PCR (Polymerase Chain Reaction
{AOD,CHV,CSP,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_NCI-GLOSS,PDQ,SNOMEDCT_US}) [mbrt]

623 Antigen Receptor (Receptors, Antigen
{AOD,CHV,CSP,MSH,NCI,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US})
[aapp,imft,rcpt]

767 Gene Amplification (Gene Amplification Abnormality {MTH,NCI})
[comd]

<<<< Mappings

Phrase: has

>>>> Phrase

<<<< Phrase

Phrase: supplanted

>>>> Phrase

supplanted

<<<< Phrase

Phrase: early morphologic assessment of the bone marrow

>>>> Phrase

early morphologic assessment of the bone marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (728):

581 Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US} [tmco]

510 Morphology {CHV,CSP,LCH,LNC,MTH,SNOMEDCT_US} [qlco]

804 bone marrow Assessment (bone marrow assessments {NLMSubSyn})
[lbpr]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: assumed increasing importance in risk-stratification schemes.

177 Generally,

>>>> Phrase

assumed increasing importance in risk stratification schemes 177

generally

<<<< Phrase

>>>> Mappings

Meta Mapping (655):

575 Assumed {HL7V3.0} [inpr]

575 Increasing {CHV,SNOMEDCT_US} [ftcn]

670 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]

575 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]

575 Stratification {HL7V3.0,NCI} [resa]

542 Scheme {NCI} [inpr]

<<<< Mappings

Phrase: the faster

>>>> Phrase

faster

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

966 Fast (Rapid {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: a patient

>>>> Phrase

patient

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 *^patient (Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US}) [podg]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: rendered

>>>> Phrase

rendered

<<<< Phrase

Phrase: MRD negative,
>>>> Phrase
mrd negative
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 MRD Negative (Minimal Residual Disease Negativity
{NCI,NCI_CDISC}) [fndg]
<<<< Mappings

Phrase: the better
>>>> Phrase
better
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: the prognosis.
>>>> Phrase
prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Prognosis (Forecast of outcome
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings
Processing text_000N_10055.tx.4: MRD levels that are undetectable or
at least less than 104 at the end of a standard induction (or
preferably earlier) are associated with the best prognosis (Fig.
19.13).176,178 Persistent or rising MRD at later time points after
induction is associated with a poor outcome both for newly diagnosed
ALL and also for relapsed patients treated with salvage chemotherapy
or hematopoietic stem cell transplant (HSCT).166,177

Phrase: MRD levels
>>>> Phrase
mrd levels
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDVRT,NLMSubSyn}) [neop]
 861 Levels (Levels (qualifier value)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: undetectable
>>>> Phrase
undetectable
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Undetectable {NCI} [cIna]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: at least less than 104
>>>> Phrase
at least less than 104
<<<< Phrase

Phrase: at the end of a standard induction
>>>> Phrase
at the end of a standard induction
<<<< Phrase
>>>> Mappings
Meta Mapping (656):
 748 End (Stop (qualifier value) {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
 581 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
 581 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
 [ftcn]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: preferably earlier
>>>> Phrase
preferably earlier
<<<< Phrase

```
>>>> Mappings
Meta Mapping (861):
  861  Earlier (Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US})
  [tmco]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: associated with the best prognosis
>>>> Phrase
  associated with the best prognosis
<<<< Phrase
>>>> Mappings
Meta Mapping (752):
  806  Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
  760  Best (best (quality) {MTH,NCI}) [qlco]
  760  Prognosis (Forecast of outcome
  {AOD,CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
  GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: (Fig. 19.13
>>>> Phrase
  fig 19 13
<<<< Phrase
>>>> Mappings
Meta Mapping (827):
  827  FIG (Fig Flavor {MTH,NCI,NCI_FDA}) [food]
<<<< Mappings

Phrase: ).176,178 Persistent
>>>> Phrase
  176 178 persistent
<<<< Phrase
>>>> Mappings
Meta Mapping (827):
  827  Persistent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: rising MRD at later time points
```

```
>>>> Phrase
rising mrd at later time points
<<<< Phrase
>>>> Mappings
Meta Mapping (724):
    553 RiSE (Relational and Item-Specific Encoding Task {MTH,NCI})
[inpr]
    753 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
    586 Later (Late {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
    590 Time Point (Timepoint {MTH,NCI}) [tmco]
<<<< Mappings

Phrase: after induction
>>>> Phrase
induction
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: associated with a poor outcome
>>>> Phrase
associated with a poor outcome
<<<< Phrase
>>>> Mappings
Meta Mapping (779):
    806 Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
    806 Poor outcome {NLMSubSyn,OMIM} [fndg]
<<<< Mappings

Phrase: both for newly diagnosed ALL
>>>> Phrase
both for newly diagnosed all
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
    760 newly {CHV} [idcn]
    760 Diagnosed (Diagnosis
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_
NCI-GLOSS,NCI_NICHD,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: and
```

```
>>>> Phrase
<<<< Phrase

Phrase: also for relapsed patients
>>>> Phrase
also for relapsed patients
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
    770    relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
    770    Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: treated with salvage chemotherapy
>>>> Phrase
treated with salvage chemotherapy
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
    833    Treated with {MTH,SNMI,SNOMEDCT_US} [topp]
    770    SALVAGE (Salvage Therapy {CHV,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS}) [topp]
    770    Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: hematopoietic stem cell transplant (HSCT).166,177
>>>> Phrase
hematopoietic stem cell transplant 166 177
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
    901    Haematopoietic stem cell transplant {NLMSubSyn} [hlca]
<<<< Mappings
Processing text_000N_8184.tx.1: The two main techniques used currently
for MRD detection are flow cytometric identification of aberrant
immunophenotypes and PCR amplification of immunoglobulin or TCR genes,
or of leukemia-specific fusion transcripts, where applicable.179 Real-
time PCR can detect as few as one leukemic cell in 105 to 106 normal
bone marrow cells, and flow cytometry approximately 104 to 105.179
Flow cytometry has the added advantage of detecting intact cells, in
contrast to PCR, in which contaminating nucleic acid material from
dead cells can complicate interpretation.
```

Phrase: The two main techniques

>>>> Phrase

two main techniques

<<<< Phrase

>>>> Mappings

Meta Mapping (851):

660 Two {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

660 Main {MTH,NCI} [qlco]

827 techniques (Methods aspects {MSH,MTH,NLMSubSyn}) [ftcn]

<<<< Mappings

Phrase: used

>>>> Phrase

used

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 used (Used by {CHV,SNOMEDCT_US}) [fndg]

<<<< Mappings

Phrase: currently for MRD detection

>>>> Phrase

currently for mrd detection

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

770 Currently (Current (present time)
{CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]

770 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]

770 Detection {MTH,NCI} [topp]

<<<< Mappings

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: flow cytometric identification of aberrant immunophenotypes

>>>> Phrase

flow cytometric identification of aberrant immunophenotypes

<<<< Phrase

>>>> Mappings

Meta Mapping (720):

587 Flow Cytometries (Flow Cytometry
{CHV,CSP,LCH,LCH_NW,LNC,MSH,NCI,NCI_CDISC,NCI_NCI-GLOSS,PDQ,SNMI,SNOMEDCT_US}) [lbpr]

753 Identification (Identified
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_NICHHD,SNMI,SNOMEDCT_US}) [qlco]

586 Aberrant {CHV,SNOMEDCT_US} [qlco]

553 Immunophenotype (Immunophenotyping
{CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: PCR amplification of immunoglobulin

>>>> Phrase
pcr amplification of immunoglobulin

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

604 PCR (Polymerase Chain Reaction
{AOD,CHV,CSP,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,PDQ,SNOMEDCT_US}) [mbrt]

770 Amplification (Gene Amplification Technique
{MTH,NCI,NLMSubSyn}) [mbrt]

604 Immunoglobulin (Immunoglobulins
{AOD,ATC,CHV,CSP,CVX,FMA,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,PDQ,SNM,SNMI,SNOMEDCT_US,UWDA,VANDF}) [aapp,imft]

<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: TCR genes,

>>>> Phrase

tcr genes

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 TcR Genes (Genes, T-Cell Receptor {LCH_NW,MSH,NCI,NLMSubSyn})
[gngm]

<<<< Mappings

Phrase: or of leukemia-specific fusion transcripts,

>>>> Phrase

or of leukemia specific fusion transcripts

<<<< Phrase

>>>> Mappings

Meta Mapping (735):

753 LEUKEMIA (leukemia
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICHHD,NDFRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
[neop]

753 Specific (Specific qualifier value

```
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
    773    fusion transcript {LNC} [bacs,nnon]
<<<< Mappings

Phrase: where applicable.179 Real-time PCR
>>>> Phrase
where applicable 179 real time pcr
<<<< Phrase
>>>> Mappings
Meta Mapping (817):
    632    applicable (Not Applicable
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_UCUM,SNOMEDCT_US})
[qlco]
    861    Real Time PCR (Real-Time Polymerase Chain Reaction
{MSH,MTH,NCI,NCI_CDISC,NLMSubSyn}) [mbrt]
<<<< Mappings

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: detect as few
>>>> Phrase
detect as few
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
    790    detect (Detected (finding) {CHV,HL7V3.0,LNC,MTH,SNOMEDCT_US})
[fndg]
<<<< Mappings

Phrase: as one leukemic cell in 105
>>>> Phrase
as one leukemic cell in 105
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
    586    ONE (One {LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
    790    Leukemic Cell {MTH,NCI} [cell]
<<<< Mappings

Phrase: to 106 normal bone marrow cells,
>>>> Phrase
106 normal bone marrow cells
<<<< Phrase
>>>> Mappings
Meta Mapping (854):
    637    NORMAL (Normal
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
    884    Bone Marrow Cells {CHV,FMA,LCH_NW,MSH,NCI,NLMSubSyn} [cell]
```

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: flow cytometry approximately 104 to 105.179 Flow cytometry

>>>> Phrase

flow cytometry approximately 104 to 105 179 flow cytometry

<<<< Phrase

>>>> Mappings

Meta Mapping (691):

764 FLOW CYTOMETRY (Flow Cytometry
{CHV,CSP,LCH,LCH_NW,LNC,MSH,NCI,NCI_CDISC,NCI_NCI-GLOSS,PDQ,SNMI,SNOMEDCT_US}) [lbpr]

742 Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
[qlco]

<<<< Mappings

Phrase: has

>>>> Phrase

<<<< Phrase

Phrase: the added advantage of detecting intact cells,

>>>> Phrase

the added advantage of detecting intact cells

<<<< Phrase

>>>> Mappings

Meta Mapping (517):

581 Added (Additional {LNC,MTH,NCI}) [ftcn]

548 detect (Detected (finding) {CHV,HL7V3.0,LNC,MTH,SNOMEDCT_US})
[fndg]

595 intact cell {AOD} [cell]

<<<< Mappings

Phrase: in contrast to PCR,

>>>> Phrase

pcr

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 PCR (Polymerase Chain Reaction
{AOD,CHV,CSP,HL7V3.0,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,PDQ,SNOMEDCT_US}) [mbrt]

<<<< Mappings

Phrase: in which

>>>> Phrase

<<<< Phrase

Phrase: contaminating

>>>> Phrase

contaminating

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

 966 contaminate (Contaminated {CHV,MTH,SNMI,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Phrase: nucleic acid material from dead cells

>>>> Phrase

nucleic acid material from dead cells

<<<< Phrase

>>>> Mappings

Meta Mapping (741):

 623 Nucleic Acid (Nucleic Acids
 {AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_FDA,NDFRT,SNM,SNMI,SNOMEDCT_US
 }) [bacs,nnon]

 753 Material (Materials
 {CHV,CSP,HL7V3.0,LCH_NW,LNC,MTH,NCI,NCI_BRIDG,SNOMEDCT_US}) [sbst]

 586 DEAD (Cessation of life
 {AOD,CHV,CSP,CST,ICPC,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_CTCAE,NCI_FDA,NCI_NCI-GLOSS,NCI_NICH,NDFT,SNOMEDCT_US}) [orgf]

 586 Cells {CHV,CSP,FMA,GO,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_UCUM,NDFT,SNM,SNMI,SNOMEDCT_US,UWDA} [cell]

<<<< Mappings

Phrase: can

>>>> Phrase

<<<< Phrase

Phrase: complicate

>>>> Phrase

complicate

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 complicate (Complicated {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
 [ftcn]

<<<< Mappings

Phrase: interpretation.

>>>> Phrase

interpretation

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 INTERPRETATION (Interpretation Process
 {CHV,LNC,MTH,NCI,NCI_CDSC,SNOMEDCT_US}) [inpr]

<<<< Mappings

Processing text_000N_8184.tx.2: Both are limited somewhat because the dominant immunophenotype and/or Ig/TCR rearrangement can evolve over time and hence escape recognition.

Phrase: Both

>>>> Phrase

<<<< Phrase

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: limited

>>>> Phrase

limited

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Limited (Limited (extensiveness) {CHV,LNC,MTH,SNOMEDCT_US})
 [ftcn]

<<<< Mappings

Phrase: somewhat

>>>> Phrase

somewhat

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Somewhat {LNC,NCI} [fndg]
<<<< Mappings

Phrase: because

>>>> Phrase

<<<< Phrase

Phrase: the dominant immunophenotype

>>>> Phrase

dominant immunophenotype

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 Dominant {MTH,NCI} [ftcn]
 861 Immunophenotype (Immunophenotyping
 {CHV,CSP,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: and/or

>>>> Phrase

<<<< Phrase

Phrase: Ig/TCR rearrangement
>>>> Phrase
ig tcr rearrangement
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
 660 IG (Immunoglobulins
 {AOD,ATC,CHV,CSP,CVX,FMA,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NC
 I_NCI-GLOSS,NDFRT,PDQ,SNM,SNMI,SNOMEDCT_US,UWDA,VANDF}) [aapp,imft]
 660 TCR (T-Cell Receptor
 {CHV,CSP,LCH_NW,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US})
 [aapp,imft,rcpt]
 827 Rearrangement (DNA Sequence Rearrangement
 {LNC,NCI,NLMSubSyn}) [genf]
<<<< Mappings

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: evolve over time
>>>> Phrase
evolve over time
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790 TIME (Time
 {CHV,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NICHHD,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: hence
>>>> Phrase
hence
<<<< Phrase

Phrase: escape
>>>> Phrase
escape
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 escape (Escape (mental process) {CHV,MTH}) [menp]
<<<< Mappings

Phrase: recognition.
>>>> Phrase

recognition
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Recognition (Recognition (Psychology)
 {CHV,CSP,LCH_NW,MSH,NCI,NLMSubSyn,SNOMEDCT_US}) [menp]
<<<< Mappings
Processing text_000N_8184.tx.3: Use of high-throughput sequencing technologies for MRD detection is being undertaken on a research basis and may hold promise as a future clinical test with even higher sensitivity and precision.180 Certain host factors may also affect response to treatment.

Phrase: Use of high-throughput sequencing technologies
>>>> Phrase
use of high throughput sequencing technologies
<<<< Phrase
>>>> Mappings
Meta Mapping (858):
 790 Use of {MTH,SNOMEDCT_US} [ftcn]
 655 High Throughput Sequence (High-Throughput DNA Sequencing {MSH,NLMSubSyn}) [mbrt]
 586 technologies (Technology {CHV,LCH,LCH_NW,MSH,NCI}) [ocdi]
Meta Mapping (858):
 790 Use of {MTH,SNOMEDCT_US} [ftcn]
 643 high throughput technology {CSP} [inpr]
 586 Sequencing (Nucleic acid sequencing {LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: for MRD detection
>>>> Phrase
mrd detection
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 MRD (Neoplasm, Residual
 {CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
 861 Detection {MTH,NCI} [topp]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: being
>>>> Phrase
<<<< Phrase

Phrase: undertaken on a research basis

```
>>>> Phrase
undertaken on a research basis
<<<< Phrase
>>>> Mappings
Meta Mapping (806):
    797 Basis research (basic research {AOD,CHV,NCI,NLMSubSyn})
    [resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: hold
>>>> Phrase
hold
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Hold (Hold – dosing instruction fragment {MTH,SNOMEDCT_US})
    [inpr]
<<<< Mappings

Phrase: promise as a future clinical test
>>>> Phrase
promise as a future clinical test
<<<< Phrase
>>>> Mappings
Meta Mapping (697):
    753 promise {HL7V3.0} [idcn]
    586 Future {AOD,CHV,MSH,NCI} [tmco]
    586 Clinical {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US} [qlco]
    586 Test (Laboratory Procedures
    {AOD,CHV,MEDLINEPLUS,MTH,NCI,NCI_NCI-
    GLOSS,NCI_NICHD,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: with even higher sensitivity
>>>> Phrase
even higher sensitivity
<<<< Phrase
>>>> Mappings
Meta Mapping (884):
    884 High sensitivity {LNC,NLMSubSyn} [lbpr]
<<<< Mappings
```

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: precision.180 Certain host factors

>>>> Phrase

precision 180 certain host factors

<<<< Phrase

>>>> Mappings

Meta Mapping (740):

637 Precision (Precision – temporal {HL7V2.5,MTH}) [tmco]

566 Certainty (Certain (qualifier value)

{CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

637 Host (Host (organism) {CHV,G0,MTH,NCI}) [orgm]

771 Factor {LNC,MTH,NCI} [ftcn]

<<<< Mappings

Phrase: may

>>>> Phrase

<<<< Phrase

Phrase: also

>>>> Phrase

also

<<<< Phrase

Phrase: affect

>>>> Phrase

affect

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Affect (Affect (mental function)

{CSP,MSH,MTH,SNM,SNMI,SNOMEDCT_US}) [menp]

<<<< Mappings

Phrase: response to treatment.

>>>> Phrase

response to treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Response to treatment {CHV,MTH,NLMSubSyn,SNMI,SNOMEDCT_US}

[clna]

<<<< Mappings

Processing text_000N_8184.tx.4: For example, some recent data suggests that in addition to quantification of leukemia cell response to therapy, the measure of host absolute lymphocyte count (ALC) during induction may also have prognostic impact.

Phrase: For example,

>>>> Phrase

example

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Example {NCI} [cnce]

<<<< Mappings

Phrase: some recent data

>>>> Phrase

recent data

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]

861 Data {MTH,NCI} [idcn]

<<<< Mappings

Phrase: suggests

>>>> Phrase

suggests

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Suggest (suggestion {MTH,NCI}) [idcn]

<<<< Mappings

Phrase: that in addition to quantification of leukemia cell response

>>>> Phrase

that in addition to quantification of leukemia cell response

<<<< Phrase

>>>> Mappings

Meta Mapping (722):

790 In addition to {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [ftcn]

742 Quantification (Quantitation {NCI}) [qncn]

742 LEUKEMIA (leukemia

{AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-SDC,NCI_NCI-GLOSS,NCI_NICH,NDFT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
[neop]

742 Cell (Cells

{CHV,CSP,FMA,G0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-

GLOSS,NCI_UCUM,NDFT,SNM,SNMI,SNOMEDCT_US,UWDA}) [cell]

742 Response (Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn})

[fndg]

<<<< Mappings

Phrase: to therapy,

>>>> Phrase

therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]
<<<< Mappings

Phrase: the measure of host absolute lymphocyte count
>>>> Phrase
the measure of host absolute lymphocyte count
<<<< Phrase
>>>> Mappings
Meta Mapping (755):
 748 Measure (Measurement
{AOD,CHV,CSP,LCH,LNC,MTH,NCI,NCI_CDISC,NCI_UCUM,NLMSubSyn,SNOMEDCT_US}
) [ftcn]
 581 Host (Host (organism) {CHV,GO,MTH,NCI}) [orgm]
 647 Absolute Lymphocyte Count (Absolute Blood Lymphocyte Count
{MTH,NCI,NLMSubSyn}) [lbpr]
<<<< Mappings

Phrase: during induction
>>>> Phrase
induction
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
 [ftcn]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: prognostic impact.
>>>> Phrase
prognostic impact

```
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
    694 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
    861 IMPACT (IMPACT gene {HGNC,MTH,OMIM}) [gngm]
<<<< Mappings
Processing text_000N_8184.tx.5: Lower ALC during induction has been shown to have an adverse prognostic impact on survival in several studies: in some studies independently significant and in others associated with MRD.181,182,183 This association suggests that host immune status may play an important role in disease control and ultimate outcome.

Phrase: Lower
>>>> Phrase
lower
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 LOWER (Lower – spatial qualifier
{CHV,LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [spco]
<<<< Mappings

Phrase: ALC during induction
>>>> Phrase
absolute lymphocyte count during induction
<<<< Phrase
>>>> Mappings
Meta Mapping (816):
    862 Absolute Lymphocyte Count (Absolute Blood Lymphocyte Count
{MTH,NCI,NLMSubSyn}) [lbpr]
    593 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: shown
>>>> Phrase
shown
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
    966 Show {HL7V2.5,HL7V3.0} [anim]
```

<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: an adverse prognostic impact on survival
>>>> Phrase

an adverse prognostic impact on survival
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
 586 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
 753 IMPACT (IMPACT gene {HGNC,MTH,OMIM}) [gngm]
 586 Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: in several studies

>>>> Phrase
several studies
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Several (Numerous
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
 861 studies (Scientific Study {CHV,MTH}) [lbpr]
<<<< Mappings

Phrase: :
>>>> Phrase
<<<< Phrase

Phrase: in some
>>>> Phrase
<<<< Phrase

Phrase: studies
>>>> Phrase
studies

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  studies (Scientific Study {CHV,MTH}) [lbpr]
<<<< Mappings

Phrase: independently significant
>>>> Phrase
independently significant
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861  significant (Statistical Significance {CHV,MTH,NCI,NCI_NCI-
GLOSS}) [qnco]
<<<< Mappings

Phrase: and in others
>>>> Phrase
and in others
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790  Others (Others - Allergy {LNC,MTH}) [fndg]
<<<< Mappings

Phrase: associated with MRD.181,182,183
>>>> Phrase
associated with mrd 181 182 183
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
 790  Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
 753  MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
<<<< Mappings

Phrase: This association
>>>> Phrase
association
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Association (Relationships
{CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: suggests
>>>> Phrase
suggests
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (1000):
  1000  Suggest (suggestion {MTH,NCI}) [idcn]
<<<< Mappings

Phrase: that host immune status
>>>> Phrase
host immune status
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
  660  Host (Host (organism) {CHV,GO,MTH,NCI}) [orgm]
  901  Immune status, NOS (Immunity
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,MSH,NCI,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [phsf]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: play
>>>> Phrase
play
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  play (Does play {CHV,MTH,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: an important role in disease control
>>>> Phrase
an important role in disease control
<<<< Phrase
>>>> Mappings
Meta Mapping (719):
  586  Important (Importance Rating Score 0 {MTH,NCI}) [inpr]
  753  Role (Social Role {AOD,CHV,CSP,LCH_NW,MSH,MTH,NCI}) [socb]
  623  disease control (disorder control (procedure)
{CHV,CSP,MTH,NLMSubSyn}) [topp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: ultimate outcome.
>>>> Phrase
ultimate outcome
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (861):
  861  Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings
Processing text_000N_8184.tx.6: Nutritional Status

Phrase: Nutritional Status
>>>> Phrase
nutritional status
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Nutritional Status (Nutritional status
{AOD,CHV,CSP,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US})
[fndg]
<<<< Mappings
Processing text_000N_8224.tx.1: Both malnutrition and obesity at the
time of presentation and ongoing poor nutritional status throughout
the several months of intensive postinduction treatment have been
reported as significant adverse prognostic factors in many, though not
all, studies.184,185 Malnutrition at diagnosis is most prevalent in
developing countries, where studies have reported inferior disease
response and survival, increased treatment-related toxicities,
increased treatment delays and modifications, and decreased quality of
life.

Phrase: Both malnutrition
>>>> Phrase
malnutrition
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  MALNUTRITION (Malnutrition
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,M
EDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET})
[dsyn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: obesity at the time of presentation
>>>> Phrase
obesity at the time of presentation
<<<< Phrase
>>>> Mappings
Meta Mapping (666):
```

753 OBESITY (Obesity
{AOD,CCS,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,MEDL
INEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CTCASE,NCI_NCI-
GLOSS,NDFRT,OMIM,PDQ,QMR,SNM,SNMI,SNOMEDCT_US}) [dsyn]
586 TIME (Time
{CHV,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NICHED,SNOMEDCT_US}) [tmco]
586 Presentation {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: ongoing poor nutritional status throughout the several months
of intensive postinduction treatment

>>>> Phrase
ongoing poor nutritional status throughout the several months of
intensive postinduction treatment

<<<< Phrase
>>>> Mappings

Meta Mapping (671):

570 ONGOING (Continuous
{CHV,LNC,MTH,NCI,NCI_CDISH,NCI_FDA,SNMI,SNOMEDCT_US}) [idcn]
770 poor Nutritional status (Malnutrition
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,M
EDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET})
[dsyn]
570 MONTHS (month
{CHV,HL7V3.0,MTH,NCI,NCI_CDISH,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
570 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: reported as significant adverse prognostic factors

>>>> Phrase
reported as significant adverse prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (712):

753 Reported (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
753 Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
790 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]

<<<< Mappings

Phrase: in many,
>>>> Phrase
<<<< Phrase

Phrase: though
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]

<<<< Mappings

Phrase: all,
>>>> Phrase
<<<< Phrase

Phrase: studies.184,185 Malnutrition at diagnosis

>>>> Phrase

studies 184 185 malnutrition at diagnosis

<<<< Phrase

>>>> Mappings

Meta Mapping (704):

 753 N MALNUTRITION (Malnutrition
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,M
EDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET})
[dsyn]

 600 Diagnosis Study {CCS_10,MTH,NCI,NCI_CDISC} [resa]

Meta Mapping (704):

 753 N MALNUTRITION (Malnutrition
{AOD,CCS,CCS_10,CHV,COSTAR,CSP,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,M
EDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET})
[dsyn]

 600 N Study diagnosis {LNC} [fnfg]

<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: most prevalent in developing countries,
>>>> Phrase
most prevalent in developing countries
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
 593 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
 688 Prevalences (Statistical Prevalence
{AOD,CHV,CSP,MSH,MTH,NCI}) [qnco]
 640 Developing Countries {AOD,CHV,LCH,LCH_NW,MSH,MTH,NLMSubSyn}
[qlco]
<<<< Mappings

Phrase: where
>>>> Phrase
where
<<<< Phrase

Phrase: studies
>>>> Phrase
studies
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 studies (Scientific Study {CHV,MTH}) [lbpr]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: reported inferior disease response
>>>> Phrase
reported inferior disease response
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 645 Reported (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
 645 inferior (inferiority {AOD,CHV,MTH}) [socb]
 861 Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [fndg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: survival,
>>>> Phrase
survival

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: increased treatment-related toxicities,
>>>> Phrase
increased treatment related toxicities
<<<< Phrase
>>>> Mappings
Meta Mapping (833):
  645  Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
  645  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[ topp]
  645  Related (Relationships {CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US})
[qlco]
  812  toxicities (Toxic effect
{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_FDA,NCI_NCI-
GLOSS,SNM,SNMI,SNOMEDCT_US}) [inpo]
<<<< Mappings

Phrase: increased treatment delays
>>>> Phrase
increased treatment delays
<<<< Phrase
>>>> Mappings
Meta Mapping (840):
  660  Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
  660  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[ topp]
  793  Delay (Deferred {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: modifications,
>>>> Phrase
modifications
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Modification (Changing
```

{CHV, HL7V3.0, LNC, MTH, NCI, NCI_CDISC, SNMI, SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: decreased quality of life.

>>>> Phrase
decreased quality of life
<<<< Phrase
>>>> Mappings

Meta Mapping (916):

604 decreased (Decreasing {CHV, LNC, MTH, SNOMEDCT_US}) [fndg]
909 Quality of life (Perceived quality of life

{AOD, CHV, CSP, LCH, LCH_NW, MTH, NCI, NCI_CDISC, NCI_NCI-GLOSS, NLMSubSyn, PDQ, SNOMEDCT_US, SNOMEDCT_VET}) [sosy]

<<<< Mappings

Processing text_000N_8224.tx.2: More generally, it should be noted that the prognostic factors significant in developing countries often differ from those reported in developed countries because of many differences in disease features, comorbidities, adequacy of supportive care, and access to care.¹⁸⁶ Obesity at diagnosis also has been associated with poorer survival and an increased risk of relapse, particularly in patients above 10 years of age.¹⁸⁷ It remains unclear whether differences in outcome are attributable to differences in chemotherapy pharmacokinetics or to more complex factors such as differences in secretion of obesity-related growth factors and lymphokines that affect tumor biology and host toxicity.

Phrase: More generally,

>>>> Phrase
more generally
<<<< Phrase

>>>> Mappings

Meta Mapping (861):

861 More {CHV, LNC, MTH, NCI, SNMI, SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: it
>>>> Phrase
<<<< Phrase

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: noted
>>>> Phrase
noted
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Noted (Notable {NCI}) [qlco]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: the prognostic factors
>>>> Phrase
prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]
<<<< Mappings

Phrase: significant in developing countries
>>>> Phrase
significant in developing countries
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
 770 Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
 666 Developing Countries {AOD,CHV,LCH,LCH_NW,MSH,MTH,NLMSubSyn}
 [qlco]
<<<< Mappings

Phrase: often
>>>> Phrase
often
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Often (Frequently {CHV,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US})
 [tmco]
<<<< Mappings

Phrase: differ from those
>>>> Phrase
differ from those
<<<< Phrase

Phrase: reported in developed countries

>>>> Phrase
reported in developed countries
<<<< Phrase
>>>> Mappings
Meta Mapping (783):
 770 Reported (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
 833 Developed Countries {AOD,CHV,MSH} [qlco]
<<<< Mappings

Phrase: because of many differences in disease features,
>>>> Phrase

because of many differences in disease features
<<<< Phrase
>>>> Mappings
Meta Mapping (675):
 581 Of (Within {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
 714 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qncos]
 595 disease Feature (disease characteristic {CHV,CSP,NLMSubSyn})
[patf]
<<<< Mappings

Phrase: comorbidities,

>>>> Phrase
comorbidities
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Comorbidities (Comorbidity
{AOD,CHV,CSP,LCH_NW,MSH,NCI,NCI_NCI-GLOSS}) [idcn]
<<<< Mappings

Phrase: adequacy of supportive care,

>>>> Phrase
adequacy of supportive care
<<<< Phrase
>>>> Mappings
Meta Mapping (747):
 699 Adequate (Sufficient {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 666 Supportive Care (Supportive care {CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,PDQ,SNM,SNMI,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: and

>>>> Phrase
<<<< Phrase

Phrase: access

>>>> Phrase
access
<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  access (Role Class - access {HL7V3.0,MTH}) [ftcn]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: care.186 Obesity at diagnosis
>>>> Phrase
care 186 obesity at diagnosis
<<<< Phrase
>>>> Mappings
Meta Mapping (687):
  593  Care (care activity {MTH,NCI}) [acty]
  760  OBESITY (Obesity
{AOD,CCS,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,MEDL
INEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CTCAE,NCI_NCI-
GLOSS,NDFRT,OMIM,PDQ,QMR,SNM,SNMI,SNOMEDCT_US}) [dsyn]
  593  DIAGNOSIS (Diagnosis
{AOD,CCS,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MSH,MTH,NCI,NCI_CDISC,NCI_
NCI-GLOSS,NCI_NICH,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: associated with poorer survival
>>>> Phrase
associated with poorer survival
<<<< Phrase
>>>> Mappings
Meta Mapping (852):
  833  Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
```

737 Poor (Poor – qualifier {LNC,MTH,NCI,NCI_FDA}) [qlco]
770 Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: an increased risk of relapse,
>>>> Phrase
an increased risk of relapse
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
760 Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
760 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
593 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]
<<<< Mappings

Phrase: particularly in patients
>>>> Phrase
particularly in patients
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
790 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: above 10 years of age.187
>>>> Phrase
above 10 years of age 187
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
790 < 10 years (Life Expectancy Less than Ten Years {NCI}) [inpr]
586 AGE (Age
{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHHD,SN
OMEDCT_US}) [orga]
Meta Mapping (722):
586 10% {LNC} [qnco]
783 Age-Years {NCI,NCI_NCPDP} [tmco]
<<<< Mappings

Phrase: It
>>>> Phrase
<<<< Phrase

Phrase: remains

>>>> Phrase

remains

<<<< Phrase

Phrase: unclear

>>>> Phrase

unclear

<<<< Phrase

Phrase: whether

>>>> Phrase

<<<< Phrase

Phrase: differences in outcome

>>>> Phrase

differences in outcome

<<<< Phrase

>>>> Mappings

Meta Mapping (730):

756 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]

623 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: attributable to differences

>>>> Phrase

attributable to differences

<<<< Phrase

>>>> Mappings

Meta Mapping (730):

790 Attributable (attribution {CHV,CSP,NCI}) [menp]

590 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]

<<<< Mappings

Phrase: in chemotherapy pharmacokinetics

>>>> Phrase

chemotherapy pharmacokinetics

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Chemotherapy (Pharmacotherapy

{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICH,NLMSubSyn,SNOMEDCT_US}) [topp]

861 Pharmacokinetics (Drug Kinetics

{AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [phsf]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: to more complex factors such as differences

>>>> Phrase

to more complex factors such as differences

<<<< Phrase

>>>> Mappings

Meta Mapping (634):

581 Complex {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

714 Factor {LNC,MTH,NCI} [ftcn]

548 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]

Meta Mapping (647):

581 To {MTH,NCI} [qlco]

581 Complex {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

714 Factor {LNC,MTH,NCI} [ftcn]

548 *Difference (Delta (difference) {HL7V2.5,MTH,NCI}) [qnco]

<<<< Mappings

Phrase: in secretion of obesity-related growth factors

>>>> Phrase

in secretion of obesity related growth factors

<<<< Phrase

>>>> Mappings

Meta Mapping (719):

748 secretion (Process of secretion {AOD,CSP,MSH,MTH}) [biof]

581 OBESITY (Obesity

{AOD,CCS,CHV,COSTAR,CSP,CST,DXP,HP0,ICD10CM,ICD9CM,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CTCAE,NCI_NCI-GLOSS,NDFRT,OMIM,PDQ,QMR,SNM,SNMI,SNOMEDCT_US}) [dsyn]

581 Related (Relationships {CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

612 GROWTH FACTORS (Growth Factor

{AOD,CHV,CSP,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [aapp,bacs]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: lymphokines

>>>> Phrase

lymphokines

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Lymphokines
{AOD,CHV,CSP,FMA,LCH,LCH_NW,MSH,MTH,NCI,NDFRT,SNM,SNMI,SNOMEDCT_US}
[aapp,imft]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: affect
>>>> Phrase
affect
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Affect (Affect (mental function)
{CSP,MSH,MTH,SNM,SNMI,SNOMEDCT_US}) [menp]
<<<< Mappings

Phrase: tumor biology
>>>> Phrase
tumor biology
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Tumor Biology {NCI,NLMSubSyn} [resa]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: host toxicity.
>>>> Phrase
host toxicity
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 Host (Host (organism) {CHV,GO,MTH,NCI}) [orgm]
861 toxicity (Toxicity aspects {MSH,MTH}) [qlco]
<<<< Mappings

Processing text_000N_8224.tx.3: Additional studies to define the prognostic role of nutritional status and effective interventions during therapy are needed.

Phrase: Additional studies
>>>> Phrase
additional studies
<<<< Phrase
>>>> Mappings

Meta Mapping (888):
694 Additional {LNC,MTH,NCI} [ftcn]
861 studies (Scientific Study {CHV,MTH}) [lbpr]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 To {MTH,NCI} [qlco]
<<<< Mappings

Phrase: define
>>>> Phrase
define
<<<< Phrase

Phrase: the prognostic role of nutritional status
>>>> Phrase
the prognostic role of nutritional status
<<<< Phrase
>>>> Mappings

Meta Mapping (719):
586 Prognostic (prognostic {CHV,MTH,NCI}) [inpr]
753 Role (Social Role {AOD,CHV,CSP,LCH_NW,MSH,MTH,NCI}) [socb]
623 Nutritional Status (Nutritional status
{AOD,CHV,CSP,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US})
[fndg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: effective interventions during therapy
>>>> Phrase
effective interventions during therapy
<<<< Phrase
>>>> Mappings

Meta Mapping (783):
604 Effective {MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
819 interventions therapy (Therapeutic Intervention
{CHV,CSP,LNC,MTH,NLMSubSyn}) [topp]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: needed.

>>>> Phrase
needed

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Needed (Needs {CHV,MSH,MTH,NCI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Processing text_000N_154041.tx.1: Treatment

Phrase: Treatment

>>>> Phrase
treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings

Processing text_000N_1267.tx.1: Recognition of ALL as a heterogeneous
disease treatable by risk stratification has profoundly influenced
therapy for this disease.

Phrase: Recognition of ALL

>>>> Phrase
recognition of all

<<<< Phrase

>>>> Mappings

Meta Mapping (790):

 790 Recognition (Recognition (Psychology)
{CHV,CSP,LCH_NW,MSH,NCI,NLMSubSyn,SNOMEDCT_US}) [menp]

<<<< Mappings

Phrase: as a heterogeneous disease

>>>> Phrase
heterogeneous disease

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Heterogeneous Disease (Heterogeneous disorder
{NLMSubSyn,OMIM}) [fnfdg]

<<<< Mappings

Phrase: treatable by risk stratification

>>>> Phrase
treatable by risk stratification

<<<< Phrase

```
>>>> Mappings
Meta Mapping (555):
 604 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
 604 Stratification {HL7V3.0,NCI} [resa]
<<<< Mappings

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: profoundly influenced therapy for this disease.
>>>> Phrase
profoundly influenced therapy for this disease
<<<< Phrase
>>>> Mappings
Meta Mapping (661):
 553 Influence {NCI} [cnce]
 753 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
 586 Disease {CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICH,NDFRT,SNMI,SNOMEDCT_US} [dsyn]
<<<< Mappings
Processing text_000N_1267.tx.2: The initial evaluation of the patient
with ALL requires sophisticated laboratory tests to derive appropriate
cytogenetic, immunologic, and molecular information.

Phrase: The initial evaluation of the patient
>>>> Phrase
the initial evaluation of the patient
<<<< Phrase
>>>> Mappings
Meta Mapping (820):
 814 Initial patient evaluation (Initial patient assessment
{LNC,NLMSubSyn,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: with ALL
>>>> Phrase
all
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 ALL (All
{CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: requires
>>>> Phrase
```

requires
<<<< Phrase

Phrase: sophisticated laboratory tests

>>>> Phrase

sophisticated laboratory tests

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

901 Laboratory Tests (Laboratory Procedures

{AOD, CHV, MEDLINEPLUS, MTH, NCI, NCI_NCI-GLOSS, NCI_NICHD, NLMSubSyn, SNM, SNMI, SNOMEDCT_US}) [lbpr]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 T0 (Tryptophanase

{CSP, MSH, MTH, NCI, NDFRT, NLMSubSyn, PDQ, SNMI, SNOMEDCT_US}) [aapp, enzy]

<<<< Mappings

Phrase: derive

>>>> Phrase

derive

<<<< Phrase

Phrase: appropriate cytogenetic, immunologic,

>>>> Phrase

appropriate cytogenetic immunologic

<<<< Phrase

>>>> Mappings

Meta Mapping (851):

660 Appropriate {HL7V2.5} [qlco]

660 Cytogenetic (Cytogenetics

{AOD, CHV, CSP, LCH, LCH_NW, LNC, MSH, NCI, NCI_NCI-GLOSS}) [bmod]

827 Immunologic (Immunology {CHV, CSP, LCH_NW, MSH, MTH, NCI, NCI_NCI-GLOSS, OMIM}) [bmod]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: molecular information.

>>>> Phrase

molecular information

<<<< Phrase

>>>> Mappings
Meta Mapping (888):
694 Molecular {MTH,NCI} [qlco]
861 INFORMATION (Information {CHV,MTH,NCI,NDFRT,VANDF}) [idcn]
<<<< Mappings
Processing text_000N_1267.tx.3: Modern protocols require real-time monitoring (e.g., MRD assessments at specific time points), rigorous application of supportive care guidelines, and prompt reporting of adverse events (AEs).

Phrase: Modern protocols
>>>> Phrase
modern protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
861 Protocols (Protocols documentation {CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: require
>>>> Phrase
require
<<<< Phrase

Phrase: real-time monitoring
>>>> Phrase
real time monitoring
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
734 Real Time {HL7V2.5,HL7V3.0} [tmco]
827 Monitoring (Preventive monitoring {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: e.g.
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: MRD assessments at specific time points
>>>> Phrase

```
mrd assessments at specific time points
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
    586    MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]
    753    assessments (Evaluation procedure
{AOD,CHV,LNC,MTH,NCI,NCI_FDA,NLMSubSyn,SNOMEDCT_US}) [hlca]
    623    Specific time (Specified time {NLMSubSyn,SNOMEDCT_US}) [tmco]
    553    point (Point Name {HL7V3.0,MTH,NCI,NCI_NCI-HL7}) [qnco]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: rigorous application of supportive care guidelines,
>>>> Phrase
    rigorous application of supportive care guidelines
<<<< Phrase
>>>> Mappings
Meta Mapping (723):
    514    Rigor (Muscle Rigidity
{CHV,CSP,CST,DXP,HP0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHHD,NDFR
T,OMIM,SNM,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [sosy]
    753    Application (Application procedure
{CHV,MTH,SNMI,SNOMEDCT_US}) [hlca]
    623    Supportive Care (Supportive care {CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,PDQ,SNM,SNMI,SNOMEDCT_US}) [topp]
    586    Guidelines {CHV,MSH,MTH,NCI} [inpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: prompt reporting of adverse events
>>>> Phrase
    prompt reporting of adverse events
<<<< Phrase
>>>> Mappings
Meta Mapping (752):
    593    prompt (Prompting {CHV,MTH}) [ftcn]
    760    Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US} [hlca]
    640    Adverse Events (Adverse Event Domain {MTH,NCI,NCI_CDISC})
[inpr]
```

<<<< Mappings

Phrase: (AEs

>>>> Phrase

aes

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 AES (AES gene {HGNC,MTH,OMIM}) [gngm]

<<<< Mappings

Phrase:).

>>>> Phrase

<<<< Phrase

Processing text_000N_1267.tx.4: Thus, there is a clear need for children with ALL to be evaluated and managed at established pediatric cancer centers that utilize state-of-the-art treatment protocols.¹⁸⁸ Although the specific approaches to patients in various risk groups and the terminology describing the phases of therapy may vary between clinical trials, modern ALL treatment regimens divide therapy into three to five main treatment elements: remission induction, CNS preventive therapy/consolidation, interim maintenance, delayed intensification, and maintenance (sometimes called continuation) therapy.

Phrase: Thus,

>>>> Phrase

thus

<<<< Phrase

Phrase: there

>>>> Phrase

there

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: a clear need for children

>>>> Phrase

a clear need for children

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

593 Clear (Negative Surgical Margin {MSH,MTH,NCI,NLMSubSyn})
[fndg]

760 Need (Needs {CHV,MSH,MTH,NCI,SNOMEDCT_US}) [qlco]

593 Children (Offspring
{AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]

<<<< Mappings

Phrase: with ALL

>>>> Phrase

all

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 ALL (All

{CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 TO (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: evaluated

>>>> Phrase

evaluated

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Evaluated (Evaluation

{AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICHD,NLMSubSyn}) [hlca]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: managed at established pediatric cancer centers

>>>> Phrase

managed at established pediatric cancer centers

<<<< Phrase

>>>> Mappings

Meta Mapping (753):

753 Managed (Management procedure

{CHV,LCH_NW,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [ocac]

753 Established (Accepted {CHV,MTH,NCI,SNOMEDCT_US}) [qlco]

790 Pediatric Cancer (Malignant Childhood Neoplasm

```
{CHV,CSP,LCH_NW,MEDLINEPLUS,MTH,NCI,NLMSubSyn,PDQ}) [neop]
    753 centers (Central
{CHV,HPO,LNC,MTH,NCI,NCI_CDISC,NLMSubSyn,SNMI,SNOMEDCT_US,UWDA})
[spco]
Meta Mapping (753):
    753 Managed (Management procedure
{CHV,LCH_NW,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [ocac]
    753 Established (Accepted {CHV,MTH,NCI,SNOMEDCT_US}) [qlco]
    753 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOM
EDCT_US}) [bmod]
    790 Cancer Centers (NCI-Designated Cancer Center {NCI,NLMSubSyn})
[hcro]
<<<< Mappings
```

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: utilize
>>>> Phrase
utilize
<<<< Phrase

Phrase: state-of-the-art treatment protocols.188
>>>> Phrase

state of the art treatment protocols 188
<<<< Phrase

>>>> Mappings

Meta Mapping (747):

```
    795 Art (Arts {CHV,CSP,LCH,LCH_NW,MSH,MTH}) [ocdi]
    818 Treatment Protocols {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}
[topp]
```

Meta Mapping (756):

```
    795 State {LNC,MTH,NCI} [ftcn]
    795 Art (Arts {CHV,CSP,LCH,LCH_NW,MSH,MTH}) [ocdi]
    818 Treatment Protocols {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}
[topp]
```

Meta Mapping (747):

```
    795 Art (Arts {CHV,CSP,LCH,LCH_NW,MSH,MTH}) [ocdi]
    818 Treatment Protocols {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}
[topp]
<<<< Mappings
```

Phrase: Although
>>>> Phrase
<<<< Phrase

Phrase: the specific approaches to patients
>>>> Phrase

the specific approaches to patients

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

 593 Specific (Specific qualifier value {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

 760 Approaches (Approach {CHV,MTH,NCI,SNOMEDCT_US}) [spco]

 593 Patients {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD_A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: in various risk groups

>>>> Phrase

various risk groups

<<<< Phrase

>>>> Mappings

Meta Mapping (884):

 660 Various (Various patch test substance {CHV,MTH,SNOMEDCT_US}) [irda]

 867 risk Group (Population at Risk {CHV,MSH,MTH,NCI,NLMSubSyn}) [popg]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: the terminology

>>>> Phrase

terminology

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Terminology (Nomenclature {CHV,CSP,MSH,MTH,NCI}) [inpr]

<<<< Mappings

Phrase: describing

>>>> Phrase

describing

<<<< Phrase

Phrase: the phases of therapy

>>>> Phrase

the phases of therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

 770 Phases (Numerical phases {CHV,MTH,NLMSubSyn,SNOMEDCT_US}) [tmco]

604 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHID,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: vary between clinical trials,
>>>> Phrase

vary between clinical trials

<<<< Phrase

>>>> Mappings

Meta Mapping (833):

833 CLINICAL TRIALS (Clinical Trials
{AOD,CHV,CSP,HL7V3.0,LCH,LCH_NW,LNC,MCM,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI
I-GLOSS,SNOMEDCT_US}) [resa]
<<<< Mappings

Phrase: modern ALL treatment regimens

>>>> Phrase

modern all treatment regimens

<<<< Phrase

>>>> Mappings

Meta Mapping (844):

844 Treatment Regimen (Treatment Protocols
{CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [topp]
<<<< Mappings

Phrase: divide

>>>> Phrase

divide

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Divide {CHV,NCI,SNMI,SNOMEDCT_US} [ftcn]
<<<< Mappings

Phrase: therapy into three to five main treatment elements

>>>> Phrase

therapy into three to five main treatment elements

<<<< Phrase

>>>> Mappings

Meta Mapping (693):

744 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHID,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

```
578 Three {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
578 Five {MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
578 Main {MTH,NCI} [qlco]
578 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
578 Elements {AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US} [elii]
<<<< Mappings
```

```
Phrase: :
>>>> Phrase
<<<< Phrase
```

```
Phrase: remission induction,
>>>> Phrase
remission induction
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Induction, Remission (Remission Induction
{CHV,MSH,NLMSubSyn}) [topp]
<<<< Mappings
```

```
Phrase: CNS preventive therapy/consolidation,
>>>> Phrase
cns preventive therapy consolidation
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
756 CNS preventive therapy (Central Nervous System Prophylaxis
{NCI,NCI_NCI-GLOSS,NLMSubSyn}) [topp]
812 Consolidation (Lung consolidation
{CHV,MTH,NCI,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [dsyn]
<<<< Mappings
```

```
Phrase: interim maintenance,
>>>> Phrase
interim maintenance
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 Interim {LNC,NCI} [tmco]
861 Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI} [acty]
<<<< Mappings
```

```
Phrase: delayed intensification,
>>>> Phrase
delayed intensification
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (694):
  694  Delayed (Deferred {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: maintenance
>>>> Phrase
maintenance
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI} [acty]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: sometimes
>>>> Phrase
sometimes
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Sometimes {LNC,NCI} [tmco]
<<<< Mappings

Phrase: called
>>>> Phrase
called
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Call (Decision {AOD,CHV,MTH,NCI}) [menp]
<<<< Mappings

Phrase: continuation
>>>> Phrase
continuation
<<<< Phrase

Phrase: )
>>>> Phrase
<<<< Phrase
```

Phrase: therapy.

>>>> Phrase

therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Therapy (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]

<<<< Mappings

Processing text_000N_1267.tx.5: The intensity of therapy is always scaled to the risk of relapse, with the most intense therapy being delivered within the first 6 months to 1 year of typically 2 to 3 years of treatment.

Phrase: The intensity of therapy

>>>> Phrase

the intensity of therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

 770 Intensity (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
 [qlco]

 604 Therapy (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: always

>>>> Phrase

always

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Always (Always (frequency) {LNC,MTH,NCI}) [tmco]

<<<< Mappings

Phrase: scaled to the risk of relapse,

>>>> Phrase

scaled to the risk of relapse

<<<< Phrase

>>>> Mappings

Meta Mapping (655):

 719 Scale, NOS (Weight measurement scales

```
{CHV,MSH,MTH,SNMI,SNOMEDCT_US}) [medd]
  753 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
  753 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]
<<<< Mappings

Phrase: with the most intense therapy
>>>> Phrase
most intense therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
  660 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
  660 Intense (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
[qlco]
  827 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: being
>>>> Phrase
<<<< Phrase

Phrase: delivered within the first 6 months
>>>> Phrase
delivered within the first 6 months
<<<< Phrase
>>>> Mappings
Meta Mapping (666):
  753 Delivered (Transfer Technique {LNC,MTH,NCI,NLMSubSyn}) [ftcn]
  753 First (Firstly {MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
  753 MONTHS (month
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: to 1 year of typically 2
>>>> Phrase
to 1 year of typically 2
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
  617 1-2 (Phase I/II Trial {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS})
[resa]
  753 /Year (per year {CHV,MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: to 3 years of treatment.
>>>> Phrase
to 3 years of treatment
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
    593  <3 (<3 (qualifier value) {MTH,SNOMEDCT_US}) [qnco]
    760  YEARS (year
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]
    593  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings
Processing text_000N_1267.tx.6: Higher risk patients receive a greater
number of agents, used at increased dosage, and longer periods of
intensive treatment than lower risk patients.

Phrase: Higher risk patients
>>>> Phrase
higher risk patients
<<<< Phrase
>>>> Mappings
Meta Mapping (884):
    701  HIGH RISK (High risk of
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]
    827  Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: receive
>>>> Phrase
receive
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  Receive {NCI,NCI_CDISC} [qlco]
<<<< Mappings

Phrase: a greater number of agents,
>>>> Phrase
a greater number of agents
<<<< Phrase
>>>> Mappings
Meta Mapping (685):
    593  Greater {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
    760  *Number (Numbers
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_UCUM,SNMI,SNOMEDCT_US}) [qnco]
    560  Agent (Pharmacologic Substance
{LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_NCI-GLOSS,NCI_NICHHD}) [phsu]
<<<< Mappings
```

Phrase: used at increased dosage,
>>>> Phrase
used at increased dosage
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 770 used (Used by {CHV,SNOMEDCT_US}) [fndg]
 770 Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
 770 Dosage
{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI-GLOSS,NCI_UCUM,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: longer periods of intensive treatment
>>>> Phrase
longer periods of intensive treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (856):
 807 Length of periods (Duration of menstrual flow
{CHV,SNOMEDCT_US}) [fndg]
 581 Treatment intent {CHV,HL7V3.0,MTH,NLMSubSyn,SNOMEDCT_US}
 [ftcn]
<<<< Mappings

Phrase: than lower risk patients.
>>>> Phrase
lower risk patients
<<<< Phrase
>>>> Mappings
Meta Mapping (890):
 717 LOW RISK (Low Risk {LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US})
 [qnco]
 827 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FA,SNOMEDCT_US} [podg]
<<<< Mappings
Processing text_000N_1267.tx.7: The least complicated protocols (for the lowest risk patients) may consist of only three phases (induction, consolidation, and maintenance) while more intensive protocols for higher risk patients may add intensified treatment phases such as interim maintenance (which is significantly more intense than standard maintenance) and delayed intensification phases (which usually include a reinduction and reconsolidation phase).

Phrase: The least complicated protocols

>>>> Phrase
least complicated protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (840):
 627 Less (Less Than {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qnco]
 660 Complicated {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [ftcn]
 827 Protocols (Protocols documentation
 {CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: (

>>>> Phrase
<<<< Phrase

Phrase: for the lowest risk patients

>>>> Phrase
lowest risk patients
<<<< Phrase
>>>> Mappings
Meta Mapping (890):
 717 LOW RISK (Low Risk {LNC,MTH,NCI,NCI_CDISC,SNOMEDCT_US})
 [qnco]
 827 Patients
 {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
 A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase:)

>>>> Phrase
<<<< Phrase

Phrase: may

>>>> Phrase
<<<< Phrase

Phrase: consist of only three phases

>>>> Phrase
consist of only three phases
<<<< Phrase
>>>> Mappings
Meta Mapping (752):
 760 CONSIST (Consistency
 {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qlco]
 760 Three {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
 781 Phase only (Stage only {LNC,NLMSubSyn}) [inpr]
<<<< Mappings

Phrase: (induction,

>>>> Phrase

```
induction
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
  [ftcn]
<<<< Mappings

Phrase: consolidation,
>>>> Phrase
consolidation
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Consolidation (Lung consolidation
  {CHV,MTH,NCI,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [dsyn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: maintenance
>>>> Phrase
maintenance
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI} [acty]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: while
>>>> Phrase
<<<< Phrase

Phrase: more intensive protocols for higher risk patients
>>>> Phrase
more intensive protocols for higher risk patients
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
  581  More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
  748  Protocols (Protocols documentation
  {CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
  533  High intensity {SNOMEDCT_US} [clas]
  581  Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
```

581 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: add
>>>> Phrase
add
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Add (Add - instruction imperative {HL7V3.0,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: intensified treatment phases such as interim maintenance
>>>> Phrase
intensified treatment phases such as interim maintenance
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
778 treatment phases {AOD,NLMSubSyn} [idcn]
581 Interim {LNC,NCI} [tmco]
581 Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI} [acty]
Meta Mapping (696):
748 Phases (Numerical phases {CHV,MTH,NLMSubSyn,SNOMEDCT_US})
[tmco]
581 Interim {LNC,NCI} [tmco]
607 maintenance treatment (treatment and maintenance
{AOD,CHV,HL7V3.0,NLMSubSyn}) [topp]
Meta Mapping (696):
581 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
581 Interim {LNC,NCI} [tmco]
774 Maintenance Phases (Maintenance stage
{NLMSubSyn,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: significantly more intense than standard maintenance
>>>> Phrase
significantly more intense than standard maintenance
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
 753 Intense (With intensity {CHV,HPO,MTH,NCI,SNMI,SNOMEDCT_US})
 [qlco]
 586 Standard (Standard (document) {MTH,NCI}) [inpr]
 586 Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI} [acty]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: delayed intensification phases
>>>> Phrase
delayed intensification phases
<<<< Phrase
>>>> Mappings
Meta Mapping (802):
 660 Delayed (Deferred {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
 827 Phases (Numerical phases {CHV,MTH,NLMSubSyn,SNOMEDCT_US})
 [tmco]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: usually
>>>> Phrase
usually
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

1000 Usually (Usual {LNC,MTH,NCI}) [qlco]
<<<< Mappings

Phrase: include
>>>> Phrase
include
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Include (Include (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: a reinduction
>>>> Phrase
reinduction
<<<< Phrase

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: reconsolidation phase
>>>> Phrase
reconsolidation phase
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 Phase {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings

Phrase:).
>>>> Phrase
<<<< Phrase
Processing text_000N_1267.tx.8: There are few indications for use of HSCT in first remission in the current era.

Phrase: There
>>>> Phrase
there
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: few indications for use of HSCT
>>>> Phrase
few indications for use of hsct
<<<< Phrase
>>>> Mappings

Meta Mapping (782):
586 Few {CHV,LNC,NCI,SNMI,SNOMEDCT_US} [qnco]
822 Indication For Use (Indication
{HL7V2.5,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn}) [idcn]
586 HSCT (Allogeneic Hematopoietic Stem Cell Transplantation
{MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,PDQ}) [topp]
<<<< Mappings

Phrase: in first remission in the current era.
>>>> Phrase
in first remission in the current era
<<<< Phrase
>>>> Mappings

Meta Mapping (668):
581 First (Firstly {MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
748 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
581 CURRENT (Current (present time)
{CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
581 ERA (Enthesitis-Related Arthritis {MTH,NCI,NCI_NICHHD,NDFRT})
[dsyn]
<<<< Mappings

Processing text_000N_1267.tx.9: The presence of the Philadelphia chromosome was for many years a primary indication for transplant in CR1, but with the success of tyrosine kinase inhibitors (see section on Ph+ ALL), this is no longer true.96 Current indications for transplant in CR1 include hypodiploidy, induction failure, and in some cooperative groups, ETP (see treatment discussion for these specific subgroups below).

Phrase: The presence of the Philadelphia chromosome
>>>> Phrase
the presence of the philadelphia chromosome
<<<< Phrase
>>>> Mappings

Meta Mapping (722):
753 Presence (Providing presence (regime/therapy)
{CHV,MTH,SNOMEDCT_US}) [topp]
623 Philadelphia Chromosome {CHV,CSP,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn} [patf]
<<<< Mappings

Phrase: was for many years
>>>> Phrase
was for many years
<<<< Phrase
>>>> Mappings

Meta Mapping (770):
770 YEARS (year
{CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: a primary indication for transplant

>>>> Phrase

a primary indication for transplant

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

 806 Primary indication (Primary Reason {HL7V2.5,NLMSubSyn})
 [idcn]

 593 Transplant (Transplantation

 {AOD,CHV,CSP,LCH,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [topp]

<<<< Mappings

Phrase: in CR1,

>>>> Phrase

cr1

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 CR1 (CR1 gene {HGNC,MTH,NCI,NCI_NCI-HGNC,OMIM}) [gngm]

<<<< Mappings

Phrase: but with the success of tyrosine kinase inhibitors

>>>> Phrase

but with the success of tyrosine kinase inhibitors

<<<< Phrase

>>>> Mappings

Meta Mapping (739):

 744 Success {AOD,CHV,CSP,LCH_NW,MTH,NCI} [socb]

 800 Tyrosine Kinase Inhibitors (Tyrosine Kinase Inhibitors [MoA]
 {MTH,NDFRT,NLMSubSyn}) [moft]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: see

>>>> Phrase

see

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 see (Vision {AOD,CHV,CSP,G0,ICF,ICF-CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [orgf]

<<<< Mappings

Phrase: section on Ph+ ALL

```
>>>> Phrase
section on ph all
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
  770  Section, NOS (Transection (procedure)
{CHV,MTH,SNM,SNMI,SNOMEDCT_US}) [topp]
  604  ph+ {MTH,SNOMEDCT_US} [fnrg]
Meta Mapping (604):
  604  ph+ {MTH,SNOMEDCT_US} [fnrg]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: this
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: no longer true.96 Current indications for transplant
>>>> Phrase
no longer true 96 current indications for transplant
<<<< Phrase
>>>> Mappings
Meta Mapping (701):
  544  LONG (Long {CHV,MTH,NCI,NCI_CDISC,OMIM,SNMI,SNOMEDCT_US})
[qlco]
  578  TRUE (True {CHV,LNC,NCI,SNMI,SNOMEDCT_US}) [qlco]
  578  96 {MTH,SNOMEDCT_US} [qnc]
  578  CURRENT (Current (present time)
{CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
  744  Indications (Indication of (contextual qualifier)
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [idcn]
  578  Transplant (Transplantation
{AOD,CHV,CSP,LCH,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: in CR1
>>>> Phrase
cr1
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  CR1 (CR1 gene {HGNC,MTH,NCI,NCI_NCI-HGNC,OMIM}) [gnqm]
<<<< Mappings

Phrase: include
>>>> Phrase
include
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Include (Include (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: hypodiploidy,
>>>> Phrase
hypodiploidy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Hypodiploidy (Hypoploidy {NCI,SNM,SNMI,SNOMEDCT_US}) [comd]
<<<< Mappings

Phrase: induction failure,
>>>> Phrase
induction failure
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694  Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
 861  failure (Personal failure {AOD,CHV,MTH}) [inbe]
<<<< Mappings

Phrase: and in some cooperative groups,
>>>> Phrase
and in some cooperative groups
<<<< Phrase
>>>> Mappings
Meta Mapping (806):
 806  Cooperative Groups (Clinical Trials Cooperative Group
{NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]
<<<< Mappings

Phrase: ETP
>>>> Phrase
etp
<<<< Phrase
>>>> Mappings
```

Meta Mapping (1000):
 1000 ETP (Ethionamide
{ATC,CHV,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_FDA,NDFRT,RXNORM,SNM,SNMI
,SNOMEDCT_US,USPMG,VANDF}) [orch,phsu]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: see
>>>> Phrase

see

<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

 1000 see (Vision {AOD,CHV,CSP,G0,ICF,ICF-
CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [orgf]
<<<< Mappings

Phrase: treatment discussion for these specific subgroups

>>>> Phrase
treatment discussion for these specific subgroups
<<<< Phrase
>>>> Mappings

Meta Mapping (691):

 586 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

 753 Discussion (Discussion (procedure) {CHV,MTH,SNOMEDCT_US})
[topp]

 586 Specific (Specific qualifier value
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

 586 subgroups (Subgroup A Nepoviruses {CHV,MTH}) [virs]

<<<< Mappings

Phrase: below
>>>> Phrase
<<<< Phrase

Phrase:).

>>>> Phrase
<<<< Phrase

Processing text_000N_1267.tx.10: The various treatment schemas have
been developed within the context of different cooperative group
protocols.

Phrase: The various treatment schemas
>>>> Phrase

various treatment schemas
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
 660 Various (Various patch test substance {CHV,MTH,SNOMEDCT_US})
[irda]
 660 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
 827 schemas (schema {CHV}) [inpr]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: developed within the context of different cooperative group protocols.

>>>> Phrase
developed within the context of different cooperative group protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (678):

 742 context (contextual factors {AOD,CHV,MTH}) [menp]
 742 Different {MTH,NCI} [qlco]
 764 Cooperative Group (Clinical Trials Cooperative Group
{NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]
 742 Protocols (Protocols documentation
{CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]

Meta Mapping (678):
 742 Different {MTH,NCI} [qlco]
 742 cooperative {AOD,CHV} [orgt]
 762 Group Context (Group setting {HCPCS,NLMSubSyn}) [topp]
 742 Protocols (Protocols documentation
{CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Processing text_000N_1267.tx.11: Decisions as to which specific treatment blocks to use in a given situation (particularly if drawing from different cooperative group data sets) are challenging, since effects on outcome are unpredictable when elements of a tested protocol are modified.

Phrase: Decisions as to which specific treatment
>>>> Phrase
decisions as to which specific treatment

```
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
    753 decisions (Decision {AOD,CHV,MTH,NCI}) [menp]
    586 Specific (Specific qualifier value
{CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
    586 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
    [topp]
<<<< Mappings

Phrase: blocks
>>>> Phrase
blocks
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Blocks (Block Specimens {MTH,NCI,NLMSubSyn}) [bdsu]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: use in a given situation
>>>> Phrase
use in a given situation
<<<< Phrase
>>>> Mappings
Meta Mapping (760):
    760 use (utilization qualifier {MSH,MTH}) [ftcn]
<<<< Mappings

Phrase: (particularly
>>>> Phrase
particularly
<<<< Phrase

Phrase: if
>>>> Phrase
<<<< Phrase

Phrase: drawing from different cooperative group data sets
```

```
>>>> Phrase
drawing from different cooperative group data sets
<<<< Phrase
>>>> Mappings
Meta Mapping (763):
  748  drawing (Drawings (art) {AOD,CHV,MSH,MTH,NCI}) [inpr]
  581  Different {MTH,NCI} [qlco]
  612  Cooperative Group (Clinical Trials Cooperative Group
{NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]
  612  data sets (Data Set {AOD,CHV,MCM,MSH,MTH,NCI}) [inpr]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: challenging,
>>>> Phrase
challenging
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  Challenge (Challenge:Type:Point in time:^Patient:Nominal
{LNC,MTH}) [clna]
<<<< Mappings

Phrase: since
>>>> Phrase
<<<< Phrase

Phrase: effects on outcome
>>>> Phrase
effects on outcome
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
  790  Effects (Effect {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
  623  Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: unpredictable
```

```
>>>> Phrase
unpredictable
<<<< Phrase

Phrase: when
>>>> Phrase
<<<< Phrase

Phrase: elements of a tested protocol
>>>> Phrase
elements of a tested protocol
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
  760 Elements {AOD,CHV,CSP,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US} [elii]
  623 test protocol (Test protocol used {CHV,SNOMEDCT_US}) [resa]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: modified.
>>>> Phrase
modified
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Modified (Changing
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings
Processing text_000N_1267.tx.12: The following sections describe the
general principles of treatment for new diagnoses and specific relapse
situations, but do not constitute comprehensive treatment
recommendations.

Phrase: The following sections
>>>> Phrase
following sections
<<<< Phrase
>>>> Mappings
Meta Mapping (872):
  694 Following {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
  827 Section, NOS (Transection (procedure)
{CHV,MTH,SNM,SNMI,SNOMEDCT_US}) [topp]
Meta Mapping (694):
  694 Following {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
<<<< Mappings
```

Phrase: describe
>>>> Phrase
describe
<<<< Phrase

Phrase: the general principles of treatment
>>>> Phrase
the general principles of treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (631):
 631 General treatment {CHV,NLMSubSyn,SNMI,SNOMEDCT_US} [hlca]
<<<< Mappings

Phrase: for new diagnoses
>>>> Phrase
new diagnoses
<<<< Phrase
>>>> Mappings
Meta Mapping (983):
 983 New diagnosis (New diagnosis (finding)
 {MTH,NLMSubSyn,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: specific relapse situations,
>>>> Phrase
specific relapse situations
<<<< Phrase
>>>> Mappings
Meta Mapping (623):
 660 Specific (Specific qualifier value
 {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 660 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]
<<<< Mappings

Phrase: but
>>>> Phrase
<<<< Phrase

Phrase: do
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: constitute
>>>> Phrase
constitute
<<<< Phrase

Phrase: comprehensive treatment recommendations.
>>>> Phrase
comprehensive treatment recommendations
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
 660  Comprehensive {NCI} [qlco]
 660  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
 827  recommendations (Recommendation {CHV,HL7V3.0,LNC,MTH,NCI})
[idcn]
<<<< Mappings
Processing text_000N_99421.tx.1: Induction Therapy

Phrase: Induction Therapy
>>>> Phrase
induction therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Induction Therapy (Neoadjuvant Therapy {CHV,MSH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,PDQ}) [topp]
<<<< Mappings
Processing text_000N_26752.tx.1: The aim of initial ALL treatment is
induction of remission.

Phrase: The aim of initial ALL treatment
>>>> Phrase
the aim of initial all treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (666):
 753  AIM (CD69 protein, human {MSH,MTH,NCI}) [aapp,imft]
 586  Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
 586  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
```

CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHDI,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: induction of remission.

>>>> Phrase
induction of remission
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 Induction of Remission (Remission Induction
{CHV,MSH,NLMSubSyn}) [topp]
<<<< Mappings

Processing text_000N_26752.tx.2: By the standard definition, patients
in remission have no evidence of leukemia when evaluated by physical
examination and hematologic assessment (by light microscopy) of bone
marrow and peripheral blood.

Phrase: By the standard definition,

>>>> Phrase
standard definition
<<<< Phrase
>>>> Mappings

Meta Mapping (888):

694 Standard (Standard (qualifier) {LNC,MTH,NCI}) [qlco]
861 definition (definition - ActMoodCompletionTrack
{HL7V3.0,MTH}) [idcn]
<<<< Mappings

Phrase: patients in remission

>>>> Phrase
patients in remission
<<<< Phrase
>>>> Mappings

Meta Mapping (988):

988 Patient in remission {CHV,NLMSubSyn,SNOMEDCT_US} [fndg]
<<<< Mappings

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: no evidence of leukemia

>>>> Phrase
no evidence of leukemia
<<<< Phrase

>>>> Mappings

Meta Mapping (708):

 770 Evidence {NCI} [idcn]
 604 N LEUKEMIA (leukemia
 {AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH
 _NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-
 SDC,NCI_NCI-GLOSS,NCI_NICH,NDVRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
 [neop]

<<<< Mappings

Phrase: when

>>>> Phrase

<<<< Phrase

Phrase: evaluated by physical examination

>>>> Phrase

evaluated by physical examination

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

 770 Evaluated (Evaluation
 {AOD,CHV,LCH,LCH_NW,LNC,MTH,NCI,NCI_NICH,NLMSubSyn}) [hlca]
 833 PHYSICAL EXAMINATION (Physical Examination
 {AIR,AOD,AOT,CHV,ICD9CM,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-
 GLOSS,NCI_NICH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [hlca]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: hematologic assessment

>>>> Phrase

hematologic assessment

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 Hematologic {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [ftcn]
 861 Assessment (Assessed {MTH,NCI,NCI_NCI-GLOSS}) [acty]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: by light microscopy

>>>> Phrase

light microscopy

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 LIGHT MICROSCOPY (Light Microscopy
 {CSP,HL7V3.0,LNC,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNMI,SNOMEDCT_US})
 [lbpr]
 <<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: of bone marrow

>>>> Phrase

bone marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-
 CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-
 GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]
 <<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: peripheral blood.

>>>> Phrase

peripheral blood

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Peripheral Blood (peripheral blood
 {CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]
 <<<< Mappings

Processing text_000N_26752.tx.3: For remission to be achieved,
peripheral blood values must be within the normal ranges, and the bone
marrow must be of normal cellularity with fewer than 5% lymphoblasts.
55 Complete remission status also assumes the absence of detectable
CNS or extramedullary disease by traditional light microscopy on CSF
and physical examination findings.

Phrase: For remission

>>>> Phrase

remission

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
 GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
 <<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: achieved
>>>> Phrase
achieved
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: peripheral blood values
>>>> Phrase
peripheral blood values
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 734 Peripheral Blood (peripheral blood
{CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]
 827 Values {MTH} [qlco]
<<<< Mappings

Phrase: must
>>>> Phrase
<<<< Phrase

Phrase: be within the normal ranges,
>>>> Phrase
be within the normal ranges
<<<< Phrase
>>>> Mappings
Meta Mapping (806):
 806 Normal Ranges (Normal Range
{CHV,HL7V2.5,MSH,MTH,NCI,NCI_CareLex,NCI_NCI-
GLOSS,NLMSubSyn,SNOMEDCT_US}) [qnc0]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: the bone marrow

>>>> Phrase

bone marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]

<<<< Mappings

Phrase: must

>>>> Phrase

<<<< Phrase

Phrase: be of normal cellularity

>>>> Phrase

be of normal cellularity

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

783 Normal Cell (Cells

{CHV,CSP,FMA,G0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_UCUM,NDFRT,SNM,SNMI,SNOMEDCT_US,UWDA}) [cell]

<<<< Mappings

Phrase: with fewer than 5% lymphoblasts.55 Complete remission status

>>>> Phrase

with fewer than 5 lymphoblasts 55 complete remission status

<<<< Phrase

>>>> Mappings

Meta Mapping (689):

708 Few {CHV,LNC,NCI,SNMI,SNOMEDCT_US} [qnco]

575 Lymphoblasts (lymphblast

{AOD,CHV,CSP,FMA,LNC,MTH,NCI,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US})
[cell]

575 55 {SNOMEDCT_US} [inpr]

598 Complete Remission (In complete remission

{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fnndg]

575 Status {CHV,HL7V3.0,LNC,MTH,NCI,SNOMEDCT_US} [qlco]

<<<< Mappings

Phrase: also

>>>> Phrase

also

<<<< Phrase

Phrase: assumes

>>>> Phrase

assumes

<<<< Phrase

Phrase: the absence of detectable CNS

>>>> Phrase

the absence of detectable cns

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

760 absence (Absent {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[ftcn]

593 Detectable {NCI} [clna]

593 CNS (Central Nervous System
{AOD,CHV,CSP,CST,FMA,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,OMIM,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsy]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: extramedullary disease by traditional light microscopy

>>>> Phrase

extramedullary disease by traditional light microscopy

<<<< Phrase

>>>> Mappings

Meta Mapping (741):

753 Extramedullary {NCI} [spco]

753 N Disease {CHV,CSP,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NDFRT,SNMI,SNOMEDCT_US} [dsyn]

586 Traditional (Dispense Method – Traditional {HL7V2.5,MTH})

[idcn]

623 LIGHT MICROSCOPY (Light Microscopy

{CSP,HL7V3.0,LNC,MSH,MTH,NCI,NCI_CDISC,NLMSubSyn,SNMI,SNOMEDCT_US})
[lbpr]

<<<< Mappings

Phrase: on CSF

>>>> Phrase

csf

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 CSF (Circumferential Supracrestal Fiberotomy {MTH,NCI})
[topp]

<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: physical examination findings.
>>>> Phrase
physical examination findings
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 N Physical Examination findings (Physical findings
{CHV,CST,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings
Processing text_000N_26752.tx.4: Achievement of a traditionally
defined remission is a basic premise of antileukemic treatment and a
known prerequisite for prolonged survival.

Phrase: Achievement of a traditionally defined remission
>>>> Phrase
achievement of a traditionally defined remission
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
 753 Achievement {CHV,MSH,MTH} [bhvr]
 586 Defined (Definition {HL7V3.0,MTH,NCI,NCI_CareLex}) [inpr]
 586 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: a basic premise of antileukemic treatment
>>>> Phrase
a basic premise of antileukemic treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (506):
 586 Basic (Basis – conceptual entity {MTH,NCI}) [ftcn]
 586 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: a known prerequisite for prolonged survival.

>>>> Phrase
a known prerequisite for prolonged survival

<<<< Phrase

>>>> Mappings

Meta Mapping (691):

 586 Known {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
 753 prerequisite {AOD,CHV} [idcn]
 586 Prolonged {CHV,HP0,MTH,SNMI,SNOMEDCT_US} [tmco]
 586 Survival (Continuance of life
{CHV,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS}) [acty]

<<<< Mappings

Processing text_000N_26752.tx.5: Contemporary treatment regimens include some assessment of MRD (in peripheral blood or bone marrow) often during the induction period (Day 8 or 15), and at the end of induction (Days 29 to 36).

Phrase: Contemporary treatment regimens

>>>> Phrase
contemporary treatment regimens

<<<< Phrase

>>>> Mappings

Meta Mapping (884):

 884 Treatment Regimen (Treatment Protocols
{CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [topp]

<<<< Mappings

Phrase: include

>>>> Phrase
include

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Include (Include (action) {MTH,NCI}) [acty]

<<<< Mappings

Phrase: some assessment of MRD

>>>> Phrase
some assessment of mrd

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

 770 Assessment (Assessed {MTH,NCI,NCI_NCI-GLOSS}) [acty]
 604 MRD (Neoplasm, Residual
{CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn}) [neop]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: in peripheral blood

>>>> Phrase

peripheral blood

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Peripheral Blood (peripheral blood

{CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,SNM,SNMI,SNOMEDCT_US}) [bdsu]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: bone marrow

>>>> Phrase

bone marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 BONE MARROW (Bone Marrow {AOD,CHV,CSP,FMA,HL7V2.5,ICF,ICF-CY,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-

GLOSS,SNM,SNMI,SNOMEDCT_US,UWDA}) [tisu]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: often during the induction period

>>>> Phrase

often during the induction period

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

760 Often (Frequently {CHV,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US})
[tmco]

760 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]

760 Period (Period (temporal qualifier)

{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: (Day 8

>>>> Phrase

day 8

<<<< Phrase

>>>> Mappings

Meta Mapping (861):
861 Day (day
{AOD,CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_NCPDP,SNOMEDCT_US})
[tmco]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: 15
>>>> Phrase
15
<<<< Phrase

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: and at the end of induction
>>>> Phrase
and at the end of induction
<<<< Phrase
>>>> Mappings

Meta Mapping (672):

753 End {CHV,MTH,SNOMEDCT_US} [spco]
753 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: (Days 29 to 36
>>>> Phrase
days 29 to 36
<<<< Phrase
>>>> Mappings

Meta Mapping (733):

770 DAYS (day
{AOD,CHV,HL7V3.0,LNC,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_NCPDP,SNOMEDCT_US})
[tmco]
770 29+ {LNC} [fndg]
770 36 {MTH,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase:).
>>>> Phrase
<<<< Phrase

Processing text_000N_26752.tx.6: In clinically overt ALL, the leukemic cell burden is estimated to be approximately 1012 leukemic cells (Fig. 19.14).

Phrase: In clinically overt ALL,

>>>> Phrase

clinically overt all

<<<< Phrase

Phrase: the leukemic cell burden

>>>> Phrase

leukemic cell burden

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

 734 Leukemic Cell {MTH,NCI} [cell]

 827 Burden {NCI} [idcn]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: estimated

>>>> Phrase

estimated

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Estimated {CHV,LNC,MTH,NCI,NCI_FDA,SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 T0 (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: approximately 1012 leukemic cells

>>>> Phrase

approximately 1012 leukemic cells

<<<< Phrase

```
>>>> Mappings
Meta Mapping (824):
  645  Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
  [qlco]
    861  Leukemic Cells (Leukemic Cells Measurement
{MTH,NCI,NCI_CDISC}) [lbpr]
<<<< Mappings
```

```
Phrase: (Fig. 19.14
>>>> Phrase
fig 19 14
<<<< Phrase
>>>> Mappings
Meta Mapping (827):
  827  FIG (Fig Flavor {MTH,NCI,NCI_FDA}) [food]
<<<< Mappings
```

```
Phrase: .
>>>> Phrase
<<<< Phrase
Processing text_000N_26752.tx.7: To induce a complete remission,
chemotherapy must reduce the total number of leukemic cells by >99%.
```

```
Phrase: To
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings
```

```
Phrase: induce
>>>> Phrase
induce
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Induce (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
  [ftcn]
<<<< Mappings
```

```
Phrase: a complete remission,
>>>> Phrase
complete remission
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Complete Remission (In complete remission
```

{AOD,CHV,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US})
[fndg]
<<<< Mappings

Phrase: chemotherapy

>>>> Phrase
chemotherapy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Chemotherapy (Pharmacotherapy
{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: must

>>>> Phrase
<<<< Phrase

Phrase: reduce

>>>> Phrase
reduce
<<<< Phrase

Phrase: the total number of leukemic cells

>>>> Phrase
the total number of leukemic cells
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
790 Total Number {NCI,NCI_CDISC} [qnco]
623 Leukemic Cells (Leukemic Cells Measurement
{MTH,NCI,NCI_CDISC}) [lbpr]
<<<< Mappings

Phrase: by

>>>> Phrase
<<<< Phrase

Phrase: >99%.

>>>> Phrase
99
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 99 {NCI,SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_26752.tx.8: The rapidity of this response as well
as the total reduction in leukemic cell burden are also important
factors in determining eventual treatment success.^{176,178} Early

intensification of chemotherapy can rescue many high-risk slow-responders so that their EFS is comparable to similarly grouped patients who had more rapid initial responses to therapy.

Phrase: The rapidity of this response

>>>> Phrase

the rapidity of this response

<<<< Phrase

>>>> Mappings

Meta Mapping (650):

688 Rapid {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US} [qlco]

593 Response (Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn})

[fndg]

<<<< Mappings

Phrase: as well as

>>>> Phrase

<<<< Phrase

Phrase: the total reduction in leukemic cell burden

>>>> Phrase

the total reduction in leukemic cell burden

<<<< Phrase

>>>> Mappings

Meta Mapping (710):

581 Total {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]

748 Reduction (Reduced {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

612 Leukemic Cell {MTH,NCI} [cell]

581 Burden {NCI} [idcn]

<<<< Mappings

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: also important factors in determining eventual treatment success.176,178 Early intensification of chemotherapy

>>>> Phrase

also important factors in determining eventual treatment success 176

178 early intensification of chemotherapy

<<<< Phrase

>>>> Mappings

Meta Mapping (626):

568 Important (Importance Rating Score 0 {MTH,NCI}) [inpr]

747 treatment factors {AOD,CHV,NCI,NLMSubSyn} [inpr]

568 Success {AOD,CHV,CSP,LCH_NW,MTH,NCI} [socb]

568 Early {CHV,LNC,MTH,NCI,NLMSubSyn,SNMI,SNOMEDCT_US} [tmco]

568 Chemotherapy (Pharmacotherapy

{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]

<<<< Mappings

Phrase: can

>>>> Phrase

<<<< Phrase

Phrase: rescue

>>>> Phrase

rescue

<<<< Phrase

Phrase: many high-risk slow-responders

>>>> Phrase

high risk slow responders

<<<< Phrase

>>>> Mappings

Meta Mapping (658):

694 HIGH RISK (High risk of

{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]

645 Slow {AOD,CHV,LNC,NCI,SNOMEDCT_US} [qlco]

<<<< Mappings

Phrase: so

>>>> Phrase

so

<<<< Phrase

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: their EFS

>>>> Phrase

efs

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 EFS (Disease-Free Survival {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: comparable to similarly grouped patients

>>>> Phrase

comparable to similarly grouped patients

<<<< Phrase

>>>> Mappings

Meta Mapping (728):
637 Grouped (Grouped (qualifier value) {MTH,SNOMEDCT_US}) [spco]
804 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: who
>>>> Phrase
<<<< Phrase

Phrase: had
>>>> Phrase
<<<< Phrase

Phrase: more rapid initial responses to therapy.

>>>> Phrase
more rapid initial responses to therapy
<<<< Phrase
>>>> Mappings

Meta Mapping (735):

586 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
586 Rapid {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US} [qlco]
586 Initial (Initial (abbreviation) {HL7V3.0,MTH,NCI,NCI_BRIDG})
[idcn]
753 responses (Response process {CHV,MTH,NCI}) [orga]
586 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings
Processing text_000N_53654.tx.1: Although the basic two-drug combination of vincristine and a glucocorticoid induces remission in approximately 85% of children with ALL, the addition of L-asparaginase, an anthracycline, or both improves the remission induction rate to approximately 95%.

Phrase: Although
>>>> Phrase
<<<< Phrase

Phrase: the basic two-drug combination of vincristine
>>>> Phrase
the basic two drug combination of vincristine
<<<< Phrase
>>>> Mappings

Meta Mapping (719):

581 Basic (Basis - conceptual entity {MTH,NCI}) [ftcn]
748 Two {LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
778 drug combination (Drug Combinations {CHV,LNC,MSH,NLMSubSyn})

[phsu]
581 VINCERISTINE (Vincristine
{ATC,CHV,CSP,DRUGBANK,LCH,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF})
[orch,phsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: a glucocorticoid
>>>> Phrase
glucocorticoid
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Glucocorticoid (Glucocorticoids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHED,NDFRT,PDQ,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF}) [horm,orch]
<<<< Mappings

Phrase: induces
>>>> Phrase
induces
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Induce (Induce (action) {CHV,MTH,NCI,SNM,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: remission in approximately 85% of children
>>>> Phrase
remission in approximately 85 of children
<<<< Phrase
>>>> Mappings
Meta Mapping (685):
753 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
586 Approximately (Approximate {CHV,LNC,NCI,SNM,SNOMEDCT_US})
[qlco]
586 85 {SNOMEDCT_US} [qnco]
586 Children (Child
{AOD,CHV,CSP,DXP,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_FDA,NCI_NICHED,NDFRT,SNM,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: with ALL,
>>>> Phrase

all
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 ALL (All
 {CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: the addition of L-asparaginase,
>>>> Phrase
the addition of l asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
 760 Addition (In addition to {LNC,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
 593 ASPARAGINASE
 {ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]
<<<< Mappings

Phrase: an anthracycline,
>>>> Phrase
anthracycline
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Anthracycline (Anthracycline Antibiotics
 {CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: both
>>>> Phrase
<<<< Phrase

Phrase: improves
>>>> Phrase
improves
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Improves (Improved {CHV,LNC,MTH,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: the remission induction rate to approximately 95%.
>>>> Phrase

the remission induction rate to approximately 95

<<<< Phrase

>>>> Mappings

Meta Mapping (710):

612 Induction, Remission (Remission Induction
{CHV,MSH,NLMSubSyn}) [topp]

748 Rate {LNC,MTH,NCI} [qnco]

581 Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
[qlco]

581 95 {SNOMEDCT_US} [qnco]

<<<< Mappings

Processing text_000N_53654.tx.2: Prednisone and prednisolone were the original glucocorticoids used for this purpose; however, dexamethasone is more effective in inducing marrow remission and treating the CNS (largely due to its superior CNS exposure).¹⁸⁹ It is not yet clear whether dexamethasone use in induction results in superior disease control in later phases of therapy.¹⁸⁹ There are, however, data showing significant increases in steroid-related complications with the use of dexamethasone.

Phrase: Prednisone

>>>> Phrase

prednisone

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 PREDNISONE (Prednisone
{AOD,ATC,CHV,CSP,DRUGBANK,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[horm,orch,phsu]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: prednisolone

>>>> Phrase

prednisolone

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 PREDNISOLONE (prednisolone
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[orch,phsu]

<<<< Mappings

Phrase: were

>>>> Phrase
<<<< Phrase

Phrase: the original glucocorticoids
>>>> Phrase
original glucocorticoids
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Original {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [idcn]
 861 GLUCOCORTICOIDS (Glucocorticoids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHHD,NDFRT,PDQ,SNMI,SNOMEDCT_US,USPMG,VANDF}) [horm,orch]
<<<< Mappings

Phrase: used for this purpose
>>>> Phrase
used for this purpose
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 used (Used by {CHV,SNOMEDCT_US}) [fndg]
 770 Purpose {CHV,MTH,NCI,NCI_BRIDG,SNOMEDCT_US} [ftcn]
<<<< Mappings

Phrase: ; however,
>>>> Phrase
however
<<<< Phrase

Phrase: dexamethasone
>>>> Phrase
dexamethasone
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 DEXAMETHASONE (Dexamethasone
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_F
DA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[orch,phsu]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: more effective in inducing marrow remission
>>>> Phrase
more effective in inducing marrow remission
<<<< Phrase

```
>>>> Mappings
Meta Mapping (723):
  586 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
  753 Effective {MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
  586 Inducing (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [ftcn]
  586 Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]
  586 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: treating
>>>> Phrase
treating
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 Treating {CHV,MTH,NCI} [ftcn]
<<<< Mappings

Phrase: the CNS
>>>> Phrase
cns
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 CNS (Central Nervous System
{AOD,CHV,CSP,CST,FMA,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,OMIM,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsy]
<<<< Mappings

Phrase: (largely due to its superior CNS exposure
>>>> Phrase
largely due to its superior cns exposure
<<<< Phrase
>>>> Mappings
Meta Mapping (710):
  778 Due To (Due to {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [ftcn]
  748 SUPERIOR (Upper
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US,UWDA}) [spco]
  748 CNS (Central Nervous System
{AOD,CHV,CSP,CST,FMA,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,OMIM,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsy]
  748 Exposure NOS (Injury due to exposure to external cause
{CHV,ICD10CM,MTH,MTHICD9,SNMI,SNOMEDCT_US}) [inpo]
<<<< Mappings
```

Phrase:).189
>>>> Phrase
189
<<<< Phrase

Phrase: It
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: yet
>>>> Phrase
yet
<<<< Phrase

Phrase: clear
>>>> Phrase
clear
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Clear (Negative Surgical Margin {MSH,MTH,NCI,NLMSubSyn})
[fndg]
<<<< Mappings

Phrase: whether
>>>> Phrase
<<<< Phrase

Phrase: dexamethasone use in induction
>>>> Phrase
dexamethasone use in induction
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 604 DEXAMETHASONE (Dexamethasone
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_F

DA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[orch,phsu]

770 use (utilization qualifier {MSH,MTH}) [ftcn]
604 induction (Induction procedure {CHV,MTH}) [topp]

<<<< Mappings

Phrase: results in superior disease control

>>>> Phrase

results in superior disease control

<<<< Phrase

>>>> Mappings

Meta Mapping (761):

760 Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US} [ftcn]
760 SUPERIOR (Upper
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US,UWDA}) [spco]
806 disease control (disorder control (procedure)
{CHV,CSP,MTH,NLMSubSyn}) [topp]

Meta Mapping (761):

760 SUPERIOR (Upper
{CHV,HL7V2.5,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US,UWDA}) [spco]
797 Disease Result (Disease Outcome {AOD,CHV,MTH,NCI,NLMSubSyn})
[fndg]
760 control (control aspects {MSH,MTH}) [qlco]

<<<< Mappings

Phrase: in later phases of therapy.189

>>>> Phrase

in later phases of therapy 189

<<<< Phrase

>>>> Mappings

Meta Mapping (711):

773 Late Phases (Late stage {MTH,NCI_NCI-GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [tmco]
586 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]

<<<< Mappings

Phrase: There

>>>> Phrase

there

<<<< Phrase

Phrase: are

>>>> Phrase

<<<< Phrase

Phrase: ,

>>>> Phrase

```
<<<< Phrase

Phrase: however,
>>>> Phrase
however
<<<< Phrase

Phrase: data
>>>> Phrase
data
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Data {MTH,NCI} [idcn]
<<<< Mappings

Phrase: showing
>>>> Phrase
showing
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966  Show {HL7V2.5,HL7V3.0} [anim]
<<<< Mappings

Phrase: significant increases in steroid-related complications
>>>> Phrase
significant increases in steroid related complications
<<<< Phrase
>>>> Mappings
Meta Mapping (723):
 586  Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
 753  increases (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
 586  Steroid (Steroids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NDFRT,SNMI,SNOMEDCT_US}) [orch]
 586  Related (Relationships {CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US})
[qlco]
 586  Complications (Complication
{CCS,CCS_10,CHV,LNC,MTH,MTHMST,NCI,NCI_NCI-
GLOSS,NCI_NICHD,SNM,SNMI,SNOMEDCT_US}) [patf]
<<<< Mappings

Phrase: with the use of dexamethasone.
>>>> Phrase
with the use of dexamethasone
<<<< Phrase
>>>> Mappings
Meta Mapping (763):
 806  Use of {MTH,SNOMEDCT_US} [ftcn]
```

593 DEXAMETHASONE (Dexamethasone
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_F
DA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[orch,phsu]
<<<< Mappings

Processing text_000N_53654.tx.3: These range from life-threatening infections and sleep disturbance to longer-term problems such as avascular necrosis and neurocognitive impairment (see Late Effects section).^{189,190,191} These latter, long-term effects may be related to the use of dexamethasone in later phases of therapy, where there is less evidence that it improves disease outcomes.^{189,192}

Phrase: These range from life-threatening infections

>>>> Phrase

these range from life threatening infections

<<<< Phrase

>>>> Mappings

Meta Mapping (780):

753 Range {HL7V2.5,LNC,MTH,NCI,NCI_NICHD} [qnco]

666 Life-threatening infections {OMIM} [fndg]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: sleep disturbance to longer-term problems

>>>> Phrase

sleep disturbance to longer term problems

<<<< Phrase

>>>> Mappings

Meta Mapping (750):

790 Sleep disturbance (Dyssomnias

{AOD,CHV,CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US}) [dsyn]

590 Long Term (Long-term {CHV,MTH,NCI,SNOMEDCT_US}) [tmco]

586 Problems (Problems – What subject filter {HL7V2.5,MTH})

[idcn]

<<<< Mappings

Phrase: such as avascular necrosis

>>>> Phrase

avascular necrosis

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Avascular necrosis (Avascular necrosis of bone

{CHV,ICD10CM,MSH,MTH,NCI,NCI_CTCAE,NLMSubSyn,SNOMEDCT_US}) [patf]

<<<< Mappings

Phrase: and

```
>>>> Phrase
<<<< Phrase

Phrase: neurocognitive impairment
>>>> Phrase
neurocognitive impairment
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
    694 Neurocognitive (neurocognitive {CHV,NCI,NCI_NCI-GLOSS})
    [inpr]
    861 Impairment (Impaired health
    {AOD,CHV,LNC,MTH,SNMI,SNOMEDCT_US}) [patf]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: see
>>>> Phrase
see
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 see (Vision {AOD,CHV,CSP,G0,ICF,ICF-
    CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [orgf]
<<<< Mappings

Phrase: Late Effects
>>>> Phrase
late effects
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 late effects (Sequela of disorder
    {AOD,CHV,HL7V2.5,MTH,NCI,SNMI,SNOMEDCT_US}) [patf]
<<<< Mappings

Phrase: section
>>>> Phrase
section
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Section (section sample {MTH,NCI,NLMSubSyn}) [sbst]
<<<< Mappings

Phrase: ).189,190,191
>>>> Phrase
```

189 190 191
<<<< Phrase

Phrase: These latter,
>>>> Phrase
latter
<<<< Phrase

Phrase: long-term effects
>>>> Phrase
long term effects
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Long-Term Effects (Longterm Effects {CHV,MSH}) [phpr]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: related to the use of dexamethasone
>>>> Phrase
related to the use of dexamethasone
<<<< Phrase
>>>> Mappings
Meta Mapping (725):
 753 Related (Relationships {CHV,HL7V2.5,LNC,MTH,NCI,SNOMEDCT_US})
 [qlco]
 790 Use of {MTH,SNOMEDCT_US} [ftcn]
 753 DEXAMETHASONE (Dexamethasone
 {AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_F
 DA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
 [orch,phsu]
<<<< Mappings

Phrase: in later phases of therapy,
>>>> Phrase
in later phases of therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (734):
 790 Late Phases (Late stage {MTH,NCI_NCI-
 GLOSS,NLMSubSyn,SNMI,SNOMEDCT_US}) [tmco]
 593 Therapy (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N

CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHDI,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: where
>>>> Phrase
where
<<<< Phrase

Phrase: there
>>>> Phrase
there
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: less
>>>> Phrase
less
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Less (Smaller {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: evidence
>>>> Phrase
evidence
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Evidence {NCI} [idcn]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: it
>>>> Phrase
<<<< Phrase

Phrase: improves
>>>> Phrase
improves
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

1000 Improves (Improved {CHV,LNC,MTH,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: disease outcomes.189,192

>>>> Phrase
disease outcomes 189 192
<<<< Phrase
>>>> Mappings

Meta Mapping (844):

844 Disease Outcome {AOD,CHV,MTH,NCI,NLMSubSyn} [fndg]

<<<< Mappings
Processing text_000N_44116.tx.1: The addition of L-asparaginase (L-ASP) to vincristine and a glucocorticoid not only improves induction response rates but also significantly prolongs remission duration.

Phrase: The addition of L-asparaginase

>>>> Phrase
the addition of l asparaginase
<<<< Phrase
>>>> Mappings

Meta Mapping (686):

760 Addition (Add – instruction imperative {HL7V3.0,MTH,NCI})
[ftcn]
593 ASPARAGINASE
{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC_I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]
<<<< Mappings

Phrase: to vincristine

>>>> Phrase
vincristine
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 VINCRISTINE (Vincristine)
{ATC,CHV,CSP,DRUGBANK,LCH,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NC_I_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF})
[orch,phsu]
<<<< Mappings

Phrase: and

>>>> Phrase
<<<< Phrase

Phrase: a glucocorticoid

>>>> Phrase
glucocorticoid
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):

1000 Glucocorticoid (Glucocorticoids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHHD,NDFRT,PDQ,SNMI,SNOMEDCT_US,USPMG,VANDF}) [horm,orch]
<<<< Mappings

Phrase: not
>>>> Phrase
not
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Not (Negation {LNC,MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: only
>>>> Phrase
only
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Only (Only - dosing instruction fragment {MTH,SNOMEDCT_US})
[inpr]
<<<< Mappings

Phrase: improves
>>>> Phrase
improves
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 N Improves (Improved {CHV,LNC,MTH,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: induction response rates
>>>> Phrase
induction response rates
<<<< Phrase
>>>> Mappings
Meta Mapping (884):
660 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
867 Response Rate (Frequency of Responses {CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn}) [tmco]
<<<< Mappings

Phrase: but
>>>> Phrase
<<<< Phrase

Phrase: also

```
>>>> Phrase
also
<<<< Phrase

Phrase: significantly
>>>> Phrase
significantly
<<<< Phrase

Phrase: prolongs
>>>> Phrase
prolongs
<<<< Phrase

Phrase: remission duration.
>>>> Phrase
remission duration
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
  861 Duration (Duration (temporal concept)
{CHV,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings
Processing text_000N_44116.tx.2: Asparaginase is also used in
postinduction phases of treatment (nearly always in delayed
intensification but also in more intensive consolidation regimens).

Phrase: Asparaginase
>>>> Phrase
asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000 ASPARAGINASE
{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: used in postinduction phases of treatment
```

>>>> Phrase
used in postinduction phases of treatment

<<<< Phrase

>>>> Mappings

Meta Mapping (716):

 767 Use of {MTH,SNOMEDCT_US} [ftcn]
 753 Phases (Numerical phases {CHV,MTH,NLMSubSyn,SNOMEDCT_US})
 [tmco]
 753 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]

Meta Mapping (716):

 753 used (Used by {CHV,SNOMEDCT_US}) [fndg]
 783 treatment phases {AOD,NLMSubSyn} [idcn]

<<<< Mappings

Phrase: (nearly always in delayed intensification

>>>> Phrase
nearly always in delayed intensification

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

 760 Nearly {NCI} [qlco]
 760 Always (Always (frequency) {LNC,MTH,NCI}) [tmco]
 760 Delayed (Deferred {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: also in more intensive consolidation regimens

>>>> Phrase
also in more intensive consolidation regimens

<<<< Phrase

>>>> Mappings

Meta Mapping (651):

 653 intent (Intention – mental process
{AOD,CHV,LCH_NW,MSH,MTH,SNOMEDCT_US}) [menp]
 753 Consolidation (Lung consolidation
{CHV,MTH,NCI,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [dsyn]
 753 regimens (Regimen – CHV concept {CHV,MTH}) [inpr]

<<<< Mappings

Phrase:).

>>>> Phrase

<<<< Phrase

Processing text_000N_44116.tx.3: Depletion of plasma asparagine triggers an apoptotic program in most B- and T-ALL blasts because they

lack the ability to synthesize it.

Phrase: Depletion of plasma asparagine

>>>> Phrase

depletion of plasma asparagine

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

 770 Depletion {CHV,MTH,SNM,SNMI,SNOMEDCT_US} [ftcn]

 604 PLASMA (Plasma

{AOD,ATC,CHV,CSP,FMA,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsu]

 604 ASPARAGINE (Asparagine

{AOD,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_CRCH,NCI_DCP,NCI_FDA,NDFRT,RXNORM,SNM,SNMI,SNOMEDCT_US}) [aapp,bacs]

<<<< Mappings

Phrase: triggers

>>>> Phrase

triggers

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 triggers (Precipitating Factors {CHV,MSH,MTH,SNOMEDCT_US})
[clna]

<<<< Mappings

Phrase: an apoptotic program in most B-

>>>> Phrase

an apoptotic program in most b

<<<< Phrase

>>>> Mappings

Meta Mapping (790):

 790 apoptotic program {GO} [celf]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: T-ALL blasts

>>>> Phrase

t all blasts

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

 734 T-ALL (Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
{CSP,HPO,MSH,MTH,NCI,NCI_CTEP-SDC,NCI_NCI-

GLOSS,NCI_NICHHD,NDFRT,NLMSubSyn,SNOMEDCT_US}) [neop]

 827 Blasts (Blast count procedure

{MTH,NCI,NCI_CDISC,NLMSubSyn,SNMI,SNOMEDCT_US}) [lbpr]
<<<< Mappings

Phrase: because
>>>> Phrase
<<<< Phrase

Phrase: they
>>>> Phrase
<<<< Phrase

Phrase: lack
>>>> Phrase
lack
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 lack (Lacking {CHV,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: the ability
>>>> Phrase
ability
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Ability {CHV,LCH,LCH_NW,MSH,MTH,NCI} [orga]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]
<<<< Mappings

Phrase: synthesize
>>>> Phrase
synthesize
<<<< Phrase

Phrase: it.
>>>> Phrase
<<<< Phrase
Processing text_000N_44116.tx.4: The development of pegylated L-asparaginase (PEG) represented a further advance because the pegylated form provides more sustained levels with less frequent dosing and is

reported to be less immunogenic, reducing the frequency of both silent and clinical allergic reactions.¹⁹³ When PEG cannot be given due to allergy to the E.

Phrase: The development of pegylated L-asparaginase

>>>> Phrase

the development of pegylated l asparaginase

<<<< Phrase

>>>> Mappings

Meta Mapping (780):

 753 development (development aspects {MSH,MTH,NLMSubSyn}) [phsf]

 666 pegylated-L-asparaginase {MSH} [aapp,phsu]

<<<< Mappings

Phrase: (PEG

>>>> Phrase

peg

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 PEG {LNC,MTH} [inpr]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: represented

>>>> Phrase

represented

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

 966 Represent (Representation (action) {MTH,NCI}) [acty]

<<<< Mappings

Phrase: a further advance

>>>> Phrase

further advance

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 Further {NCI} [spco]

 861 Advance (Advance -- medical device {CHV,MTH}) [medd]

<<<< Mappings

Phrase: because

>>>> Phrase

<<<< Phrase

Phrase: the pegylated form
>>>> Phrase
pegylated form
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 Form (Formation {MTH,NCI}) [ftcn]
<<<< Mappings

Phrase: provides
>>>> Phrase
provides
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Provide (Providing (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: more sustained levels with less frequent dosing
>>>> Phrase
more sustained levels with less frequent dosing
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
 581 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
 581 Sustained {CHV,MTH,SNOMEDCT_US} [ftcn]
 748 Levels (Levels (qualifier value)
 {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
 571 Dosing Frequency (Dose Frequency {MTH,NCI,NCI_CDISC}) [ftcn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: reported
>>>> Phrase
reported
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Reported (Report (document)
 {AOD,CHV,LNC,MSH,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: to

```
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: less immunogenic,
>>>> Phrase
less immunogenic
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694  Less (Smaller {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 861  immunogenic {CHV,CSP} [ftcn]
<<<< Mappings

Phrase: reducing
>>>> Phrase
reducing
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Reducing (Reduced {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: the frequency of both silent
>>>> Phrase
the frequency of both silent
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
 760  Frequency (Frequencies (time pattern)
{CHV,LNC,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [tmco]
 593  Silent {CHV,MTH,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: clinical allergic reactions.193
>>>> Phrase
clinical allergic reactions 193
```

```
<<<< Phrase
>>>> Mappings
Meta Mapping (824):
    812 Clinical {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US} [qlco]
        861 Allergic reactions (Allergic Reaction
{CCS,CCS_10,ICD10CM,MSH,MTH,NCI,NCI_CTCAE,NCI_NCI-
GLOSS,NCI_NICHHD,SNOMEDCT_US}) [patf]
<<<< Mappings

Phrase: When
>>>> Phrase
<<<< Phrase

Phrase: PEG
>>>> Phrase
peg
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 PEG {LNC,MTH} [inpr]
<<<< Mappings

Phrase: cannot
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: given due to allergy
>>>> Phrase
given due to allergy
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
    770 Given (Give – dosing instruction imperative
{MTH,NCI,SNOMEDCT_US}) [ftcn]
        833 Due To (Due to {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [ftcn]
            770 Allergy (Allergy Specialty {CHV,HL7V2.5,MSH,MTH,SNOMEDCT_US})
[bmod]
<<<< Mappings

Phrase: to the E.
>>>> Phrase
e
<<<< Phrase
Processing text_000N_44116.tx.5: Coliderived protein, Erwinia-derived
L-ASP is an acceptable alternative, although higher and more frequent
intramuscular dosing of the nonpegylated Erwinia formulation is
```

necessary to achieve comparable asparagine depletion levels and adds to the morbidity of treatment.¹⁹⁴

Phrase: Coliderived protein,
>>>> Phrase
coliderived protein
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 861 PROTEIN (Proteins
 {AOD,CHV,CSP,FMA,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_DCP,NCI_NC
 I-GLOSS,NDFRT,RXNORM,SNM,SNMI,SNOMEDCT_US,UWDA,VANDF}) [aapp,bacs]
<<<< Mappings

Phrase: Erwinia-derived L-ASP
>>>> Phrase
erwinia derived l asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (916):
 923 Erwinia L-asparaginase (Erwinia asparaginase
 {CHV,MTH,NCI,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US}) [aapp,enzy,phsu]
 645 Derived (Derivation {LNC,MTH,NCI}) [qlco]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: an acceptable alternative,
>>>> Phrase
acceptable alternative
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Acceptable {LNC,MTH,NCI} [qlco]
 861 Alternative {MTH,NCI} [cnce]
<<<< Mappings

Phrase: although
>>>> Phrase
<<<< Phrase

Phrase: higher
>>>> Phrase
higher
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Higher (High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: more frequent intramuscular dosing of the nonpegylated Erwinia formulation

>>>> Phrase

more frequent intramuscular dosing of the nonpegylated erwinia formulation

<<<< Phrase

>>>> Mappings

Meta Mapping (676):

575 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

575 Intramuscular {CHV,LNC,MTH,NCI,NCI_GLOSS,SNOMEDCT_US}

[spco]

726 Dosing Frequency (Dose Frequency {MTH,NCI,NCI_CDISC}) [ftcn]

575 Erwinia (Genus Erwinia

{CHV,LCH_NW,MSH,MTH,NCBI,SNM,SNMI,SNOMEDCT_US}) [bact]

575 Formulation (Drug Formulation Process {CHV,MSH,MTH,NCI})

[resa]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: necessary

>>>> Phrase

necessary

<<<< Phrase

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 T0 (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]

<<<< Mappings

Phrase: achieve

>>>> Phrase

achieve

<<<< Phrase

Phrase: comparable asparagine depletion levels

>>>> Phrase

comparable asparagine depletion levels

<<<< Phrase

>>>> Mappings

Meta Mapping (775):

 645 ASPARAGINE (Asparagine
 {AOD,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_CRCH,NCI_DCP,NCI_FDA,
 NDFRT,RXNORM,SNM,SNMI,SNOMEDCT_US}) [aapp,bacs]

 645 Depletion {CHV,MTH,SNM,SNMI,SNOMEDCT_US} [ftcn]

 812 Levels (Levels (qualifier value)
 {CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: adds to the morbidity of treatment.194

>>>> Phrase

adds to the morbidity of treatment 194

<<<< Phrase

>>>> Mappings

Meta Mapping (641):

 714 Add (Add – instruction imperative {HL7V3.0,MTH,NCI}) [ftcn]

 581 Morbidity (Morbidity – disease rate
 {AOD,CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]

 581 Treatment (Therapeutic procedure
 {AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
 CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
 [topp]

<<<< Mappings

Processing text_000N_42088.tx.1: Allergic reactions to asparaginase
are a significant problem in ALL treatment, both clinical allergies
(often IgE-mediated anaphylaxis) and silent inactivation, an IgG-
mediated increased clearance of the medication.

Phrase: Allergic reactions to asparaginase

>>>> Phrase

allergic reactions to asparaginase

<<<< Phrase

>>>> Mappings

Meta Mapping (783):

 833 Allergic reactions (Allergic Reaction
 {CCS,CCS_10,ICD10CM,MSH,MTH,NCI,NCI_CTCAE,NCI_NCI-
 GLOSS,NCI_NICH,SNOMEDCT_US}) [patf]

 604 ASPARAGINASE
 {ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
 I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]

<<<< Mappings

Phrase: are

```
>>>> Phrase
<<<< Phrase

Phrase: a significant problem in ALL treatment,
>>>> Phrase
a significant problem in all treatment
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
  586  Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
  753  Problem {CHV,LNC,MTH,NCI,SNM,SNMI,SNOMEDCT_US} [fndg]
  586  Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: both clinical allergies
>>>> Phrase
clinical allergies
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  Clinical {CHV,MTH,NCI,NCI_NCI-GLOSS,SNMI,SNOMEDCT_US} [qlco]
  861  Allergies (Hypersensitivity
{AOD,CHV,COSTAR,CSP,CST,G0,HL7V2.5,HL7V3.0,HPO,ICD10CM,ICF,ICF-
CY,ICPC,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_FDA,NCI_NCI-
GLOSS,NCI_NICH,NDFT,NLMSubSyn,OMIM,SNM,SNMI,SNOMEDCT_US}) [patf]
<<<< Mappings

Phrase: (often IgE-mediated anaphylaxis
>>>> Phrase
often ige mediated anaphylaxis
<<<< Phrase
>>>> Mappings
Meta Mapping (775):
  645  Often (Frequently {CHV,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US})
[tmco]
  645  Mediated (Mediator brand of benfluorex hydrochloride
{CHV,MTH,NCI}) [orch,phsu]
  812  ANAPHYLAXIS (anaphylaxis
{AOD,COSTAR,CST,DXP,G0,HL7V2.5,HPO,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,
MTHICD9,NCI,NCI_CTCAE,NCI_NICH,NDFT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
[patf]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase
```

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: silent inactivation,
>>>> Phrase
silent inactivation
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 Silent {CHV,MTH,SNOMEDCT_US} [qlco]
861 Inactivation (inactivation {CHV,LNC,SNM}) [ftcn]
<<<< Mappings

Phrase: an IgG-
>>>> Phrase
igg
<<<< Phrase

Phrase: mediated
>>>> Phrase
mediated
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Mediated (Mediator brand of benfluorex hydrochloride {CHV,MTH,NCI}) [orch,phsu]
<<<< Mappings

Phrase: increased clearance of the medication.

>>>> Phrase
increased clearance of the medication
<<<< Phrase
>>>> Mappings
Meta Mapping (696):

593 Increased (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
760 Clearance (Clearance [PK] {MTH,NDFRT}) [npop]
593 Medication (Pharmaceutical Preparations {CHV,CSP,HL7V2.5,ICF,ICF-CY,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NDFRT,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [phsu]
<<<< Mappings

Processing text_000N_42088.tx.2: Silent inactivation increases the risk of relapse due to both decreased asparaginase exposure and the subsequent rise in baseline asparagine levels, which results in increased synthesis of proteins that clear other medications, particularly dexamethasone.¹⁹⁵ Therapeutic monitoring of nadir serum asparaginase activity in order to adjust asparaginase dose to maintain a therapeutic level of asparagine depletion may improve outcomes and is therefore being incorporated by some cooperative groups.¹⁹⁶

Phrase: Silent inactivation
>>>> Phrase
silent inactivation
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Silent {CHV,MTH,SNOMEDCT_US} [qlco]
 861 Inactivation (inactivation {CHV,LNC,SNM}) [ftcn]
<<<< Mappings

Phrase: increases
>>>> Phrase
increases
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 increases (Increase {CHV,MTH,NCI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the risk of relapse
>>>> Phrase
the risk of relapse
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
 604 relapse (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: due to both decreased asparaginase exposure
>>>> Phrase
decreased asparaginase exposure
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
 660 Decreased {CHV,MTH,SNMI,SNOMEDCT_US} [qnco]
 660 ASPARAGINASE
 {ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC_I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]
 827 Exposure (Exposure to
 {CHV,HL7V3.0,LNC,MTH,NCI,NCI_DICOM,SNM,SNMI,SNOMEDCT_US}) [qlco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: the subsequent rise in baseline asparagine levels,
>>>> Phrase

the subsequent rise in baseline asparagine levels

<<<< Phrase

>>>> Mappings

Meta Mapping (692):

581 Subsequent (Following {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]

748 RiSE (Relational and Item-Specific Encoding Task {MTH,NCI})

[inpr]

581 Baseline {LNC,MTH,NCI,NCI_NCI-GLOSS} [qnco]

581 ASPARAGINE (Asparagine

{AOD,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_CRCH,NCI_DCP,NCI_FDA,
NDFRT,RXNORM,SNM,SNMI,SNOMEDCT_US}) [aapp,bacs]

581 Levels (Levels (qualifier value)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: which

>>>> Phrase

<<<< Phrase

Phrase: results in increased synthesis of proteins

>>>> Phrase

results in increased synthesis of proteins

<<<< Phrase

>>>> Mappings

Meta Mapping (760):

753 Result {MTH,NCI,NCI_BRIDG,NCI_NCI-GLOSS,SNOMEDCT_US} [ftcn]

803 Increased Protein Synthesis (Increased Protein Synthesis [PE]
{NDFRT,NLMSubSyn}) [moft]

<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: clear

>>>> Phrase

clear

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Clear (Negative Surgical Margin {MSH,MTH,NCI,NLMSubSyn})
[fndg]

<<<< Mappings

Phrase: other medications,

>>>> Phrase

medications

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Medications (Medications:-:Point in time:^Patient:-{LNC,MTH}) [clna]
<<<< Mappings

Phrase: particularly dexamethasone.195 Therapeutic monitoring of nadir serum asparaginase activity

>>>> Phrase
particularly dexamethasone 195 therapeutic monitoring of nadir serum asparaginase activity

<<<< Phrase

>>>> Mappings

Meta Mapping (680):

573 DEXAMETHASONE (Dexamethasone)
{AOD,ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF}
[torch,phsu]

573 Therapeutic (Therapeutic procedure)
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US}
[topp]

739 Monitoring (Preventive monitoring {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [hlca]

573 Nadir (Lowest {MTH,NCI}) [qlco]

573 SERUM (Serum

{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsu]

593 asparaginase activity {GO,MTH,NLMSubSyn} [moft]

Meta Mapping (680):

573 Therapeutic (Therapeutic procedure)
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US}
[topp]

739 Monitoring (Preventive monitoring {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [hlca]

573 Nadir (Lowest {MTH,NCI}) [qlco]

573 SERUM (Serum

{AOD,CHV,CSP,FMA,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US,UWDA}) [bdsu]

591 Asparaginase/Dexamethasone (asparaginase/dexamethasone {NCI,PDQ}) [topp]

573 Activity (Active {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: in order to

>>>> Phrase

in order to

<<<< Phrase

>>>> Mappings

Meta Mapping (790):

790 Order (Order (arrangement) {MTH,NCI}) [qlco]

<<<< Mappings

Phrase: adjust

>>>> Phrase

adjust

<<<< Phrase

Phrase: asparaginase dose

>>>> Phrase

asparaginase dose

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 ASPARAGINASE

{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI_GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]

861 DOSE (Dosage

{CHV,CSP,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NCI_GLOSS,NCI_UCUM,SNOMEDCT_US}) [qnco]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 T0 (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: maintain

>>>> Phrase

maintain

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Maintain (Maintenance {CHV,LCH,LCH_NW,MSH,MTH,NCI}) [acty]

<<<< Mappings

Phrase: a therapeutic level of asparagine depletion

>>>> Phrase

a therapeutic level of asparagine depletion

<<<< Phrase

>>>> Mappings

Meta Mapping (691):

753 Therapeutic (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI_GLOSS,NCI_NCI_HL7,NCI_NICHHD,NLMSubSyn,SNMI,SNOMEDCT_US}) [topp]

753 Level (Levels (qualifier value)
{CHV,LNC,MTH,NCI,SNOMEDCT_US}) [qlco]
586 ASPARAGINE (Asparagine
{AOD,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_CRCH,NCI_DCP,NCI_FDA,
NDFRT,RXNORM,SNM,SNMI,SNOMEDCT_US}) [aapp,bacs]
586 Depletion {CHV,MTH,SNM,SNMI,SNOMEDCT_US} [ftcn]
Meta Mapping (672):
753 Therapeutic (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
586 ASPARAGINE (Asparagine
{AOD,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_CRCH,NCI_DCP,NCI_FDA,
NDFRT,RXNORM,SNM,SNMI,SNOMEDCT_US}) [aapp,bacs]
586 Depletion {CHV,MTH,SNM,SNMI,SNOMEDCT_US} [ftcn]
<<<< Mappings

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: improve
>>>> Phrase
improve
<<<< Phrase

Phrase: outcomes
>>>> Phrase
outcomes
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
966 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: therefore
>>>> Phrase
therefore
<<<< Phrase

Phrase: being

>>>> Phrase
<<<< Phrase

Phrase: incorporated by some cooperative groups.196
>>>> Phrase
incorporated by some cooperative groups 196
<<<< Phrase
>>>> Mappings
Meta Mapping (790):
 790 Cooperative Groups (Clinical Trials Cooperative Group {NCI,NCI_BRIDG,NCI_NCI-GLOSS,NLMSubSyn}) [prog]
<<<< Mappings
Processing text_000N_42247.tx.1: Asparaginase can also cause thrombosis and pancreatitis, most often in patients >10 years of age.
197 Thrombosis can be managed if treatment with asparaginase is resumed, utilizing close monitoring and low-molecular-weight heparin.
198 Pancreatitis occurs in approximately 7% of patients, and unfortunately the rates of recurrence are high (approximately 66%) when patients are rechallenged with asparaginase.197 Other medications used in ALL therapy (glucocorticoids, mercaptopurine, and trimethoprim sulfamethoxazole) can also cause pancreatitis and/or contribute to cases that were initiated by asparaginase.

Phrase: Asparaginase
>>>> Phrase
asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 ASPARAGINASE {ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]
<<<< Mappings

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: cause
>>>> Phrase
cause
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Cause (Science of Etiology {MTH,NCI,NCI_NCI-GLOSS}) [cnce]

<<<< Mappings

Phrase: thrombosis

>>>> Phrase

thrombosis

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 thrombosis (Thrombosis of blood vessel {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US,SNOMEDCT_VET}) [patf]

<<<< Mappings

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: pancreatitis,

>>>> Phrase

pancreatitis

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Pancreatitis (Pancreatitis Adverse Event {MTH,NCI,NCI_CTCAE}) [fnndg]

<<<< Mappings

Phrase: most often in patients

>>>> Phrase

most often in patients

<<<< Phrase

>>>> Mappings

Meta Mapping (733):

 770 Most {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]

 770 Often (Frequently {CHV,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US})

[tmco]

 770 Patients

{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: >10 years of age.197 Thrombosis

>>>> Phrase

10 years of age 197 thrombosis

<<<< Phrase

>>>> Mappings

Meta Mapping (712):

 790 < 10 years (Life Expectancy Less than Ten Years {NCI}) [inpr]

 586 AGE (Age

{AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHHD,SN
OMEDCT_US}) [orga]

586 thrombosis (Thrombosis of blood vessel {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US,SNOMEDCT_VET}) [patf]

Meta Mapping (712):

586 10% {LNC} [qnco]

783 Age-Years {NCI,NCI_NCPDP} [tmco]

586 thrombosis (Thrombosis of blood vessel {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US,SNOMEDCT_VET}) [patf]

<<<< Mappings

Phrase: can

>>>> Phrase

<<<< Phrase

Phrase: be

>>>> Phrase

<<<< Phrase

Phrase: managed

>>>> Phrase

managed

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Managed (Management procedure

{CHV,LCH_NW,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [ocac]

<<<< Mappings

Phrase: if

>>>> Phrase

<<<< Phrase

Phrase: treatment with asparaginase

>>>> Phrase

treatment with asparaginase

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 Treatment (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHED,NLMSubSyn,SNMI,SNOMEDCT_US}) [toppl]

623 ASPARAGINASE

{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: resumed
>>>> Phrase
resumed
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
 966 Resume (Resume – Remote control command {HL7V2.5,MTH}) [idcn]
<<<< Mappings

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: utilizing
>>>> Phrase
utilizing
<<<< Phrase

Phrase: close monitoring
>>>> Phrase
close monitoring
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Close (Closed {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [ftcn]
 861 Monitoring (Preventive monitoring {AOD,CHV,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: low-molecular-weight heparin.198 Pancreatitis
>>>> Phrase
low molecular weight heparin 198 pancreatitis
<<<< Phrase
>>>> Mappings
Meta Mapping (870):
 734 Heparin, Low-Molecular-Weight
 {CHV,LNC,MSH,MTH,NCI,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US} [orch,phsu]
 799 Pancreatitis (Pancreatitis Adverse Event {MTH,NCI,NCI_CTCAE})
 [fndg]
<<<< Mappings

Phrase: occurs in approximately 7% of patients,
>>>> Phrase
occurs in approximately 7 of patients
<<<< Phrase
>>>> Mappings

Meta Mapping (666):
753 Occur (Occur (action) {MTH,NCI}) [acty]
753 Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
[qlco]
753 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: unfortunately
>>>> Phrase
unfortunately
<<<< Phrase

Phrase: the rates of recurrence
>>>> Phrase
the rates of recurrence
<<<< Phrase
>>>> Mappings

Meta Mapping (691):
737 Rate {LNC,MTH,NCI} [qnco]
604 Recurrence {CHV,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US} [phpr]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: high
>>>> Phrase
high
<<<< Phrase
>>>> Mappings

Meta Mapping (1000):
1000 High {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
<<<< Mappings

Phrase: (approximately 66%
>>>> Phrase
approximately 66
<<<< Phrase
>>>> Mappings

Meta Mapping (888):
861 Approximately (Approximate {CHV,LNC,NCI,SNMI,SNOMEDCT_US})
[qlco]
861 66 {SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: when
>>>> Phrase
<<<< Phrase

Phrase: patients
>>>> Phrase
patients
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: rechallenged with asparaginase.197
>>>> Phrase
rechallenged with asparaginase 197
<<<< Phrase
>>>> Mappings
Meta Mapping (691):
737 Rechallenge {NCI} [topp]
770 ASPARAGINASE
{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]
<<<< Mappings

Phrase: Other medications
>>>> Phrase
medications
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Medications (Medications:-:Point in time:^Patient:-
{LNC,MTH}) [clna]
<<<< Mappings

Phrase: used in ALL therapy
>>>> Phrase
used in all therapy

<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 used (Used by {CHV,SNOMEDCT_US}) [fndg]
 770 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings

Phrase: (glucocorticoids,
>>>> Phrase
glucocorticoids
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 GLUCOCORTICOIDS (Glucocorticoids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICH,DNDRT,PDQ,SNMI,SNOMEDCT_US,USPMG,VANDF}) [horm,orch]
<<<< Mappings

Phrase: mercaptopurine,
>>>> Phrase
mercaptopurine
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 MERCAPTOPURINE (mercaptopurine
{ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NCI_FDA,N
CI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,USPMG,VANDF})
[nnon,phsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: trimethoprim sulfamethoxazole
>>>> Phrase
trimethoprim sulfamethoxazole
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Trimethoprim-sulphamethoxazole (Trimethoprim-Sulfamethoxazole
Combination {CHV,LCH_NW,LNC,MSH,MTH,NCI,NCI_DTP,NCI_NCI-
GLOSS,NDFRT,PDQ,RXNORM,SNMI,SNOMEDCT_US,USPMG,VANDF}) [phsu]
<<<< Mappings

Phrase:)
>>>> Phrase

<<<< Phrase

Phrase: can
>>>> Phrase
<<<< Phrase

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: cause
>>>> Phrase
cause
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Cause (Science of Etiology {MTH,NCI,NCI_NCI-GLOSS}) [cnce]
<<<< Mappings

Phrase: pancreatitis
>>>> Phrase
pancreatitis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Pancreatitis (Pancreatitis Adverse Event {MTH,NCI,NCI_CTCAE})
 [fndg]
<<<< Mappings

Phrase: and/or
>>>> Phrase
<<<< Phrase

Phrase: contribute to cases
>>>> Phrase
contribute to cases
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 Contribute (Contribution {NCI}) [acty]
 790 Cases (Case (situation) {CHV,LCH,MTH,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: that
>>>> Phrase
<<<< Phrase

Phrase: were
>>>> Phrase

<<<< Phrase

Phrase: initiated by asparaginase.

>>>> Phrase

initiated by asparaginase

<<<< Phrase

>>>> Mappings

Meta Mapping (730):

 756 Initiate (Initiate (source type) {HL7V2.5,MTH}) [idcn]

 790 ASPARAGINASE

{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF} [aapp,enzy,phsu]

<<<< Mappings

Processing text_000N_42247.tx.2: The decision about when and whether
to rechallenge a patient after pancreatitis should be individualized
and monitored carefully.

Phrase: The decision about

>>>> Phrase

decision about

<<<< Phrase

>>>> Mappings

Meta Mapping (861):

 861 Decision {AOD,CHV,MTH,NCI} [menp]

<<<< Mappings

Phrase: when

>>>> Phrase

<<<< Phrase

Phrase: and

>>>> Phrase

<<<< Phrase

Phrase: whether

>>>> Phrase

<<<< Phrase

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 T0 (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNM,SNOMEDCT_US}) [aapp,enzy]

<<<< Mappings

Phrase: rechallenge

>>>> Phrase

```
rechallenge
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Rechallenge {NCI} [topp]
Meta Mapping (1000):
  1000  re-challenge {HL7V3.0} [idcn]
<<<< Mappings

Phrase: a patient after pancreatitis
>>>> Phrase
a patient after pancreatitis
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
  770  *^patient (Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US}) [podg]
  604  Pancreatitis (Pancreatitis Adverse Event {MTH,NCI,NCI_CTCAE})
[fndg]
<<<< Mappings

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: individualized
>>>> Phrase
individualized
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Individualized {NCI} [qlco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: monitored
>>>> Phrase
monitored
<<<< Phrase
>>>> Mappings
Meta Mapping (966):
  966  monitor (Patient Monitoring
```

{AOD,CHV,LCH_NW,MSH,MTH,NCI,NCI_FDA,NCI_NCI-GLOSS,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: carefully.

>>>> Phrase

carefully

<<<< Phrase

Processing text_000N_42247.tx.3: Efforts to prevent or ameliorate
pancreatitis with octreotide or use of short-acting Erwinia
asparaginase should be considered investigational.4

Phrase: Efforts

>>>> Phrase

efforts

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

966 Effort (Exertion {CHV,NCI,SNMI,SNOMEDCT_US}) [orgf]

<<<< Mappings

Phrase: to

>>>> Phrase

to

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 TO (Tryptophanase

{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enz]

<<<< Mappings

Phrase: prevent

>>>> Phrase

prevent

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 PREVENT (PREVENT (product) {CHV,MTH,SNMI,SNOMEDCT_US}) [phsu]

<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: ameliorate

>>>> Phrase

ameliorate

<<<< Phrase

Phrase: pancreatitis with octreotide

>>>> Phrase

pancreatitis with octreotide
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 Pancreatitis (Pancreatitis Adverse Event {MTH,NCI,NCI_CTCAE})
[fnndg]
 623 OCTREOTIDE (Octreotide
{ATC,CHV,CSP,DRUGBANK,LNC,MSH,MTHSPL,NCI,NCI_FDA,NCI_NCI-
GLOSS,NDFRT,RXNORM,SNOMEDCT_US,USPMG,VANDF}) [aapp,horm,phsu]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: use of short-acting Erwinia asparaginase

>>>> Phrase
use of short acting erwinia asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (833):
 790 Use of {MTH,SNOMEDCT_US} [ftcn]
 586 Short (Short Value {MTH,NCI}) [qnco]
 553 ACT (Adoptive Immunotherapy {CSP,MSH,MTH,NCI,NCI_NCI-GLOSS})
[topp]
 623 Erwinia Asparaginase (Erwinia asparaginase
{CHV,MTH,NCI,NLMSubSyn,PDQ,RXNORM,SNOMEDCT_US}) [aapp,enzy,phsu]
<<<< Mappings

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: considered
>>>> Phrase
considered
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 considered (consider {CHV}) [idcn]
<<<< Mappings

Phrase: investigational.4
>>>> Phrase
investigational 4
<<<< Phrase

```
>>>> Mappings
Meta Mapping (861):
  861  Investigational {MTH,NCI,NCI_NCI-GLOSS} [qlco]
<<<< Mappings
Processing text_000N_42008.tx.1: Protocols using the four-drug
induction combination of vincristine, glucocorticoid, L-asparaginase,
and an anthracycline with intensive consolidation and maintenance
therapy uniformly demonstrate improved overall remission duration for
high-risk patients.

Phrase: Protocols
>>>> Phrase
protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Protocols (Protocols documentation
{CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: using
>>>> Phrase
using
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Using (Use of {MTH,SNOMEDCT_US}) [ftcn]
<<<< Mappings

Phrase: the four-drug induction combination of vincristine,
>>>> Phrase
the four drug induction combination of vincristine
<<<< Phrase
>>>> Mappings
Meta Mapping (719):
  581  Four {MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
  774  drug combination (Drug Combinations {CHV,LNC,MSH,NLMSubSyn})
[phsu]
  581  Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
  581  VINCRISTINE (Vincristine
{@ATC,CHV,CSP,DRUGBANK,LCH,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NC
I_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF})
[orch,phsu]
<<<< Mappings

Phrase: glucocorticoid,
>>>> Phrase
glucocorticoid
<<<< Phrase
```

```
>>>> Mappings
Meta Mapping (1000):
  1000  Glucocorticoid (Glucocorticoids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NDFRT,PDQ,SNMI,SNOMEDCT_US,USPMG,VANDF}) [horm,orch]
<<<< Mappings

Phrase: L-asparaginase,
>>>> Phrase
l asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  L-Asparaginase (ASPARAGINASE
{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF}) [aapp,enzym,phsu]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: an anthracycline with intensive consolidation
>>>> Phrase
an anthracycline with intensive consolidation
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
  760  Anthracycline (Anthracycline Antibiotics
{CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]
  593  Consolidation (Lung consolidation
{CHV,MTH,NCI,SNMI,SNOMEDCT_US,SNOMEDCT_VET}) [dsyn]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: maintenance therapy
>>>> Phrase
maintenance therapy
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Maintenance Therapy (Maintenance therapy {CHV,NCI,NCI_NCI-
GLOSS,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: uniformly
>>>> Phrase
```

uniformly
<<<< Phrase

Phrase: demonstrate
>>>> Phrase
demonstrate
<<<< Phrase

Phrase: improved overall remission duration for high-risk patients.
>>>> Phrase
improved overall remission duration for high risk patients
<<<< Phrase
>>>> Mappings
Meta Mapping (739):
 578 Improved {CHV,LNC,MTH,SNOMEDCT_US} [fndg]
 578 Overall (Overall Publication Type {MSH,MTH}) [inpr]
 744 Duration (Duration (temporal concept)
{CHV,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
 604 HIGH RISK (High risk of
{CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]
 600 patients remission (Patient in remission
{CHV,NLMSubSyn,SNOMEDCT_US}) [fndg]
<<<< Mappings
Processing text_000N_42008.tx.2: Because the use of a fourth drug
(usually an anthracycline) or additional drugs during induction may
increase treatment-related morbidity and mortality, many centers
reserve the use of induction drug combinations employing four or more
agents for patients in the higher risk or relapse populations.

Phrase: Because
>>>> Phrase
<<<< Phrase

Phrase: the use of a fourth drug
>>>> Phrase
the use of a fourth drug
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
 586 Fourth (Fourth (suffix) {MTH,NCI}) [qlco]
 783 Drug use (Drug usage {AOD,CHV,HL7V3.0,LNC,MTH}) [mobd]
<<<< Mappings

Phrase: (usually
>>>> Phrase
usually
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Usually (Usual {LNC,MTH,NCI}) [qlco]

<<<< Mappings

Phrase: an anthracycline

>>>> Phrase

anthracycline

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Anthracycline (Anthracycline Antibiotics

 {CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: additional drugs during induction

>>>> Phrase

additional drugs during induction

<<<< Phrase

>>>> Mappings

Meta Mapping (749):

 783 additive drugs (Drug additive

 {CHV,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [bodm]

 604 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})

[ftcn]

<<<< Mappings

Phrase: may

>>>> Phrase

<<<< Phrase

Phrase: increase

>>>> Phrase

increase

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Increase {CHV,MTH,NCI,SNOMEDCT_US} [ftcn]

<<<< Mappings

Phrase: treatment-related morbidity

>>>> Phrase

treatment related morbidity

<<<< Phrase

>>>> Mappings

Meta Mapping (851):
660 Treatment (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICH,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
660 Related (Related personal status {CHV,MTH,SNOMEDCT_US})
[fndg]
827 Morbidity (Morbidity – disease rate
{AOD,CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: mortality,

>>>> Phrase

mortality

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Mortality (Mortality Vital Statistics

{AOD,CHV,LCH,LCH_NW,MSH,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}) [qnco]

<<<< Mappings

Phrase: many centers

>>>> Phrase

centers

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 centers (Central

{CHV,HPO,LNC,MTH,NCI,NCI_CDISC,NLMSubSyn,SNMI,SNOMEDCT_US,UWDA})

[spco]

<<<< Mappings

Phrase: reserve

>>>> Phrase

reserve

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Reserve (Reservation (action) {MTH,NCI}) [acty]

<<<< Mappings

Phrase: the use of induction drug combinations

>>>> Phrase

the use of induction drug combinations

<<<< Phrase

>>>> Mappings

Meta Mapping (796):
 790 Use of {MTH,SNOMEDCT_US} [ftcn]
 586 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
 [ftcn]
 623 Drug Combinations {CHV,LNC,MSH,NLMSubSyn} [phsu]
<<<< Mappings

Phrase: employing

>>>> Phrase

employing

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 employing (Employed {AOD,CHV,LNC,MTH,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: four

>>>> Phrase

four

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Four {MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: more agents for patients

>>>> Phrase

more agents for patients

<<<< Phrase

>>>> Mappings

Meta Mapping (772):

 604 More {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qnco]
 802 Agents, Patient (Patient Agent {MSH}) [grup]
<<<< Mappings

Phrase: in the higher risk

>>>> Phrase

higher risk

<<<< Phrase

>>>> Mappings

Meta Mapping (966):

 966 HIGH RISK (High risk of
 {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: or

>>>> Phrase
<<<< Phrase

Phrase: relapse populations.
>>>> Phrase
relapse populations
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Relapse {AOD,CHV,MSH,MTH,SNMI,SNOMEDCT_US} [phpr]
 861 Population (Population Group
 {CHV,LNC,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [popg]
<<<< Mappings
Processing text_000N_42008.tx.3: When added to induction regimens with vincristine, glucocorticoids, and L-asparaginase, anthracyclines are the main cause of acute myelosuppression and mucositis, as well as later risk of cardiomyopathy.

Phrase: When
>>>> Phrase
<<<< Phrase

Phrase: added to induction regimens
>>>> Phrase
added to induction regimens
<<<< Phrase
>>>> Mappings
Meta Mapping (733):
 770 Added (Additional {LNC,MTH,NCI}) [ftcn]
 770 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
 [ftcn]
 770 regimens (Regimen – CHV concept {CHV,MTH}) [inpr]
<<<< Mappings

Phrase: with vincristine,
>>>> Phrase
vincristine
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 VINCRISTINE (Vincristine
 {@ATC,CHV,CSP,DRUGBANK,LCH,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DCP,NCI_DTP,NC
 I_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF})
 [orch,phsu]
<<<< Mappings

Phrase: glucocorticoids,
>>>> Phrase
glucocorticoids
<<<< Phrase

```
>>>> Mappings
Meta Mapping (1000):
  1000  GLUCOCORTICOIDS (Glucocorticoids
{AOD,CHV,CSP,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
GLOSS,NCI_NICHD,NDFRT,PDQ,SNMI,SNOMEDCT_US,USPMG,VANDF}) [horm,orch]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: L-asparaginase,
>>>> Phrase
l asparaginase
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  L-Asparaginase (ASPARAGINASE
{ATC,CHV,CSP,DRUGBANK,LCH_NW,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NCI_NC
I-GLOSS,NDFRT,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF}) [aapp,enzv,phsu]
<<<< Mappings

Phrase: anthracyclines
>>>> Phrase
anthracyclines
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Anthracyclines (Anthracycline Antibiotics
{CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]
<<<< Mappings

Phrase: are
>>>> Phrase
<<<< Phrase

Phrase: the main cause of acute myelosuppression
>>>> Phrase
the main cause of acute myelosuppression
<<<< Phrase
>>>> Mappings
Meta Mapping (691):
  586  Main {MTH,NCI} [qlco]
  753  Cause (Science of Etiology {MTH,NCI,NCI_NCI-GLOSS}) [cnce]
  586  ACUTE (acute {CHV,DXP,HPO,LNC,MTH,NCI,NCI_CDISC,NCI_NCI-
GLOSS,SNMI,SNOMEDCT_US}) [tmco]
  586  Myelosuppression {CHV,MTH,NCI,NCI_NCI-GLOSS,SNOMEDCT_US}
  [fnndg]
<<<< Mappings
```

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: mucositis,
>>>> Phrase
mucositis
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Mucositis (Gastrointestinal mucositis
 {MTH,NCI,NDFRT,NLMSubSyn,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: as well as
>>>> Phrase
<<<< Phrase

Phrase: later
>>>> Phrase
later
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Later (Late {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: risk of cardiomyopathy.

>>>> Phrase
risk of cardiomyopathy
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
 790 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]
 790 CARDIOMYOPATHY (Cardiomyopathies
 {AOD,CCS,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH_NW,LNC,MEDLINEP
 LUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,OM
 IM,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings
Processing text_000N_42008.tx.4: Although cardiomyopathy occurs
infrequently at the cumulative doses given on frontline ALL protocols,
it may become a concern in treatment of relapsed patients.

Phrase: Although
>>>> Phrase
<<<< Phrase

Phrase: cardiomyopathy
>>>> Phrase
cardiomyopathy

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  CARDIOMYOPATHY (Cardiomyopathies
{AOD,CCS,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH_NW,LNC,MEDLINEP
LUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,OM
IM,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: occurs
>>>> Phrase
occurs
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  OCCUR (Occurrence {MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: infrequently at the cumulative doses
>>>> Phrase
infrequently at the cumulative doses
<<<< Phrase
>>>> Mappings
Meta Mapping (729):
  760  Infrequently (Infrequent
{CHV,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
  773  Cumulative Dose {NCI,NCI_NCI-GLOSS} [cnce]
<<<< Mappings

Phrase: given on frontline ALL protocols,
>>>> Phrase
given on frontline all protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
  760  GIVEN {LNC,MTH} [cnce]
  760  Protocols (Protocols documentation
{CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: it
>>>> Phrase
<<<< Phrase

Phrase: may
>>>> Phrase
<<<< Phrase

Phrase: become
>>>> Phrase
```

become
<<<< Phrase

Phrase: a concern
>>>> Phrase
concern
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Concern {HL7V3.0,NCI} [idcn]
<<<< Mappings

Phrase: in treatment of relapsed patients.
>>>> Phrase
in treatment of relapsed patients
<<<< Phrase
>>>> Mappings
Meta Mapping (743):
 760 In (Within {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
 781 relapse treatment {AOD,CHV} [topp]
 593 Patients
 {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
Meta Mapping (743):
 760 In (Within {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [spco]
 593 relapsed (Relapsing course {CHV,MTH,SNOMEDCT_US}) [tmco]
 781 Patient Treatment (HL7CommitteeIDInRIM <Patient
Administration> {HL7V3.0,MTH,NLMSubSyn}) [inpr]
<<<< Mappings
Processing text_000N_42008.tx.5: Nevertheless, any child receiving anthracycline should have baseline and follow-up cardiac echocardiography, and the total anthracycline dose should not exceed 300 to 350 mg/m² (in doxorubicin equivalents), since the rate of clinically significant cardiomyopathy rises from 1%2% to >10% with cumulative doses of 400 to 450 mg/m².¹⁹⁹ Many low- and standard-risk ALL protocols include no anthracycline or a very low cumulative dose (e.g., 75 mg/m²).

Phrase: Nevertheless,
>>>> Phrase
nevertheless
<<<< Phrase

Phrase: any child receiving anthracycline
>>>> Phrase
child receiving anthracycline
<<<< Phrase
>>>> Mappings
Meta Mapping (851):
 660 CHILD (Offspring {AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-

GLOSS}) [famg]
660 RECEIVING (Receive {NCI,NCI_CDISC}) [qlco]
827 Anthracycline (Anthracycline Antibiotics
{CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]
<<<< Mappings

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: have
>>>> Phrase
<<<< Phrase

Phrase: baseline
>>>> Phrase
baseline
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Baseline {LNC,MTH,NCI,NCI_NCI-GLOSS} [qnco]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: follow-up cardiac echocardiography,
>>>> Phrase
follow up cardiac echocardiography
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
694 Follow-up (Follow-up status {CHV,LNC,MTH,SNOMEDCT_US}) [fndg]
645 Cardiac (Cardiac - anatomy qualifier {LNC,MTH,NCI,NCI_NCI-GLOSS}) [qlco]
812 ECHOCARDIOGRAPHY (Echocardiography
{AOD,CHV,CSP,HL7V2.5,ICD9CM,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9
,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [diap]
Meta Mapping (851):
694 Followup (follow-up {MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [hlca]
645 Cardiac (Cardiac - anatomy qualifier {LNC,MTH,NCI,NCI_NCI-GLOSS}) [qlco]
812 ECHOCARDIOGRAPHY (Echocardiography
{AOD,CHV,CSP,HL7V2.5,ICD9CM,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9
,NCI,NCI_CDISC,NCI_NCI-GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [diap]
<<<< Mappings

Phrase: and
>>>> Phrase

<<<< Phrase

Phrase: the total anthracycline dose

>>>> Phrase

total anthracycline dose

<<<< Phrase

>>>> Mappings

Meta Mapping (901):

913 Total Dose (Cumulative Dose {NCI,NCI_NCI-GLOSS}) [cnce]

660 Anthracycline (Anthracycline Antibiotics

{CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]

<<<< Mappings

Phrase: should

>>>> Phrase

<<<< Phrase

Phrase: not

>>>> Phrase

not

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Not (Negation {LNC,MTH,NCI}) [ftcn]

<<<< Mappings

Phrase: exceed

>>>> Phrase

exceed

<<<< Phrase

Phrase: 300 to 350 mg/m²

>>>> Phrase

300 to 350 mg m²

<<<< Phrase

>>>> Mappings

Meta Mapping (761):

760 300 {MTH,SNOMEDCT_US} [qnco]

760 350 {SNOMEDCT_US} [qnco]

806 mg/m² (mg/sq.m {NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US})

[qnco]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: in doxorubicin equivalents

>>>> Phrase

doxorubicin equivalents

```
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
  694  Doxorubicine (Doxorubicin
    {ATC,CHV,CSP,DRUGBANK,LCH_NW,LNC,MSH,MTH,MTHSPL,NCI,NCI_DTP,NCI_FDA,NC
    I_NCI-GLOSS,NDFRT,NLMSubSyn,PDQ,RXNORM,SNM,SNMI,SNOMEDCT_US,VANDF})
  [antb,orch]
  861  Equivalents (Equivalent Weight
    {CHV,MTH,NCI,NCI_CDISC,NCI_NCI-HL7,NCI_UCUM,NLMSubSyn}) [qnco]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: since
>>>> Phrase
<<<< Phrase

Phrase: the rate of clinically significant cardiomyopathy
>>>> Phrase
the rate of clinically significant cardiomyopathy
<<<< Phrase
>>>> Mappings
Meta Mapping (672):
  753  Rate {LNC,MTH,NCI} [qnco]
  586  Significant {CHV,MTH,NCI,SNOMEDCT_US} [idcn]
  586  CARDIOMYOPATHY (Cardiomyopathies
    {AOD,CCS,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,LCH_NW,LNC,MEDLINEP
    LUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_FDA,NCI_NICHHD,NDFRT,NLMSubSyn,OM
    IM,SNM,SNMI,SNOMEDCT_US}) [dsyn]
<<<< Mappings

Phrase: rises from 1%2%
>>>> Phrase
rises from 1 2
<<<< Phrase
>>>> Mappings
Meta Mapping (770):
  770  RiSE (Relational and Item-Specific Encoding Task {MTH,NCI})
  [inpr]
<<<< Mappings

Phrase: to
>>>> Phrase
<<<< Phrase
```

Phrase: >10% with cumulative doses of 400
>>>> Phrase
10 with cumulative doses of 400
<<<< Phrase
>>>> Mappings
Meta Mapping (701):
 753 10% {LNC} [qnco]
 756 Cumulative Dose {NCI,NCI_NCI-GLOSS} [cnce]
 753 400 {LNC,MTH,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: to 450 mg/m².199
>>>> Phrase
450 mg m² 199
<<<< Phrase
>>>> Mappings
Meta Mapping (824):
 812 450 {LNC,SNOMEDCT_US} [qnco]
 861 mg/m² (mg/sq.m {NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US})
[qnco]
<<<< Mappings

Phrase: Many low-
>>>> Phrase
low
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 low (low confidentiality {HL7V3.0,MTH}) [inpr]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: standard-risk ALL protocols
>>>> Phrase
standard risk all protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (824):
 694 Standard Risk (Standard Risk Acute Leukemia {NCI}) [hlca]
 812 Protocols (Protocols documentation
{CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: include
>>>> Phrase
include

```
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Include (Include (action) {MTH,NCI}) [acty]
<<<< Mappings

Phrase: no anthracycline
>>>> Phrase
anthracycline
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000  Anthracycline (Anthracycline Antibiotics
{CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]
<<<< Mappings

Phrase: or
>>>> Phrase
<<<< Phrase

Phrase: a very low cumulative dose
>>>> Phrase
very low cumulative dose
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 N Very low {CHV,LNC,SNOMEDCT_US} [fndg]
 861  Cumulative Dose {NCI,NCI_NCI-GLOSS} [cnce]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: e.g.
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: 75 mg/m2
>>>> Phrase
75 mg m2
<<<< Phrase
>>>> Mappings
Meta Mapping (901):
 660  75 {MTH,SNOMEDCT_US} [qnc]
 901  mg/m2 (mg/sq.m {NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US})
```

[qnc0]
<<<< Mappings

Phrase:).
>>>> Phrase
<<<< Phrase

Processing text_000N_42008.tx.6: Higher risk patients receive anywhere from 75 to 120 mg/m2 during their initial treatment regimens.

Phrase: Higher risk patients

>>>> Phrase
higher risk patients
<<<< Phrase
>>>> Mappings

Meta Mapping (884):

 701 HIGH RISK (High risk of
 {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [fndg]
 827 Patients
 {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
 A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: receive

>>>> Phrase
receive
<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Receive {NCI,NCI_CDISC} [qlco]

<<<< Mappings

Phrase: anywhere from 75

>>>> Phrase
anywhere from 75
<<<< Phrase

>>>> Mappings

Meta Mapping (790):

 790 75 {MTH,SNOMEDCT_US} [qnc0]

<<<< Mappings

Phrase: to 120 mg/m2 during their initial treatment regimens.

>>>> Phrase
to 120 mg m2 during their initial treatment regimens
<<<< Phrase

>>>> Mappings

Meta Mapping (683):

 764 mg/m2 (mg/sq.m {NCI,NCI_CDISC,NCI_ICH,NCI_UCUM,SNOMEDCT_US})
 [qnc0]

 575 Initial (Initially {CHV,LNC,MTH,SNMI,SNOMEDCT_US}) [tmco]

 581 Treatment Regimen (Treatment Protocols

{CHV, MSH, MTH, NCI, NCI_NCI-GLOSS, NLMSubSyn}) [topp]
<<<< Mappings
Processing text_000N_42008.tx.7: Dexrazoxane (a free-radical scavenger) has been shown to decrease cardiotoxicity in both adult and pediatric patients, but is rarely used in current ALL regimens due to the low overall dosing of anthracycline.

Phrase: Dexrazoxane
>>>> Phrase
dexrazoxane
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 DEXRAZOXANE (Dexrazoxane
{ATC, CHV, DRUGBANK, MSH, MTHSPL, NCI, NCI_DCP, NCI_FDA, NCI_NCI-GLOSS, NDFRT, PDQ, RXNORM, SNOMEDCT_US, VANDF}) [orch, phsu]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: a free-radical scavenger
>>>> Phrase
free radical scavenger
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 free radical scavenger (Free Radical Scavengers
{CHV, CSP, MSH, MTH}) [chvf]
<<<< Mappings

Phrase:)
>>>> Phrase
<<<< Phrase

Phrase: has
>>>> Phrase
<<<< Phrase

Phrase: been
>>>> Phrase
<<<< Phrase

Phrase: shown
>>>> Phrase
shown
<<<< Phrase
>>>> Mappings
Meta Mapping (966):

966 Show {HL7V2.5,HL7V3.0} [anim]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 T0 (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: decrease
>>>> Phrase
decrease
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Decrease {CHV,MTH,SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: cardiotoxicity in both adult
>>>> Phrase
cardiotoxicity in both adult
<<<< Phrase
>>>> Mappings
Meta Mapping (708):
 770 Cardiotoxicity {CHV,MSH,NCI,NCI_NCI-GLOSS,NDFRT,NLMSubSyn,PDQ} [inpo]
 604 ADULT (Adult
{AOD,CHV,LNC,MSH,MTH,NCI,NCI_FDA,NDFRT,SNOMEDCT_US}) [aggp]
<<<< Mappings

Phrase: and
>>>> Phrase
<<<< Phrase

Phrase: pediatric patients,
>>>> Phrase
pediatric patients
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 paediatric (Pediatrics
{CHV,CSP,HL7V2.5,LCH,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,NCI,NLMSubSyn,SNOMEDCT_US}) [bmod]
 861 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD,A,SNOMEDCT_US} [podg]

<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: rarely

>>>> Phrase

rarely

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Rarely (Rare {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]

<<<< Mappings

Phrase: used in current ALL regimens

>>>> Phrase

used in current all regimens

<<<< Phrase

>>>> Mappings

Meta Mapping (687):

760 used (Used by {CHV,SNOMEDCT_US}) [fndg]

760 CURRENT (Current (present time))

{CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]

760 regimens (Regimen – CHV concept {CHV,MTH}) [inpr]

<<<< Mappings

Phrase: due to the low overall dosing of anthracycline.

>>>> Phrase

due to the low overall dosing of anthracycline

<<<< Phrase

>>>> Mappings

Meta Mapping (515):

604 Due To (Due to {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [ftcn]

578 low (low confidentiality {HL7V3.0,MTH}) [inpr]

578 Overall (Overall Publication Type {MSH,MTH}) [inpr]

578 Anthracycline (Anthracycline Antibiotics)

{CHV,CSP,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn,SNOMEDCT_US}) [antb,orch]

<<<< Mappings

Processing text_000N_42008.tx.8: There have also been concerns that dexrazoxane may increase the risk of developing secondary AML, but recent evidence shows that this is unlikely to be true.²⁰⁰

Phrase: There

>>>> Phrase

there

<<<< Phrase

Phrase: have

>>>> Phrase

<<<< Phrase

Phrase: also

>>>> Phrase

also

<<<< Phrase

Phrase: been

>>>> Phrase

<<<< Phrase

Phrase: concerns

>>>> Phrase

concerns

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Concerns (Concern {HL7V3.0,NCI}) [idcn]

<<<< Mappings

Phrase: that dexrazoxane

>>>> Phrase

dexrazoxane

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 DEXRAZOXANE (Dexrazoxane

{ATC,CHV,DRUGBANK,MSH,MTHSPL,NCI,NCI_DCP,NCI_FDA,NCI_NCI-GLOSS,NDFRT,PDQ,RXNORM,SNOMEDCT_US,VANDF}) [orch,phsu]

<<<< Mappings

Phrase: may

>>>> Phrase

<<<< Phrase

Phrase: increase

>>>> Phrase

increase

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Increase {CHV,MTH,NCI,SNOMEDCT_US} [ftcn]

<<<< Mappings

Phrase: the risk of developing secondary AML,

>>>> Phrase

the risk of developing secondary aml

<<<< Phrase

>>>> Mappings

Meta Mapping (722):

 753 Risk {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,NCI} [idcn]

 623 N Secondary AML (secondary acute myeloid leukemia
 {NCI,NLMSubSyn,PDQ}) [neop]

<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: recent evidence

>>>> Phrase

recent evidence

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

 694 Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]

 861 Evidence {NCI} [idcn]

<<<< Mappings

Phrase: shows

>>>> Phrase

shows

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Show {HL7V2.5,HL7V3.0} [anim]

<<<< Mappings

Phrase: that

>>>> Phrase

<<<< Phrase

Phrase: this

>>>> Phrase

<<<< Phrase

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: unlikely

>>>> Phrase

unlikely

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Unlikely (Unlikely Related to Intervention {MTH,NCI,NCI_FDA})
[qlco]
<<<< Mappings

Phrase: to
>>>> Phrase
to
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 TO (Tryptophanase
{CSP,MSH,MTH,NCI,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [aapp,enzy]
<<<< Mappings

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: true.200
>>>> Phrase
true 200
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
861 TRUE (True {CHV,LNC,NCI,SNMI,SNOMEDCT_US}) [qlco]
861 200 {MTH,SNOMEDCT_US} [qnco]
<<<< Mappings
Processing text_000N_123453.tx.1: Induction failure (IF) is an
uncommon event, occurring in fewer than 3% of children with ALL
treated with current regimens.

Phrase: Induction failure
>>>> Phrase
induction failure
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
694 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
861 failure (Personal failure {AOD,CHV,MTH}) [inbe]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: an uncommon event,
>>>> Phrase
uncommon event
<<<< Phrase

>>>> Mappings
Meta Mapping (888):
 694 Uncommon (Rare {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US}) [qlco]
 861 Event {CHV,LNC,MTH,NCI,SNOMEDCT_US} [evnt]
<<<< Mappings

Phrase: occurring in fewer
>>>> Phrase
occurring in fewer
<<<< Phrase
>>>> Mappings
Meta Mapping (756):
 756 OCCUR (Occurrence {MTH,NCI,NCI_CDISC,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: than 3% of children
>>>> Phrase
than 3 of children
<<<< Phrase
>>>> Mappings
Meta Mapping (802):
 802 Child 3 {LNC,NLMSubSyn} [famg]
<<<< Mappings

Phrase: with ALL
>>>> Phrase
all
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 ALL (All
 {CHV,HL7V3.0,HPO,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [qnco]
<<<< Mappings

Phrase: treated with current regimens.
>>>> Phrase
treated with current regimens
<<<< Phrase
>>>> Mappings
Meta Mapping (861):
 833 Treated with {MTH,SNMI,SNOMEDCT_US} [topp]
 770 CURRENT (Current (present time)
 {CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
 770 regimens (Regimen – CHV concept {CHV,MTH}) [inpr]
<<<< Mappings
Processing text_000N_123453.tx.2: IF is defined as the presence of overt leukemia (certainly >25% but in many current protocols >5%) in the marrow at the end of the induction phase on the basis of morphologic examination.

Phrase: IF
>>>> Phrase
induction failure
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
 694 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
 [ftcn]
 861 failure (Personal failure {AOD,CHV,MTH}) [inbe]
<<<< Mappings

Phrase: is
>>>> Phrase
<<<< Phrase

Phrase: defined as the presence of overt leukemia

>>>> Phrase
defined as the presence of overt leukemia
<<<< Phrase
>>>> Mappings
Meta Mapping (652):
 748 Defined (Definition {HL7V3.0,MTH,NCI,NCI_CareLex}) [inpr]
 748 Presence (Providing presence (regime/therapy)
 {CHV,MTH,SNOMEDCT_US}) [topp]
 748 LEUKEMIA (leukemia
 {AOD,CCS,CCS_10,CHV,COSTAR,CSP,CST,DXP,HPO,ICD10CM,ICD9CM,ICPC,LCH,LCH
 _NW,LNC,MEDLINEPLUS,MSH,MTH,MTHICD9,NCI,NCI_CDISC,NCI_CTEP-
 SDC,NCI_NCI-GLOSS,NCI_NICHHD,NDFRT,OMIM,PDQ,SNM,SNMI,SNOMEDCT_US})
 [neop]
<<<< Mappings

Phrase: (certainly
>>>> Phrase
certainly
<<<< Phrase

Phrase: >25%
>>>> Phrase
25
<<<< Phrase

Phrase: but in many current protocols

>>>> Phrase
but in many current protocols
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
 760 CURRENT (Current (present time)
 {CHV,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US}) [tmco]
 760 Protocols (Protocols documentation

```
{CHV,CSP,MTH,NCI,SNOMEDCT_US}) [inpr]
<<<< Mappings

Phrase: >5%
>>>> Phrase
5
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000  >5 {SNOMEDCT_US} [qnco]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: in the marrow at the end of the induction phase
>>>> Phrase
in the marrow at the end of the induction phase
<<<< Phrase
>>>> Mappings
Meta Mapping (656):
    739  Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]
    591  End Phase (End-stage
{CHV,MTH,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [qlco]
    573  Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
Meta Mapping (656):
    739  Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]
    573  End (Stop (qualifier value) {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
    593  Induction Phase (Induction Therapy Epoch {MTH,NCI,NCI_CDSC})
[resa]
<<<< Mappings

Phrase: on the basis of morphologic examination.
>>>> Phrase
morphologic examination
<<<< Phrase
>>>> Mappings
Meta Mapping (853):
    623  Morphology, NOS (Physical shape
{AOD,CHV,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
    861  Examination {MTH,NCI} [acty]
<<<< Mappings
Processing text_000N_123453.tx.3: Until recently, IF was associated
with an EFS of 16%, which was achieved primarily with bone marrow
transplant.

Phrase: Until
>>>> Phrase
```

```
<<<< Phrase

Phrase: recently,
>>>> Phrase
recently
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
    1000 Recently (Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US}) [tmco]
<<<< Mappings

Phrase: IF
>>>> Phrase
induction failure
<<<< Phrase
>>>> Mappings
Meta Mapping (888):
    694 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
    861 failure (Personal failure {AOD,CHV,MTH}) [inbe]
<<<< Mappings

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: associated with an EFS of 16%,
>>>> Phrase
associated with an efs of 16
<<<< Phrase
>>>> Mappings
Meta Mapping (722):
    790 Associated with {CHV,LNC,MTH,NCI,SNMI,SNOMEDCT_US} [qlco]
    753 EFS (Disease-Free Survival {CHV,MSH,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn}) [qnco]
<<<< Mappings

Phrase: which
>>>> Phrase
<<<< Phrase

Phrase: was
>>>> Phrase
<<<< Phrase

Phrase: achieved
>>>> Phrase
achieved
<<<< Phrase
```

Phrase: primarily with bone marrow transplant.

>>>> Phrase
primarily with bone marrow transplant
<<<< Phrase
>>>> Mappings

Meta Mapping (862):

862 BONE MARROW TRANSPLANT (Bone Marrow Transplantation {CCS,CCS_10,CHV,COSTAR,CSP,DXP,ICD9CM,LCH_NW,LNC,MEDLINEPLUS,MSH,MTH,N CI,NCI_NCI-GLOSS,NCI_NICHHD,NLMSubSyn,PDQ,SNM,SNMI,SNOMEDCT_US}) [topp]
<<<< Mappings

Processing text_000N_123453.tx.4: The overall EFS for these patients has improved only modestly with modern therapy, to 32% in a recent, large, international multi-cooperative group analysis.²⁰¹ This study also reported that IF in a subgroup of children below age 6 years with B-ALL without adverse genetic features had an EFS of 72% with chemotherapy alone.²⁰¹ However, in that study, those patients above age 10, with T-ALL, or with 11q23 rearrangements had particularly dismal outcomes.

Phrase: The overall EFS for these patients

>>>> Phrase
the overall efs for these patients
<<<< Phrase
>>>> Mappings

Meta Mapping (672):

586 Overall {CCS,CHV,LNC,MTH,NCI} [qlco]
753 EFS (Disease-Free Survival {CHV,MSH,MTH,NCI,NCI_NCI- GLOSS,NLMSubSyn}) [qnco]
586 Patients {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CD ISC,NCI_DICOM,NCI_FD A,SNOMEDCT_US} [podg]
<<<< Mappings

Phrase: has

>>>> Phrase
<<<< Phrase

Phrase: improved

>>>> Phrase
improved

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Improved (Better {CHV,MTH,NCI,NCI_FDA,SNMI,SNOMEDCT_US})
[qlco]
<<<< Mappings

Phrase: only modestly with modern therapy,

>>>> Phrase
only modestly with modern therapy

```
<<<< Phrase
>>>> Mappings
Meta Mapping (686):
  760 Only (Singular {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[qnco]
  760 Therapy (Therapeutic procedure
{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,N
CI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})
[topp]
<<<< Mappings
```

Phrase: to 32% in a recent, large, international multi-cooperative group analysis.201
>>>> Phrase
to 32 in a recent large international multi cooperative group analysis
201

```
<<<< Phrase
>>>> Mappings
Meta Mapping (695):
  736 Recent {CHV,MTH,NCI,SNMI,SNOMEDCT_US} [tmco]
  736 LARGE (Large {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[qnco]
  736 International {NCI} [idcn]
  736 Multi (Numerous {CHV,LNC,MTH,NCI,NCI_CDISC,SNMI,SNOMEDCT_US})
[qnco]
  736 cooperative {AOD,CHV} [orgt]
  751 Group A {CHV,SNOMEDCT_US} [clas]
  736 Analysis (Analysis of substances {MTH,SNOMEDCT_US}) [lbpr]
<<<< Mappings
```

Phrase: This study
>>>> Phrase
study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: also
>>>> Phrase
also
<<<< Phrase

Phrase: reported
>>>> Phrase
reported
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):

1000 Reported (Reporting {AOD,CHV,LNC,MTH,NCI,SNOMEDCT_US}) [hlca]
<<<< Mappings

Phrase: that IF in a subgroup of children

>>>> Phrase
that induction failure in a subgroup of children

<<<< Phrase
>>>> Mappings

Meta Mapping (649):

578 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]

744 failure (Personal failure {AOD,CHV,MTH}) [inbe]

578 Subgroup {MTH,NCI} [clas]

578 Children (Offspring
{AOD,CHV,HL7V3.0,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [famg]

<<<< Mappings

Phrase: below age 6 years with B-ALL

>>>> Phrase
below age 6 years with b all

<<<< Phrase

>>>> Mappings

Meta Mapping (774):

774 Age-Years {NCI,NCI_NCPDP} [tmco]

<<<< Mappings

Phrase: without adverse genetic features

>>>> Phrase
adverse genetic features

<<<< Phrase

>>>> Mappings

Meta Mapping (848):

848 Gene Feature {MTH,NCI,NLMSubSyn} [gngm]

<<<< Mappings

Phrase: had

>>>> Phrase

<<<< Phrase

Phrase: an EFS of 72%

>>>> Phrase

an efs of 72

<<<< Phrase

>>>> Mappings

Meta Mapping (708):

770 EFS (Disease-Free Survival {CHV,MSH,MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn}) [qnco]

604 72 {MTH,SNOMEDCT_US} [qnco]

<<<< Mappings

Phrase: with chemotherapy alone.201 However,
>>>> Phrase
chemotherapy alone 201 however
<<<< Phrase
>>>> Mappings
Meta Mapping (750):
 812 Chemotherapy (Pharmacotherapy
 {AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-
 GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
 812 alone (alone – group size {AOD,CHV,MTH}) [grpa]
<<<< Mappings

Phrase: in
>>>> Phrase
<<<< Phrase

Phrase: that study,
>>>> Phrase
study
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Study {MTH,NCI} [resa]
<<<< Mappings

Phrase: those patients above age 10,
>>>> Phrase
those patients above age 10
<<<< Phrase
>>>> Mappings
Meta Mapping (696):
 760 Patients
 {AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
 A,SNOMEDCT_US} [podg]
 593 AGE (Age
 {AOD,CHV,FMA,LNC,MTH,NCI,NCI_BRIDG,NCI_CDISC,NCI_FDA,NCI_NICHD,SN
 OMEDCT_US}) [orga]
 593 10% {LNC} [qncos]
<<<< Mappings

Phrase: with T-ALL,
>>>> Phrase
t all
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 t-all (Adult T-Cell Lymphoma/Leukemia
 {CHV,CSP,LCH_NW,MSH,MTH,NCI,NCI_CTEP-SDC,NCI_NCI-
 GLOSS,NDFRT,NLMSubSyn,PDQ,SNMI,SNOMEDCT_US}) [neop]
<<<< Mappings

Phrase: or with 11q23 rearrangements

>>>> Phrase
or with 11q23 rearrangements

<<<< Phrase

>>>> Mappings

Meta Mapping (722):

 770 11q23 (chromosome 11q23 {NCI,PDQ}) [celc]
 770 Rearrangements (DNA Sequence Rearrangement
{LNC,NCI,NLMSubSyn}) [genf]

<<<< Mappings

Phrase: had

>>>> Phrase

<<<< Phrase

Phrase: particularly dismal outcomes.

>>>> Phrase
particularly dismal outcomes

<<<< Phrase

>>>> Mappings

Meta Mapping (793):

 793 Outcome (Result {MTH,NCI,NCI_BRIDG,NCI_NCI-
GLOSS,SNOMEDCT_US}) [ftcn]

<<<< Mappings

Processing text_000N_123453.tx.5: A patient with marrow aplasia at the end of induction should be medically supported (e.g., blood products, antibiotics as needed) until the marrow either recovers in remission (M1) or demonstrates the presence of refractory disease.

Phrase: A patient with marrow aplasia

>>>> Phrase
a patient with marrow aplasia

<<<< Phrase

>>>> Mappings

Meta Mapping (696):

 760 *^patient (Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDSC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US}) [podg]
 593 Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]
 593 aplasia (Aplastic {MSH,MTH,SNMI}) [ftcn]

<<<< Mappings

Phrase: at the end of induction

>>>> Phrase
at the end of induction

<<<< Phrase

>>>> Mappings

Meta Mapping (686):

 760 End (Stop (qualifier value) {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]

593 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: should
>>>> Phrase
<<<< Phrase

Phrase: be
>>>> Phrase
<<<< Phrase

Phrase: medically
>>>> Phrase
medically
<<<< Phrase

Phrase: supported
>>>> Phrase
supported
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Supported (Supportive assistance {MTH,NCI}) [cnce]
<<<< Mappings

Phrase: (
>>>> Phrase
<<<< Phrase

Phrase: e.g.
>>>> Phrase
<<<< Phrase

Phrase: ,
>>>> Phrase
<<<< Phrase

Phrase: blood products,
>>>> Phrase
blood products
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
1000 Blood products (Blood product
{CHV,HL7V3.0,LNC,MTH,NCI,NCI_NICHD,NLMSubSyn,SNM,SNMI,SNOMEDCT_US})
[phsu]
<<<< Mappings

Phrase: antibiotics

```
>>>> Phrase
antibiotics
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Antibiotics (Antibiotics, Antitubercular
{AOD,ATC,MSH,MTH,NLMSubSyn,SNOMEDCT_US}) [antb]
<<<< Mappings

Phrase: as needed
>>>> Phrase
as needed
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  As Needed {HL7V3.0,LNC,MTH,NCI} [qlco]
<<<< Mappings

Phrase: )
>>>> Phrase
<<<< Phrase

Phrase: until the marrow
>>>> Phrase
marrow
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]
<<<< Mappings

Phrase: either
>>>> Phrase
either
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
  1000  Either {LNC} [fndg]
<<<< Mappings

Phrase: recovers in remission
>>>> Phrase
recovers in remission
<<<< Phrase
>>>> Mappings
Meta Mapping (746):
  790  recover (Recovery - healing process
{AOD,MTH,NCI,NCI_CDISC,NCI_NCI-GLOSS}) [orgf]
  790  Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
```

<<<< Mappings

Phrase: (M1

>>>> Phrase

m1

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 M1 (MRLN gene {HGNC,MTH,OMIM}) [gngm]

<<<< Mappings

Phrase:)

>>>> Phrase

<<<< Phrase

Phrase: or

>>>> Phrase

<<<< Phrase

Phrase: demonstrates

>>>> Phrase

demonstrates

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

 1000 Demonstrates {SNOMEDCT_VET} [acty]

<<<< Mappings

Phrase: the presence of refractory disease.

>>>> Phrase

the presence of refractory disease

<<<< Phrase

>>>> Mappings

Meta Mapping (745):

 760 Presence (Providing presence (regime/therapy)
 {CHV,MTH,SNOMEDCT_US}) [topp]

 640 Refractory Disease {NCI,NCI_NICHD,NLMSubSyn} [fndg]

<<<< Mappings

Processing text_000N_123453.tx.6: Those patients with an M2 marrow at the end of a standard induction often go into remission with further chemotherapy, but this slow response to initial therapy is generally indicative of a poor long-term prognosis (see Prognostic Factors section).

Phrase: Those patients with an M2 marrow

>>>> Phrase

those patients with an m2 marrow

<<<< Phrase

>>>> Mappings

Meta Mapping (672):

753 Patients
{AOD,CHV,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,NCI,NCI_CDISC,NCI_DICOM,NCI_FD
A,SNOMEDCT_US} [podg]
586 m² (square metres
{CHV,LNC,MTH,NCI,NCI_CDISC,NCI_ICH,NCI_NCPDP,NCI_UCUM,SNOMEDCT_US})
[qnco]
586 Marrow {CHV,HL7V2.5,MSH,MTH} [bpoc]
<<<< Mappings

Phrase: at the end of a standard induction

>>>> Phrase
at the end of a standard induction

<<<< Phrase

>>>> Mappings

Meta Mapping (656):

748 End (Stop (qualifier value) {LNC,MTH,NCI,SNOMEDCT_US}) [tmco]
581 Standard (Standard (document) {MTH,NCI}) [inpr]
581 Induction (Induce (action) {CHV,MTH,NCI,SNMI,SNOMEDCT_US})
[ftcn]
<<<< Mappings

Phrase: often

>>>> Phrase

often

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 Often (Frequently {CHV,HPO,LNC,MTH,NCI,SNMI,SNOMEDCT_US})
[tmco]
<<<< Mappings

Phrase: go into remission

>>>> Phrase

go into remission

<<<< Phrase

>>>> Mappings

Meta Mapping (746):

790 GO (GORAB gene {HGNC,MTH,OMIM}) [gnqm]
790 Remission (Disease remission {AOD,CHV,MTH,NCI,NCI_NCI-
GLOSS,NLMSubSyn,SNM,SNMI,SNOMEDCT_US}) [fndg]
<<<< Mappings

Phrase: with further chemotherapy,

>>>> Phrase

further chemotherapy

<<<< Phrase

>>>> Mappings

Meta Mapping (888):

694 Further {NCI} [spco]
861 Chemotherapy (Pharmacotherapy

{AOD,CHV,CSP,HL7V3.0,MEDLINEPLUS,MSH,MTH,NCI,NCI_NCI-GLOSS,NCI_NICHD,NLMSubSyn,SNOMEDCT_US}) [topp]
<<<< Mappings

Phrase: but

>>>> Phrase

<<<< Phrase

Phrase: this slow response to initial therapy

>>>> Phrase

this slow response to initial therapy

<<<< Phrase

>>>> Mappings

Meta Mapping (691):

586 Slow {AOD,CHV,LNC,NCI,SNOMEDCT_US} [qlco]

753 Response (Disease Response {MTH,NCI,NCI_NCI-GLOSS,NLMSubSyn})

[fndg]

586 INITIAL (Initial Usage {MTH,NCI,NCI_FDA,NLMSubSyn}) [ftcn]

586 Therapy (Therapeutic procedure

{AOD,AOT,CHV,CSP,HL7V2.5,HL7V3.0,LCH,LCH_NW,LNC,MSH,MTH,MTHHH,MTHMST,NCI,NCI_NCI-GLOSS,NCI_NCI-HL7,NCI_NICHD,NLMSubSyn,SNMI,SNOMEDCT_US})

[topp]

<<<< Mappings

Phrase: is

>>>> Phrase

<<<< Phrase

Phrase: generally indicative of a poor long-term prognosis

>>>> Phrase

generally indicative of a poor long term prognosis

<<<< Phrase

>>>> Mappings

Meta Mapping (555):

600 Poor prognosis (Prognosis bad

{CHV,NLMSubSyn,SNMI,SNOMEDCT_US}) [fndg]

604 Long Term (Long-term {CHV,MTH,NCI,SNOMEDCT_US}) [tmco]

<<<< Mappings

Phrase: (

>>>> Phrase

<<<< Phrase

Phrase: see

>>>> Phrase

see

<<<< Phrase

>>>> Mappings

Meta Mapping (1000):

1000 see (Vision {AOD,CHV,CSP,G0,ICF,ICF-

CY,LCH,LCH_NW,LNC,MSH,MTH,NCI,NLMSubSyn,SNM,SNMI,SNOMEDCT_US)}) [orgf]
<<<< Mappings

Phrase: Prognostic Factors

>>>> Phrase
prognostic factors
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Prognostic Factors {MSH,NCI,NCI_NCI-GLOSS,NLMSubSyn} [clna]

<<<< Mappings

Phrase: section

>>>> Phrase
section
<<<< Phrase
>>>> Mappings
Meta Mapping (1000):
 1000 Section (section sample {MTH,NCI,NLMSubSyn}) [sbst]

<<<< Mappings

Phrase:).

>>>> Phrase
<<<< Phrase